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ABSTRACT 
Our group is focused on experimental models of cartilage and bone development in order to 
understand the biomechanical and biological parameters that regulate skeletal tissue 
formation.  Previous results in our laboratory indicated that when mouse embryonic fibroblasts 
(MEFs) were cultured in vitro in three-dimensional (3D) scaffolds based on the self-assembling 
peptide RAD16-I, cells acquired multipotential capacity and engaged in a spontaneous process 
of chondrogenic differentiation. This thesis focuses on understanding the possible molecular 
mechanisms modulating the default cartilaginous commitment of these cells. Thus, the influence 
of matrix properties on the differentiation process was evaluated as well as the potential 
participation of genes involved in early tissue organization. Interestingly, cells only underwent 
chondrogenic differentiation under certain mechanical conditions, characterized by low stiffness 
(G’   0.1 kPa). Similarly to in vivo processes, the mentioned differentiation appeared to be 
regulated by the balance on the expression of the chondrogenic inductor BMP4 and its 
antagonist Noggin. 
Moreover, a novel and simple model was described in which the molecular events involved in 
bone formation through endochondral ossification could be studied in vitro. For this purpose, 
co-cultures of endothelial cells with 3D cultures of MEFs undergoing chondrogenesis were 
developed. Importantly, cells committed to osteogenic lineage under these new conditions. The 
osteogenic differentiation was evidenced by the expression of the hypertrophic marker collagen 
type X and the presence of calcium mineralized matrix at the interface between MEFs and 
endothelial cells, which suggested a cross-talk between both cell types.  
Finally, a newly designed biomaterial for tissue engineering applications was developed by 
combining self-assembling peptide RAD16-I and polysaccharide heparin. Interestingly, this 
material exhibited sequential binding and delivery of the growth factor -containing heparin 
binding domain- VEGF165. The new material supported the development of tubular-like 
structures in a 3D culture system of endothelial cells. These results suggested that this system 
could promote the development of a vascularized tissue and, as a consequence, promote tissue 
regeneration in an injured tissue. This platform could be used in other tissue engineering 
applications using heparin-binding affinity molecules such as TGFβ-1, which is a well-known 
chondrogenic inductor.  
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RESUMEN 
Nuestro grupo se ha centrado el en estudio de modelos experimentales de formación de cartílago 
y hueso con el objetivo de entender los parámetros biomecánicos y biológicos que regulan la 
formación de los tejidos que forman el esqueleto. En particular, resultados previos de nuestro 
laboratorio indican que cuando los fibroblastos embrionarios de ratón (del inglés, mouse 
embryonic fibroblasts , MEFs) se cultivaron in vitro en el péptido de auto-ensamblaje RAD16-I 
usando un sistema de cultivo tridimensional (3D), los MEFs adquirieron una capacidad de 
diferenciación multipotencial iniciando un proceso espontáneo de diferenciación condrogénica. 
En esta tesis, se estudió con más detalle el proceso con el objetivo de entender los posibles 
mecanismos moleculares que modulan el proceso de diferenciación condrogénica de estas 
células. Para ello se evaluó la influencia que las propiedades de la matriz ejercen en el proceso 
de diferenciación y la posible participación de genes involucrados en organización temprana de 
tejidos. De forma interesante, solamente bajo ciertas condiciones mecánicas, caracterizadas por 
la baja rigidez de la matriz (G’   0.1 kPa), el sistema inició la diferenciación condrogénica, la 
cual pareció ser regulada por el balance entre el inductor condrogénico BMP4 y su antagonista 
Noggin en una forma similar a la que ocurre in vivo. 
Además, en esta tesis se describió un nuevo y simple modelo en el cual se podrían estudiar in 
vitro los eventos moleculares involucrados en la formación de hueso a través del proceso de 
osificación endochondral. Para ello, cultivos 3D de MEFs experimentando condrogénesis 
fueron cocultivados con células endoteliales.  De manera importante, en estas nuevas 
condiciones el sistema se redirigió hacia una diferenciación osteogénica. Dicha diferenciación 
fue probada por la expresión del marcador hipertrófico colágeno tipo X y la mineralización de la 
matriz en las zonas de interacción entre los MEFs y las células endoteliales, lo que sugiere un 
diálogo entre ambos tipos celulares.  
Finalmente, se desarrolló un nuevo biomaterial para aplicaciones en ingeniería de tejidos 
formado por la simple combinación del péptido de auto-ensamblaje RAD16-I y el polisacárido 
heparina. De forma interesante, este material exhibió  la unión y liberación secuencial del factor 
de crecimiento- con dominio de unión de la heparina- VEGF165. Además, el nuevo material 
permitió la formación de estructuras tubulares en un cultivo 3D de células endoteliales. Estos 
resultados sugieren que este sistema podría promover el desarrollo de un tejido vascularizado y, 
como consecuencia, favorecer la regeneración en un tejido dañado. Esta plataforma podría ser 
usada en otras aplicaciones de ingeniería de tejidos usando moléculas con afinidad de unión de 
la heparina como el TGFβ-1, el cual es un conocido inductor condrogénico. 
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RESUM 
Durant els últims anys, el nostre grup s’ha centrat en l’estudi de models experimentals de 
formació de cartílag i ós amb l’objectiu d’entendre els paràmetres biomecànics i biològics que 
regulen la formació dels teixits que formen l’esquelet. En particular, resultats previs obtinguts 
en el nostre laboratori indiquen que quan els fibroblasts embrionaris de ratolí (de l’anglès, 
“mouse embryonic fibroblasts”, MEFs) es cultiven in vitro en el pèptid auto-ensamblable 
RAD16-I, emprant un sistema de cultiu tridimensional (3D), els MEFs són capaços d’adquirir 
una capacitat de diferenciació multipotencial, iniciant un procés espontani de diferenciació 
condrogènica. En aquesta tesis, es va estudiar amb més detall el procés amb l’objectiu 
d’entendre els possibles mecanismes moleculars que modulen el procés de diferenciació 
condrogènica d’aquestes cèl·lules. Per a tal efecte es va avaluar l’influencia que les propietats 
de la matriu poden tenir en el procés de diferenciació i la possible participació de gens 
involucrats en l’organització primerenca de teixits. De manera interesant, es va veure que només 
sota certes condicions mecàniques caracteritzades per una rigidesa de la matriu baixa 
(G’=0,1KPa), el sistema va ser capaç d’iniciar la diferenciació condrogènica, cosa que va 
semblar venir regulada per la balança entre l’inductor condrogènic BMP4 i el seu antagonista 
Noggin, d’una manera similar al que succeeix in vivo. 
Per una altra banda, en aquesta tesis es va descriure un model nou i simple en el qual es podrien 
estudiar in vitro els esdeveniments moleculars involucrats en la formació d’ós, a través del 
procés d’ossificació endocondral. Per a tal efecte, cultius tridimensionals de MEFs en procés de 
condrogènesis es van cocultivar amb cèl·lules endotelials. Aquestes noves condicions van 
permetre al sistema redirigir-se cap a una diferenciació osteogènica, provat per l’expressió del 
marcador hipertròfic col·lagen tipus X i la mineralització de la matriu en les zones d’interacció 
entre els MEFS i les cèl·lules endotelials. Tals resultat suggereixen un clar diàleg entre ambdós 
tipus cel·lulars.  
Finalment també es va desenvolupar un nou material per a diferents aplicacions en l’àmbit de 
l’enginyeria de teixits, format per la simple combinació del pèptid d’auto-assemblatge RAD16-I 
i el polisacàrid heparina. Es va observar que aquest material exhibia la unió i alliberació 
seqüencial del factor de creixement – amb domini d’unió de l’heparina – VEGF165. A part, el 
nou material va permetre la formació d’estructures tubulars en un cultiu 3D de cèl·lules 
endotelials. Aquests resultats suggereixen que aquest sistema podria promoure el 
desenvolupament d’un teixit vascularitzat i com a conseqüència, afavorir la regeneració d’un 
teixit fet malbé. Aquesta plataforma es podria emprar en diferents aplicacions de l’enginyeria de 
teixits fent servir molècules amb afinitat d’unió de l’heparina com el TGFβ-1, el qual és un 
conegut inductor condrogènic.  
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1.1 Background 
1.1.1 Overview 
Even more than 250 years ago, William Hunter wrote “we shall find that an ulcerated cartilage 
is universally allowed to be a very troublesome disease...and that, when destroyed, it is never 
recovered” 1. This is due to poor intrinsic healing ability of adult articular cartilage, and thus 
even minor injuries or lesions may lead to progressive damage and osteoarthritic joint 
degeneration resulting in significant pain and disability. Nowadays, after decades of research, 
there still remain significant challenges in the clinical application of cell-based therapies for 
cartilage repair. Although numerous strategies have been developed to address this issue, 
unfortunately, none of these approaches has provided a complete and reproducible solution to 
the problem. 
1.1.2 Tissue Engineering  
Advances in medicine over the past several decades have led to significant improvements in the 
quality of life. Despite these advances, alternative therapies must be developed to treat patients 
who suffer from loss or failure of organs and tissues 
2
. Besides, organ transplantation is severely 
limited by a critical donor shortage. Consequently, in the last decade, the tissue engineering 
field emerged attempting to address tissue recovery of this significant number of patients who 
need a new or improved organ or tissue. 
Tissue engineering was defined by Vacanti and Langer in 1993 as an interdisciplinary field that 
applies the principles of engineering and the life sciences toward the development of biological 
substitutes that restore, maintain, or improve tissue function 
3
. Nevertheless, their work started 
in the mid-1980s when it was postulated that living organs might be designed and built based on 
the principles of biologic science and technologic advances in the engineering disciplines. Their 
first published data dates from 1988 
4
. In the following decade, many other laboratories 
worldwide demonstrated the fundamental principles to a successful tissue creation and their 
practical application in many systems eventually applied to human therapy 
5
. The potential 
impact of this field includes the development of engineered tissues that could reduce the need of 
organ replacement and ease the study of physiology and pathophysiology in vitro. These studies 
could greatly accelerate the development of new drugs that may cure patients, eliminating the 
need for organ transplants altogether 
6
. 
The basic principle of tissue engineering could be simplified as cells can be isolated, expanded 
in vitro and seeded onto scaffolds. In this scaffold, a variety of factors can be modulated (such 
as biological, biomechanical or biophysical factors) to obtain specific cell differentiation and 
further re-implantation of the engineered tissue into the patient (Figure 1.1.1). As it can be 
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observed in the general scheme, tissue engineering involves three main players: cells, 
biomolecules and scaffolds.  
 
 
Figure 1.1.1. Basic principle of Tissue Engineering. First, cells are isolated from the patient or a donor 
(a), to be expanded in vitro (b). Then, cells are cultured in a scaffold (c) to obtain a 3D engineered 
scaffold (d), at this point a variety of factors can be modulated to obtain specific cell differentiation and 
be finally implanted in the patient (e). 
Due to the promising applications of tissue engineering, several strategies have been designed 
during the last years aiming to obtain cartilage tissue substitutes. For this purpose, different 
cells, biomaterials and stimulating factors have been used, as it will be discussed in the next 
sections. 
1.1.3 Cells 
The optimal cell source for cartilage tissue engineering is still being identified. The goal is to 
find an ideal cell source that can be easily isolated, expanded and cultured to express and 
synthesize cartilage-specific molecules (Table 1.1.1) 
7
. While chondrocytes should be the first 
choice, since they are found in cartilage, having the role of producing, maintaining, and 
remodeling the cartilage extracellular matrix (ECM), the main challenge is to obtain a sufficient 
cell number. Unfortunately, monolayer expansion causes their dedifferentiation, which is 
characterized by decreased production of cartilage specific ECM (mainly proteoglycans (PGs) 
and type II collagen) 
7
. However, autologous chondrocyte implantation (ACI) is a common 
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strategy used in clinical practice since 1987 
8
. Briefly, cells from a biopsy are isolated and 
expanded in vitro. Then, they are re-implanted in the cartilage defect in a second surgical 
procedure usually under a membrane, which is often made of collagen type I/III or seeded onto 
a scaffold matrix 
9
. ACI is one of the first developed FDA approved cell-therapies for articular 
cartilage repair (1997, Carticel™, Genzyme). Nowadays, some companies such as TETEC are 
currently developing similar therapeutic platforms (Novocart, Phase III clinical trials, TETEC, 
AG, Germany). Indeed, chondrocytes are the only source of cells currently approved for clinical 
use 
10
. 
Mesenchymal stem cells (MSCs) represent a viable alternative to chondrocytes as a cell source 
for cartilage tissue engineering. Their main advantages are: ease of availability, high capacity of 
in vitro expansion in undifferentiated state, while retaining the ability to differentiate into 
mesodermal lineages after exposure to suitable stimuli 
11,12
. In vitro chondrogenesis of different 
MSCs-derived sources has been described, however bone marrow and adipose derived stem 
cells are the most widely used 
7
. Their extraction techniques are less invasive than other surgical 
procedures, but still uncomfortable and painful for the patients. Furthermore, isolation of MSCs 
typically yields very low amount of cells. Hence, the search for alternative cell sources is still 
ongoing. 
Table 1.1.1. Cell sources for cartilage tissue engineering and their advantages and disadvantages. 
Cell Type Advantages Disadvantages 
Autologous 
Chondrocyte 
Native Phenotype 
Minimal risk of immunological problem 
Small cell number 
De-differentiation on expansion 
Adult Mesenchymal 
Stem Cells 
Potential to obtain large cell numbers 
Capacity to differentiate into 
mesodermal lineages 
Potential for hypertrophy 
Differentiation unstable and 
non-reproducible 
Embryonic Stem Cells Multiple cell types can be obtained Potential tumorigenic 
Ethical considerations 
Differentiation unstable and 
non-reproducible 
Induced Pluripotent 
Stem Cells(iPSCs)  
Source of patient specific cells 
Multiple cell types can be obtained 
Potential tumorigenic 
Differentiation unstable and 
non-reproducible 
Fibroblasts Source of patient specific cells 
Multiple harvest sites 
Low differentiation capacity 
 
Chondrogenic differentiation of embryonic stem cells (ESCs) has also been reported due to their 
pluripotency and self-renewal capacity. They can be expanded unlimitedly in vitro and generate 
cells of all three germ layers (endoderm, mesoderm and ectoderm) that can further differentiate 
into specific cell lineages 
13–15
. However, the main disadvantage of ESCs is that they may be 
tumorigenic due to their highly proliferative ability when undifferentiated. Hence, even a single 
one cell that is not appropriately differentiated could lead to disastrous consequences if it 
initiates a different or undesired differentiation response upon implantation 
10
. In addition, they 
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are surrounded by ethical concerns due to the need of embryo extraction. Therefore, their use 
has been limited mainly to better understand fundamental biological questions rather than study 
clinically applicable strategies.  
In addition to ESCs, few studies reported the use of induced pluripotent stem cells (iPSCs) for 
cartilage tissue engineering strategies 
16,17. iPSCs are “embryonic-like” stem cells generated 
from fibroblasts by retrovirus mediated transfection of four transcription factors: Oct3/4, Klf4, 
Sox2 and c-Myc. iPSCs are indistinguishable from ESCs in morphology, proliferation, gene 
expression, and teratoma formation. This kind of cells bypasses the need for embryo extraction 
to generate pluripotent stem cell phenotypes from autologous sources 
18
. The interest on this cell 
type is increasing as they have high differentiation capacity, but they also can be derived from 
the patient’s own cells. Although it seems to be the ideal source of cells, this approach currently 
has serious limitations for its use in regenerative medicine due to the risks of tumor formation 
and function disruption of many endogenous genes by retroviral insertion. Therefore, the main 
drawbacks concerning the use of iPSCs are: low efficiency, questionable reproducibility, 
difficult standardization and control of differentiation. Hence, their clinical application will 
require a few years of safety trials before their clinical use becomes a reality 
10
. 
Finally, in addition to chondrocytes and stem cells, fibroblasts have been widely used during the 
last years for tissue engineering applications. Different studies showed the ability of fibroblasts 
to redirect their fate towards mesodermal lineages (including adipocytes, osteoblasts and 
chondrocytes) when cultured under the appropriate conditions 
19–22
. Dermal fibroblasts represent 
an easily accessible and abundant cell source, as a substantial cell yield can be obtained from a 
relatively small biopsy following minimally invasive procedures and routine cell-expansion 
techniques as compared to MSCs. However, their main limitation is the low differentiation 
capacity compared to the other cell types. 
1.1.4 Stimulating chondrogenic factors 
Stimulatory factors are required to induce or enhance cartilage formation and can be divided 
into: biophysical stimuli, which include oxygen tension and matrix deformation by mechanical 
loading; and biological, such as growth factors and cytokines. Cartilage is an avascular tissue 
and, consequently, chondrocytes naturally experience low oxygen tension. Indeed, the oxygen 
concentration varies from 1 to 7%. It was found that low oxygen tension is a key regulatory 
factor of proliferation, differentiation and activity of chondrogenic cells since chondrocytes and 
MSCs cultured in hypoxic conditions in vitro increased the synthesis of cartilage specific ECM 
proteins 
23,24
.  In addition, under physiological conditions, articular cartilage is subjected to 
various mechanical stimuli. Different studies showed that dynamic compressive loading has a 
chondrogenic stimulatory effect on cartilage, chondrocytes, and stem cells 
20
. Therefore, 
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mechanical stimuli are important factors to take into account in the development of cartilage 
engineering products. Besides, matrix elasticity is also an important factor to consider as cells 
can “sense” and respond to the elasticity of their substrate. Moreover, compliant substrates 
appear to maintain the chondrogenic phenotype, which is indicated by round cellular 
morphology, diminished actin stress fiber formation, and chondrogenic ECM production, while 
stiffer substrates have a negative impact 
25
. These results emphasize how important it is to 
control scaffold mechanical properties to engage a cellular system to undergo chondrogenic 
differentiation. Accordingly, a variety of bioreactor systems have been applied, determined to 
reproduce the mechanical stimuli experienced in vivo 
26
. 
Similarly to most of tissue engineering applications, growth factors and other chemical additives 
may be added into the culture medium to control tissue formation in vitro. Some growth factors 
that have been widely described are TGF-β superfamily, several BMPs, insulin- like growth 
factor (IGF)-1, fibroblast growth factors (FGFs), and epidermal growth factor (EGF). Among 
them, members of the TGF-β family have been shown to play a key role on cartilage 
development 
7,12
. 
1.1.5 Scaffolds 
2D versus 3D cultures 
Nowadays, it has been well established that traditional 2 dimensional (2D) cultures do not 
recreate in vivo conditions where cells are embedded in a natural 3 dimensional (3D) 
extracellular matrix (ECM) interacting with their neighboring cells and with the ECM through 
biochemical and mechanical cues (Figure 1.1.2)  
27
. These cell–cell and cell–ECM interactions 
are essential to establish a 3D communication network to maintain the specificity and 
homeostasis of the tissue. However, cells cultured in 2D grow in physiological constrained 
conditions because they are unnaturally polarized: cells have the bottom surface attached to a 
rigid and flat substrate and, the upper surface exposed to culture media. As a consequence, in 
vivo conditions are not recreated in terms of cellular communication, gene and protein 
expression pattern and diffusion of soluble molecules such as oxygen, nutrients or growth 
factors 
28–30
.  Thus, the third dimension is required in order to capture the physiological cell 
responses and bridge the gap between simplistic 2D cultures and extremely complex animal 
models 
31
. Altogether it motivates the use of 3D cultures as cellular models that mimic better the 
functions of living tissues.  
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Figure 1.1.2. Importance of the 3D environment for engineering cell function (Griffith et al 2006  
32
) 
Ideal Scaffolds 
Currently, one major goal of tissue engineering is to develop new biomaterials similar 
structurally and mechanically to ECMs to mimic in vivo conditions (biomimetic). The ECM is 
the natural environment of cells and it is composed by a variety of proteins and polysaccharides 
assembled into an organized network in close association with the cellular surface 
32
. It serves as 
a scaffold to maintain tissue and organ structure and also regulates many aspects of cell 
behavior, including cell proliferation and growth, survival, change in cell shape, migration, 
differentiation and function 
33–35
. Variations in the relative amounts of the different types of 
matrix macromolecules and their organization in the ECM give rise to the functional 
requirements of particular tissues 
36
. 
The ideal biologically compatible scaffold to support cell attachment and growth should be 
biomimetic among several other criteria 
37
. First of all, it must be biocompatible to prevent an 
adverse tissue reaction of the immune system. Moreover, the scaffold should exhibit a 
controlled rate of degradation; ideally it should degrade and resorb at a rate that matches the 
formation of new tissue. Besides, the resulting degradation products should be non-toxic and, 
therefore, should not induce an inflammatory response. Lastly, in terms of material production, 
purification, and processing, it should be easy, cheap and scalable 
37
. 
Scaffolds for cartilage tissue engineering 
It is well known that chondrocytes reside within a complex 3D environment, which is composed 
by a highly hydrated complex network of molecules. In contrast, as detailed in the previous 
section, isolated chondrocytes lose their differentiated phenotype in two-dimensional (2D) 
culture. Pellet and micromass culture systems have traditionally been used to re‐differentiate 
chondrocytes or differentiate adult chondroprogenitors in vitro 
38
. However, biomaterial‐free 
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cultures present several disadvantages, such as the limited size, uncontrolled construct geometry 
and the poor mechanical properties. Therefore, 3D environments have been used to either 
culture chondrocytes or to promote the chondrogenic differentiation of chondroprogenitors 
12
.  
Different types of biomaterials have been used for cartilage tissue engineering which can be 
classified into natural and synthetic biomaterials. Natural biomaterials exhibit complex 
structures and a variety of properties, such as water binding capacity, biodegradability and 
biocompatibility, among many others. However, another important aspect to consider when 
using natural materials is that they can induce an undesirable immune response due to the 
presence of impurities and endotoxins, and their variability from batch to batch due to the 
inability to accurately control the processing techniques 
39
. Moreover, natural materials possess 
weak mechanical properties and the possible modifications to improve them are limited. Some 
examples that have been explored for cartilage engineering include: collagen 
40
, fibrin
41
, alginate 
42
, agarose 
43
, gelatin 
44
, chondroitin sulfate 
45
, chitosan
46
 or hyaluronic acid 
47
 (Table 1.1.2). 
Alternatively, the use of synthetic polymers enables the design of scaffolds with specific 
mechanical and biological properties, and degradation rates. Moreover, this type of materials 
can be produced cheaply and reproducibly. However, their potential limitations include toxicity 
and restricted cellular interactions, unless they are modified with adhesion peptides or designed 
to release biological molecules 
48
. Synthetic biomaterials currently used for cartilage repair 
include among others: poly (α-hydroxy esters) 49,50, poly(ethylene glycol) 51, poly(NiPAAm) 52, 
polyurethanes
53
 or self-assembling peptides 
54,55
 (Table 1.1.2). Although hydrogels show weak 
mechanical properties, they are widely used due to their similarities to native cartilage tissue 
and the potentially to be injected transcutaneously into the cartilage defects. Among synthetic 
materials, self-assembling peptides are gaining scientific interest in tissue engineering due to the 
specific properties mentioned in the next section. 
Table 1.1.2. Examples of biomaterials used in cartilage tissue engineering applications 
Biomaterials used in in cartilage engineering applications 
Naturally derived Synthetically derived 
Collagen 
40
 Poly(glycolic acid) (PGA),
50,56
 
Fibrin 
41
 Poly(lactic acid) (PLA) 
50
 
Alginate 
42
 Self-assembling peptides 
54,55
 
Agarose 
43
 Poly(ethylene glycol) 
51
 
Gelatin 
44
 Poly(NiPAAm) 
52
 
Chondroitin Sulphate 
45
 Polyurethanes 
53
 
Hyaluronic Acid 
47
 Poly(lactic-co-glycolic acid) (PLGA) 
57
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1.1.6 Self-assembling peptides 
Self-assembling concept 
Self-assembling is defined as the autonomous organization of components into patterns or 
structures without external instruction 
58
. Self-assembling of biomolecules is a phenomenon 
commonly observed in biology, from DNA self-complementary double helix annealing, to 
protein aggregation or lipid membrane formation. It consists of the spontaneous organization of 
molecules under thermodynamic equilibrium conditions into structurally stable arrangements by 
the driving force of non-covalent interactions like hydrogen bonds, ionic bonds, electrostatic 
bonds, van der Waals interactions, etc. Although these interactions are rather weak by 
themselves, when in concert they govern the self-assembling process of biomolecules 
33,59
. The 
consequence of this process is the formation of highly organized and stable macromolecular 
entities with specific functions. Among them are included the proteins forming the ECM of 
connective tissues, such as collagens, laminins and fibronectins. Some of these molecules are 
commonly used as natural biomaterials that mimic ECM milieu for the study of mammalian 
cells behavior in vitro 
33
. 
Peptide design 
First molecular self-assembling studies are dated on the seventies, when different chemical 
approaches showed that copolypeptides with alternating hydrophilic and hydrophobic residues 
formed water-soluble β-sheet structures by self-assembling in the presence of salts (high ionic 
strength) 
60,61
. Later, in the nineties, new studies were carried out in this area with the aim of 
developing new materials. Scientists identified the key parts of proteins responsible for the self-
assembling process and used them to develop simpler systems in vitro. The design of new self-
assembling materials for future applications in biomedicine has been focused on the 
development of scaffolds that can self-assemble in water. Lysβ-21, one of the first examples of 
this class of self-assembling peptides, corresponds to residues 41-61 of the egg white lysozyme 
and forms a triple-stranded β-sheet in the β-domain of the native protein 62. This peptide 
presents β-sheet configuration in water and forms insoluble macroscopic membranes depending 
on pH and ionic strength 
63
. 
Several self-assembling peptides have been molecular designed, among them, the RAD16-I is 
used in this chapter to illustrate the self-assembling process since it is the gold standard scaffold 
used in this thesis (Figure 1.1.3). RAD16-I is composed by repeating units of hydrophilic-
hydrophobic aminoacids, in which the charged residues include alternating positive and 
negative charges (with sequence: AcN-RADARADARADARADA-CONH2; where R = 
Arginine, A = Alanine and D= Aspartic acid). This peptide self-assembles under physiological 
conditions into a network of interweaving nanofibers of around 10 nm diameter, forming a 
hydrogel scaffold with pores size ranging from 50 to 200 nm and over 99% water content. The 
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size of animal cells varies from 20 to 50 μm and therefore, cells would  experience a truly 3D 
environment when cultured within this scaffold. 
 
 
Figure 1.1.3. Peptide RAD16-I self-assembles into a nanofiber network. (A) Schematic model of the 
nanofiber developed by self-assembling RAD16-I molecules. Note: The nanofiber is formed by a double 
tape of assembled RAD16-I molecules in antiparallel β-sheet configuration (top tape in blue and bottom 
tape in yellow). (B) RAD16-I nanofiber network viewed by SEM (Genové et al. 2005 
64
). (Scale bar = 1 
μm) 
Self-assembling peptides of this class are good candidates to create artificial cellular niches, 
because their nanoscale network and biomechanical properties are similar to those of natural 
ECMs. Moreover, mechanical properties can be modulated by changing peptide concentration 
65,66,  and can be defined as “non-instructive” from the point of view of cell receptor 
recognition/activation 
33
. Finally, RAD16-I peptide is easy to synthesize by solid phase 
synthesis, easy to purify and its degradation products are natural aminoacids.  Several in vitro 
studies showed its ability to support cell attachment, growth, maintenance and differentiation of 
a variety of primary and cultured mammalian cells 
37,54,64,67–71
. 
In addition to this class of self-assembling peptides, Stupp and coworkers also used rational 
molecular design for the development of new peptides that self-assemble into nanoscale fibers 
in water solutions. However, the peptide structure and its self-assembling are different from 
those of the β-sheet previously described (such as RAD16-I) 33. This kind of amphiphilic 
molecules are composed by a peptide segment containing 6-12 amino acids, forming the 
hydrophilic region of the peptide, coupled via an amide bond to a fatty acid chain that varies in 
length from 10 to 22 carbon atoms, which confers the hydrophobic characteristics to drive the 
self-assembling. At concentrations as low as 0.25%, these molecules self-assemble into self-
supporting gels via pH controlled and reversible mechanism. These gels are formed by a 
network of cylindrical nanofibers, ranging from 5 to 8 nm in diameter depending on the length 
of the self-assembling molecules forming them. The core of the nanofiber is formed by the 
hydrophobic alkyl tails and the outer surface is formed by the hydrophilic peptide segments 
(Figure 1.1.4) 
72
. 
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Figure 1.1.4. Self-assembling peptides developed by Stupp and coworkers. (A) Chemical structure 
and molecular model of the self-assembling peptide. Color scheme: C, black; H, white; O, red; N, blue; P, 
cyan; S, yellow. (B) Schematic showing the self-assembly into a cylindrical micelle. (Image adapted from 
Hartgerink et al 2001
72
)  
 
Application in cartilage tissue engineering 
Several studies reported the use of self-assembling peptides as scaffolds for cartilage tissue 
engineering applications where a major challenge is the identification of a material that can 
stimulate high rates of cell division as well as high rates of synthesis of phenotypically specific 
ECM macromolecules. The aforementioned RAD16-I was used in in vitro studies where rabbit 
chondrocytes and bone marrow mesenchymal stem cells (BMSCs) showed higher cellular 
proliferation and a better ability to synthesize cartilage-like ECM than control cultures in 
agarose 
55,73
. Moreover, the self-assembling peptide KLD-12 has been widely used for cartilage 
tissue engineering purposes. The encapsulation of bovine chondrocytes in this peptide suggested 
its potential to maintain differentiated chondrocytes for four weeks while stimulating some cell 
division and maintaining the synthesis and accumulation of a mechanically functional cartilage-
like ECM 
74
. Moreover, the maturation of ECM was accelerated and characterized by the 
enrichment in PGs when long-term alternate day dynamic compression loading was applied to 
the bovine encapsulations 
75
. Remarkably, an in vivo study showed that the injection of KLD in 
a full-thickness, critically-sized, rabbit cartilage defect model, markedly improved cartilage 
regeneration. Besides, the injection of combined chondrogenic growth factors and BMSCs did 
not result in any additional beneficial or deleterious effect compared to KLD alone 
76
.  
Finally, Stupp and coworkers designed self-assembling peptides for their specific use in 
articular cartilage regeneration. One of them contained a terminal biosignaling peptide domain 
(a TGF-β1 binding domain), which became highly exposed on the surface of the nanofibers 
after self-assembling. In this case, they used mesenchymal stem cells (MSCs) and their in vitro 
studies showed that this material maintained the cellular viability and chondrogenic 
differentiation of the cells. Moreover,  in vivo studies showed that the peptide containing the 
binding sequence for TGF-β1 enhanced the regenerative potential of micro-fracture chondral 
defects performed in rabbits without adding any external growth factor 
77
. Altogether, it was 
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evidenced the potential use of self-assembling peptides as scaffolds for cartilage tissue 
engineering and regenerative medicine purposes. 
1.2 Motivations and general aims 
Our research group has been actively studying cellular in vitro models in a way to understand 
natural processes of regeneration. Thus, our general working hypothesis is based on the in vitro 
recreation of key biological, biophysical and biomechanical parameters of a tissue undergoing 
regeneration on a damaged tissue, which would promote healing and function recovery. In 
particular, during the last years, we have been involved in projects that aimed to develop new 
strategies to study in vitro cartilage formation using mouse and human fibroblasts cultured in 
the self-assembling peptide RAD16-I 
45,67
. Besides, due to our expertise in the field of cartilage 
tissue engineering and in the development of biomaterials for tissue engineering applications, 
we are part of the project BIOCART, which consists of the development of potentially 
injectable scaffolds that mimic the natural extracellular matrix of cartilage. Remarkably, in vivo 
cartilage formation is in close interaction with bone formation since most of the bones in the 
human body are formed via a cartilage intermediate through the process of endochondral 
ossification. In fact, we have also expertise in models of in vitro osteogenesis using mouse 
embryonic stem cells, mouse fibroblasts and preosteoblastic cells 
59,68
. However, the molecular 
mechanisms involved in the differentiation processes studied remain unclear.  
Altogether this motivated us to study in detail the chondrogenic model described in our 
laboratory using mouse fibroblasts and, once obtained the cartilage-like tissues, develop a 
model for osteogenic differentiation in order to recreate most aspects of in vivo bone formation 
through the process of endochondral ossification. As part of this thesis, a new material for tissue 
engineering applications was also developed with biologically active motifs, which could be 
used, among others, for cartilage tissue engineering strategies. Thus, the general objectives of 
the present thesis are the following: 
- To develop tissue engineering strategies for cartilage tissue repair using the self-
assembling peptide RAD16-I (Chapter 2). 
- To evaluate the biologically induced osteogenic differentiation of MEFs in the self-
assembling peptide RAD16-I (Chapter 3). 
- To develop a new biomaterial for tissue engineering applications based on the self-
assembling peptide RAD16-I (Chapter 4).  
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2.1 Introduction 
2.1.1 Overview 
As introduced in Chapter 1, different strategies have been designed to restore the damaged 
cartilage whereas significant challenges still remain in the clinical application of cell-based 
therapies for cartilage repair. Novel approaches should envisage adequate cell culture models 
involving different cell sources, stimulatory factors and biomaterials, which could offer healthy 
cartilage-like tissue that would restore the functionality of the damaged cartilage.  
2.1.2 Cartilage formation in vivo   
The design of new strategies to regenerate cartilage tissue requires preliminary identification of 
key factors that regulate and control in vivo processes. Cartilage is an avascular tissue formed 
by chondrocytes embedded in a specialized extracellular matrix composed by a highly complex 
network of collagen fibrils and proteoglycans.  Chondrocytes form three different types of 
cartilage characterized by a unique molecular composition and extracellular matrix (ECM) 
organization: hyaline, fibrous and elastic cartilage (Table 2.1.1). Hyaline cartilage is the most 
abundant and it constitutes the articular cartilage. It is also present in costal cartilage, nose, 
trachea, larynx and embryonic skeleton. Moreover, it is involved in skeletal development 
through the process of endochondral ossification (reviewed in Chapter 3). Instead, fibrocartilage 
is typically found in the intervertebral discs, meniscus and it is also temporarily formed at 
fracture sites. Finally, elastic cartilage is present in the outer ear, larynx and epiglottis 
1
. 
Independently of the type of cartilage, its formation is a stepwise process: first, determination of 
cells and their aggregation into pre-chondrogenic condensations; second, differentiation into 
chondrocytes; and third, maturation (Figure 2.1.1).  
Table 2.1.1. Types of cartilage, location and function. 
Cartilage Type Location Function 
Hyaline Cartilage Articular Cartilage 
Costal cartilage 
Nose 
Trachea 
Larynx 
Embryonic skeleton 
Supports and reinforces 
Resilient cushioning properties 
Resists compressive stress 
Fibrous Cartilage Intervertebral discs 
Meniscus 
Temporarily formed at fracture 
sites 
Resists compression and tension 
Elastic Cartilage Outer ear 
Larynx 
Epiglottis 
Maintains the shape 
Great flexibility 
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Figure 2.1.1 Sequence of events leading to the differentiation of mesenchymal stem cells (MSCs) 
towards chondrocytes. The scheme illustrates the temporal expression profiles of the different growth 
and differentiation factors and proteins characteristic of the extracellular matrix (ECM). Abbreviations: 
AP, alkaline phosphatase; CD-RAP, cartilage-derived retinoic acid-sensitive protein; Col, collagen; 
COMP, cartilage oligomeric protein; MMP, matrix metalloprotease; VEGF, vascular endothelial growth 
factor. (Image from Vinatier et al 2009 
2
) 
Mesenchymal condensation is the first step in chondrogenic differentiation, which consists of 
physical compaction of resident mesenchymal cells driven by proper cell signaling. Cellular 
interactions increase; mostly N-cadherin and neural cell adhesion molecule (N-CAM) mediate 
cell–cell interactions3. At the same time, these cells synthesize new matrix that is mainly 
composed by collagen type I, fibronectin, and distinct proteoglycans, such as versican or 
syndecan
4
. After the condensation, mesenchymal cells express transcription factor Sox9 that 
controls downstream genes involved in chondrogenesis and promotes these progenitor cells to 
secrete cartilage-specific ECM molecules and differentiate to chondroblasts.  The expression of 
Sox9 is regulated by members of the families of fibroblast growth factor (FGF), transforming 
growth factor-β (TGF-β), bone morphogenetic protein (BMP) and Wnt. All these molecules are 
essential for the formation of chondrogenic mesenchymal condensation
3
. The next stage is 
characterized by the deposition of cartilage specific collagen types II, IX and XI, and 
proteoglycans, while the expression of collagen type I is turned off 
5
. Therefore, cells exchange 
their elongated fibroblastic‐like shape (typical of mesenchymal progenitors) for new round 
chondroblastic morphology and finally become mature chondrocytes that are sparsely 
distributed within the matrix. 
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Figure 2.1.2 Molecular organization of normal articular chondrocytes. (Image adapted from 
Heinegård, D. & Saxne, T. 2010 
6
) 
Mature cartilage is a tissue with an ECM composed of collagenous and noncollagenous 
elements which together form an interconnected elastic network surrounding chondrocytes 
providing its unique mechanical properties (Figure 2.1.2). Independently of the type of 
cartilage, the primary collageneous component is collagen II (about 90% of the collagenous 
fraction), however, collagens I, VI, IX, X, and XI are also present in the collagen fibrils with 
different percentages depending on the particular cartilage. Altogether, collagens form the 
fibrillar network that confers strength to the chondrogenic ECM. The noncollagenous fraction of 
cartilage is basically composed of proteoglycans, hyaluronan, link protein, and interfibrillar 
proteins like COMP or decorin 
3
. Regarding the proteoglycans, the short proteoglycans that are 
present in the mesenchymal condensation (versican and syndecan) are gradually substituted by 
larger and more complex proteoglycans, mainly aggrecan which accounts for about 90% of the 
proteoglycan content. The structural features of proteoglycans, which consist of a core protein 
and one or more covalently attached negatively charged glycosaminoglycan chains (GAGs), 
provide biomechanical properties that allow resistance to compressive loading in vivo. 
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2.1.3 Role of BMPs and their antagonist Noggin in chondrogenesis 
As mentioned before, cartilage formation is regulated by a complex and orchestrated secretion 
of biological factors. Among them, Bone Morphogenetic Proteins (BMPs), are present in the 
hole process having an essential role in the formation of chondrogenic mesenchymal 
condensation 
7
. BMPs were originally isolated from mammalian bone and they were 
characterized by their ability to induce ectopic bone formation. Further in vitro and in vivo 
studies have shown that BMP signaling not only is required for the formation of pre-
cartilaginous condensations and the differentiation of precursors into chondrocytes, but it also 
regulates the later stages of chondrocyte maturation and terminal differentiation to the 
hypertrophic phenotype.  Regulation of BMP activity occurs in several different ways including 
the direct inhibition of BMP signaling by secreted antagonists such as Noggin and Chordin 
8
. 
Noggin was first identified in Xenopus as a dorsalizing signal playing a crucial role in neural 
development 
9,10
.  Nevertheless, Noggin is also expressed in condensing cartilage and immature 
chondrocytes, like many BMPs, having an important role in the regulation of chondrocyte 
proliferation and differentiation 
11–14
. It is known that mutant mice lacking Noggin show 
excessive cartilage formation due to the enhanced BMP activity in the absence of Noggin 
antagonism (Figure 2.1.3) 
13
. In addition, these mutants failed to initiate joint formation which 
proves that Noggin is not required for cartilage initiation but is involved in regulating 
chondrocyte proliferation and differentiation 
12,13
. Moreover, misexpression of Noggin in an 
embryonic chick limb model prior to the onset of chondrogenesis leads to the total absence of 
skeletal elements 
15
. Finally, in vitro studies also showed the inhibition of chondrogenic but not 
osteogenic differentiation of a mesodermal stem cell line due to the recombinant overexpression 
of Noggin. 
16
.   
  
 
Figure 2.1.3. Noggin mice knockout phenotype Skeletal abnormalities in Noggin homozygous mutants.  
Skeletons, with forelimbs removed, from (A) wild-type and (C) mutant and Forelimbs of (B) wild type 
and (D) mutant 18.5- dpc (days post coitum) embryos were stained with alcian blue for nonmineralized 
cartilage and alizarin red for mineralized cartilage and bone. (Image adapted from Brunet et al 1998 
13
) 
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Similarly, mutations of Noggin in humans cause two autosomal dominant disorders: proximal 
symphalangism and multiple synostosis syndrome, both characterized by multiple joint fusions 
17,18
. Altogether, these features emphasize how important the balance BMP/Noggin is for the 
correct development of chondral and skeletal elements during embryogenesis. Thus, it seems to 
be a crucial factor to take into account in the development of strategies for cartilage tissue 
engineering. 
It is important to mention that Noggin is also a soluble factor secreted during the embryogenesis 
by the organizer, a signaling center which provides spatial pattern information to its 
microenvironment during gastrulation 
19
. The molecular exploration of the organizer (the node 
in mouse) showed that it is a source of nuclear transcription factors and secreted factors that 
mediate the inducing activities of the organizer. Mostly, these secreted factors are antagonists of 
growth factors, which they bind in the extracellular space, and they can act as inhibitors that 
prevent binding to the growth factor receptors 
20
. In the embryonic development, Noggin also 
acts as an antagonist of BMPs, which can modulate the formation of the three germ layers: 
mesoderm, endoderm and ectoderm 
21
. Among the transcription factors secreted by the 
organizer are included the Hepatic Nuclear Factor 3-β (HNF-3β or Foxa2) and goosecoid. 
Foxa2 has also been shown to be expressed with a dual role during early embryogenesis: as an 
organizer when expressed in the early mouse embryo, and as an endodermal marker when 
expressed in the visceral and definitive endoderm later in embryogenesis 
22
. Interestingly, it was 
recently reported to be a crucial regulator in the hypertrophic chondrocyte differentiation 
program in combination with Foxa3 
23
. Instead, goosecoid was the first organizer gene isolated 
from the Spemann organizer in Xenopus and it determines the mesodermal fates of those cells 
expressing it. It is related to the transcription factor Brachury, since they are both expressed in 
the same population of cells when the first mesodermal cells come up and as a consequence are 
some of the first mesodermal markers 
24
. 
2.1.4 Scaffold design for cartilage tissue engineering: influence of stiffness. 
Once understood the process of cartilage formation in vivo and identified the main factors 
involved in the commitment to chondrogenic differentiation, the next step is to identify 
scaffolds to design tissue engineering strategies for cartilage repair.  
Nowadays, several groups are focused on designing new biomaterials for cartilage tissue 
engineering trying to mimic the in vivo microenvironment. Although most studies are centered 
in scaffold properties such as composition, porosity, degradation or the influence of biochemical 
cues on cell behavior 
25
, an increasingly number of studies is now focusing on the influence of 
mechanical properties on cell behavior and differentiation 
26–29
.  
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It is known that cell morphology and functions can depend strongly on substrate stiffness under 
conditions where chemical signals are constant. In the body, the range of ECM stiffness is 
immense, from soft brain tissue with an elastic modulus over 1 kilopascal (kPa) to hard bones 
with hundreds of megapascals (MPa) 
30
. These tissues contain cells that are tuned to the specific 
mechanical environments in which they reside. In accordance to this, recent studies have 
demonstrated that the biomechanical properties of the substrate itself, specifically stiffness, 
directly influence the differentiation of the attached cells 
31
. As an example, it was reported that 
materials with similar mechanical attributes to those of native tissues associated with a cell type 
are most relevant for stem cell differentiation towards the corresponding phenotype than 
chemical signals.  Thus, it was demonstrated that ECM guides MSC differentiation into 
osteoblastic, skeletal muscular and neural lineages in a dependent manner on ECM stiffness 
27
.  
In terms of chondrogenic differentiation, it has been recently found that MSCs commit to 
chondrogenic lineage when cultured in more compliant scaffolds rather than stiff ones 
25,32,33
. 
The stiffness range associated with driving mesenchymal cell fate has generally been in the kPa 
– Mpa range, which is biologically relevant for cartilage and bone 31. Although mature cartilage 
may not be as soft as 1 kPa, this stiffness could be the reminiscent of the stiffness during 
cartilage development 
30
. Altogether, these results show how important it is to control scaffold 
mechanical properties to engage a cellular system to undergo chondrogenic differentiation. 
2.1.5 Mouse embryonic fibroblasts (MEFs) as a model of spontaneous 
chondrogenic differentiation in the self-assembling peptide RAD16-I 
As it has been introduced in Chapter 1, the optimal cell source for cartilage tissue engineering is 
still unclear. During the last years, cell types other than chondrocytes and MSCs have been 
widely used, such as fibroblasts, for tissue engineering applications. Different studies showed 
the ability of fibroblasts to redirect their fate towards mesodermal lineages (including 
adipocytes, osteoblasts and chondrocytes) when cultured under the appropriate conditions 
34–39
. 
In fact, clonal analysis determined that dermal fibroblasts were constituted by a heterogeneous 
population containing progenitors with different levels of differentiation 
40
. Hence, different 
studies report that dermal progenitors show a profile of cell surface markers very similar to that 
of mesenchymal stem cells 
38,40
. Remarkably, it was reported that mouse embryonic fibroblasts 
(MEFs) were not distinguishable from Bone Marrow Stem Cells (BMSCs) based on typical 
BMSCs CD surface marker expression. However, in vitro differentiation assays suggested that, 
although osteogenic, adipogenic and chondrogenic differentiations were obtained under specific 
induction using MEFs, there were differences in their cellular response to differentiation signals 
41
. 
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MEFs are derived from 13.5-day old embryos after removing head and viscera, thus 
mesodermal tissues are their major contributors. They have been mainly used as feeder layers to 
culture embryonic stem cells (ESCs). Moreover, fibroblasts have triggered studies of fibroblast 
biology, cancer and aging 
41,42
.Moreover, they have been the first cells reported in the 
generation of induced pluripotent stem cells (iPSCs); briefly, MEFs were reprogramed to a 
pluripotent state by the introduction the four transcription factors Oct3/4, Sox2, c-Myc and 
Klf4, under ESCs culture conditions 
43
. 
Thus, MEFs may represent a good alternative to BMSCs to study molecular mechanisms in the 
commitment to osteoblasts, adipocytes and chondrocytes 
41
.  Taking this into account, MEFs 
have been widely used in our laboratory to study chondrogenic, osteogenic and adipogenic 
differentiation using a 3D culture system based on the self-assembling peptide RAD16-I.  
Interestingly, it was found that MEFs 3D cultures underwent dramatic morphological changes 
mainly caused by an organized cell contraction and migration that ended, after 7‐10 days in 
culture, with the formation of a highly condense 3D construct. During this process the system 
was found to spontaneously up‐regulate the expression of a subset of chondrogenic genes 
including the transcription factor Sox9 and two main components of the chondrocytes 
extracellular matrix, collagen type II and proteoglycans. Remarkably, the default chondrogenic 
differentiation was not observed when using collagen type I or agarose as scaffolds for the 3D 
culture. These results suggested that the biomechanical and non‐instructive properties of the 
self‐assembling peptide environment might have a key role in the process (Figure 2.1.4) 44. 
 
Figure 2.1.4. Multipotential capacity of MEFs. Phenotype of MEFs cultured in three- dimensional (3D) 
self-assembling peptide hydrogel RAD16-I was assessed under different culture conditions. (A, D) Only 
after osteogenic induction, von Kossa staining showed calcium deposition. (B, E) Toluidine Blue staining 
showed default chodrogenic differentiation without need of supplements. (C) Adipocytes in non-
supplemented cell cultures were detectable by visual inspection, and (F,G) Neutral lipids present in the 
adipocytes were stained using Nile Red. (Image adapted from Quintana et al 2009 
44
) 
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In addition, Nile Red staining showed some spontaneous adipogenic differentiation restricted to 
isolated cells. Regarding the osteogenic differentiation, MEFs 3D-cultures only exhibited matrix 
mineralization (characteristic of osteogenic phenotype) after the addition of specific induction 
media. Hence, it was hypothesized that during this process MEFs could be acquiring a 
multipotent state, from which they could give rise to most of the cell types of mesodermal germ 
lineages 
44,45
.  
2.2 Hypothesis and specific aims 
In view of the multipotential capacity acquired by MEFs when embedded in the self-assembling 
peptide RAD16-I, this chapter aims to study the possible mechanisms that modulate the 
spontaneous multipotent commitment of these cells. We hypothesized that early organizer genes 
may be involved in the initial steps of the chondrogenic process and their expression could be 
regulated by the mechanical properties of the scaffold matrix. In addition, it was hypothesized 
that the scaffold RAD16-I could support the chondrogenic differentiation of other cell types. 
Therefore, the aims for this chapter are the following: 
(1) To evaluate the influence of matrix properties in the spontaneous chondrogenic 
differentiation that MEFs suffer in the self-assembling peptide RAD16-I. 
(2) To analyze the isolated adipogenic differentiation also observed in the 3D cultures of 
MEFs. 
(3) To characterize the molecular mechanisms regulating the multipotent commitment of 
MEFs in the self-assembling peptide RAD16-I. 
(4) To evaluate the self-assembling peptide RAD16-I as a support scaffold for 
chondrogenic differentiation using dedifferentiated bovine chondrocytes.  
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2.3 Materials and Methods 
2.3.1 Culture of mouse embryonic fibroblasts (MEFs) 
MEFs isolated from C57BL=6 embryos at day 14 were purchased from the American Type 
Culture Collection (scrc-1008; ATCC). The use of these cells has been approved by the Ramon 
Llull University Ethics Committee (CER URL 2013-001). MEFs (<10th passage) were cultured 
in 25 and 75-cm2 flasks in fibroblast medium (FM), which contains high-glucose Dulbecco’s 
modified Eagle medium (DMEM; D5671, Sigma) supplemented with 15% (v/v) Fetal Bovine 
Serum (FBS) (DE14-801F, Lot: 1SB003, Lonza), 100 U/mL Penicillin / 0.1 mg/mL 
Streptomycin (P11-010, PAA), 2mM L-Glutamine (M11-004, PAA), 1mM Sodium Piruvate 
(11360-039, Gibco) and 100µM Minimum Essential Medium Non-essential Amino Acid 
solution (M7145, Sigma). Cultures were maintained in the incubator in humidified atmosphere 
at 37ºC and 5% CO2.  
2.3.2 Chondrocyte isolation 
Saddle sections (7-14 kg) of 1-2 week old calves were obtained from a local abattoir (Arena, 
Hopkinton, MA) directly after slaughter. The intact femoropatellar joint was isolated by 
transecting the femur and mounting the distal segment in a drilling apparatus. The 
femoropatellar articular cartilage was then exposed by opening the joint capsule, severing the 
medial, lateral, and cruciate ligaments, and removing the tibia, patella, and surrounding tissue. 
During this entire process, the cartilage was kept moist and free of blood by frequent rinsing 
with sterile PBS supplemented with antibiotics (100 U/ml penicillin and 0.1 mg/ml 
streptomycin). Full-thickness cartilage pieces were shaved off using a sterile surgical blade. 
Care was taken not to include the underlying subchondral bone. Chondrocytes were isolated 
from whole cartilage using sequential digestions of 0.4% (w/v) pronase (P6911,Sigma) for 1 
hour at 37ºC, and 0.08% (w/v) collagenase (C5894, Sigma) overnight at 37ºC. After digestions, 
cell solution was filtered using 70µm cell strainer, centrifuged for 8 min at 1900g and 
resuspended in sterile PBS. Total cell number was determined using a hemocytometer and 
viability was assessed using Trypan Blue (T8154, Sigma). Cultures were maintained in FM in 
the incubator at 37ºC and 5% CO2. 
2.3.3 Cell harvesting and subculture from tissue culture flasks 
Tissue culture flasks were washed with 1mL Trypsin-EDTA (0.05% Trypsin, 0.02% EDTA, 
L11-004, PAA) and treated again with 2mL or 4mL Trypsin–EDTA (for T25 and T75 flasks, 
respectively) for 5 minutes at 37°C, or until cells started to detach from the flask. Trypsin’s 
activity was inhibited adding serum containing medium, then cells were disrupted mechanically 
with a micropipette until single cells were obtained as observed using phase microscopy. 
Released cells were washed with complete culture medium, counted, resuspended as needed and 
then seeded in other plaque or used for cell encapsulation in hydrogels. 
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2.3.4 3D culture technique using the self-assembling peptide RAD16-I 
To obtain a 3D culture, a solution of commercial 1% (w/v) RAD16-I (PuraMatrix™,354250, 
Beckton Dickinson) was diluted in sucrose 10% (w/v) (S1888, Sigma), to obtain a concentration 
of 0.5 % or 0.14% (w/v) (depending on the final concentration wanted). This solution was 
mixed with an equal volume of a cell suspension (4 x 10
6
 cells/mL) in sucrose 10% (w/v), to 
obtain a final concentration of 2 x 10
6
 cells/mL in 0.25% or 0.07% (w/v), respectively, of 
RAD16-I in sucrose 10% (w/v). 80µL of this mix was loaded into 9mm diameter cell culture 
inserts (PICM01250, Millipore), previously placed into a 6-well culture plate and equilibrated 
with culture media. Immediately, cell-peptide cultures were placed for 30 minutes in the 
incubator at 37°C and 5% CO2, to allow the formation of the hydrogel by the action of the high 
ionic strength and the neutral pH of the medium. Elapsed this time, when working at low 
peptide concentrations (0.07% (w/v)) and to dilute the content of sucrose, subsequent washing 
steps were performed by aspiration of the culture media in the well (outside of the insert), and 
the addition of the same amount (500µL) of fresh medium (Figure 2.3.1). The plate was placed 
again in the incubator for 10 minutes and this step was repeated 3 times, after which 2.5mL of 
fresh medium were added outside the insert and the plate placed in the incubator for 30 more 
minutes, to finally allow the construct to form, preventing its rupture. At this point, the addition 
of medium over the cell culture began, by adding 10µL in the inner wall of the insert letting it 
slowly slide to the gel, until a volume of 40µL is reached. The plate was placed once again in 
the incubator for 15 minutes and then the addition of fresh medium over the cell construct 
continued, by addition of 20µL inside the insert, until a final volume of 200µL. Instead, when 
working at higher peptide concentrations (0.25% (w/v)), washing steps were performed by 
adding 60 µL directly on top of the hydrogel (Figure 2.3.1). Lastly, after the 10 minutes 
washing steps, 250 µL of medium were loaded inside the insert and 2.5mL in the well outside 
the insert. In both cases, the 3D cell cultures were maintained in the incubator at 37°C and 5% 
CO2, for 5, 14 or 28 days. The medium was changed every second day by removing 500µL of 
medium from the well and the addition of 500µL of fresh medium inside the insert. 
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Figure 2.3.1. Schematic process of the 3D encapsulation protocol in RAD16-I 
 
2.3.5 3D culture technique using collagen type I 
Cells were harvested and re-suspended in PBS (H15-002, PAA), to obtain a final concentration 
of 4 x 10
6
 cells/mL. Aside, a solution of Phenol Red was prepared, mixing 1µL of phenol red 
(P0290, Sigma) with 99µL of PBS 10X. This solution was added to a determined volume of 
Collagen Type I (from rat tail, initial concentration: 3.81mg/mL, 354236, Lot: 2152614, BD) in 
PBS, to obtain a final concentration of 0.28% (w/v) Collagen Type I in 1ml of 1X PBS. The 
solution was stored on ice, to prevent the gelation of the Collagen. The volume was adjusted to 
1mL with tissue culture water (521-012, PAA) and the pH was raised to 8-9 by adding NaOH 
1M (tissue culture grade, S2770, Sigma), until change in the color of the pH indicator solution 
from yellow to pink, checked with pH test paper. Equal volumes of cell  suspension and 
Collagen type I solution were mixed  to obtain a suspension of 2 x 10
6
 cells/mL in 0.14% 
Collagen type I in PBS. 80µL of this suspension were loaded in wells of a 48-well culture plate 
(PAA30024X, PAA), previously coated with agarose 10 mg/mL (A9045-5G, Sigma). The 
culture plate was placed for 30 minutes in the incubator at 37°C and 5% CO2, to induce the 
gelation of the construct, which takes place by changes in the pH and temperature. After this 
time, 0.7mL of FM were carefully added to the well. The culture was maintained for 5, 14 or 28 
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days, at 37°C and 5% CO2, and the medium was changed every second day by removing 0.5mL 
of medium and the addition of 0.5mL of fresh medium (Figure 2.3.2). 
 
Figure 2.3.2 Schematic process of the 3D encapsulation protocol in collagen type I 
2.3.6 Cell lysis from 3D cultures 
After the specific cultivation time has elapsed, 3D cultures were lysed with a specific buffer 
depending on the subsequent analysis. For protein extraction, a solution of RIPA buffer (R0278, 
Sigma), with protease inhibitor cocktail (11836153001, Roche) was used. In the case of RNA 
extraction, RNA lysis buffer (12-TRK-02, PeqLab) was used. In both cases, the medium was 
carefully removed from the insert and the well, and the cell culture was washed twice with PBS. 
A volume of 250µL of lysis buffer was added, and the complete lysis of the construct was 
reached by pipetting up and down the cells several times. The samples obtained were stored at   
-80°C until their posterior analysis. 
2.3.7 Reverse transcriptase polymerase chain reaction 
The RNA was extracted from the samples using peqGOLD total RNA kit (12-6834-02, 
PeqLab). After the removal of the genomic DNA, cDNA was synthesized using QuantiTect 
Reverse Transcription kit (205311, Qiagen). The cDNA obtained was analyzed by RT-PCR 
using, using either Deep Vent DNA Polymerase (M0258S, New England Biolabs) or Taq DNA 
Polymerase master mix (D1806, Sigma) and primers designed for each gene of interest (Table 
2.3.1). In both cases, 50ng of cDNA sample were used for the analysis, dNTPs at a final 
concentration of 200µM and primers at a final concentration of 0.3µM. The amplification 
reaction was performed according the following parameters: Stage 1: 5 min at 95°C, Stage 2: 40 
cycles of 30s at 95°C, 15s at Tm (depending on the primers used) and 20s at 72°, Stage 3: 1 min 
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at 72°C. DNA fragments were visualized under UV light in a 2% (w/v) agarose gel to estimate 
their size, which allows the identification of the aforementioned fragments. 
Table 2.3.1. Designed primers used for RT-PCR 
Gene F/R Sequence (5’ - 3’) Length 
18S 
F GCTACCACATCCAAGGAAGGCAG 
234bp 
R CGCTCCCAAGATCCAACTACGAG 
BMP4 
F TGATACCTGAGACCGGGAAG 
190bp 
R AGCCGGTAAAGATCCCTCAT 
Coll I 
F TGACTGGAAGAGCGGAGAGT 
151bp 
R GTTCGGGCTGATGTACCAGT 
Coll X 
F CAAGCCAGGCTATGGAAGTC 
154bp 
R AGCTGGGCCAATATCTCCTT 
Noggin 
F GCAAGAAGCTGAGGAGGAAGTTACAGA 
184bp 
R TGCACAGACTTGGATGGCTTACACA 
PPAR 
F AGGCCGAGAAGGAGAAGCTGTTG 
276bp 
R TGGCCACCTCTTTGCTCTGCTC 
Runx2 
F GCCGGGAATGATGAGAACTA 
180bp 
R GGACCGTCCACTGTCACTTT 
Sox9 
F AAACTTCTGTGGGAGCGACA 
155bp 
R TCAGCTGCCGGCTCTAAAC 
 
2.3.8 Agarose gel for DNA visualization 
DNA amplified fragments were run in a 2%(w/v) agarose gel used to estimate their size. To 
prepare the gel, 1g or 3g agarose (depending on the gel size) (A9539, Sigma) were dissolved in 
50mL or 150mL TAE buffer 1X (from a stock solution TAE 50X: 252g Tris-Base, 57,1mL 
AcOH glacial, 100mL 18,5g solid EDTA and deionized H2O up to 1L), by heating until 
complete dissolution. Then, 4µL or 12µL of EtBr (10µg/mL) were added to the agarose 
solution. 16µL of the DNA sample were mixed with 4µL loading buffer 5X (G2526, Sigma), 
and these 20µL were loaded into the agarose gel-wells. DNA ladder was also run to estimate 
DNA fragments size (10821705001or 11062590001, Roche). The gel was run at 90V or 150V 
during 1h. Finally, the gel was observed using a UV lamp. 
2.3.9 Real-time reverse transcriptase polymerase chain reaction (qPCR) 
Real-time reverse transcriptase polymerase chain reactions were performed in SYBR green PCR 
master mix (204141, Qiagen). Commercial primers were used for mouse expression analysis of: 
18S (QT01036875, Qiagen), Sox9 (QT00163765), Aggrecan (QT00175364, Qiagen), Perlecan 
(QT01534141, Quiagen), Syndecan (QT01751029, Quiagen) and Versican (QT00143220, 
Qiagen). Designed primers used for mouse and bovine expression analysis are listed in Table 
2.3.2. The real-time polymerase chain reaction was carried out under the following conditions: 2 
min at 50 ºC, 10 min at 95ºC followed by 45 cycles of 15 s at 94ºC, 30 s at 60º C and 30 s at 72 
ºC. Finally it was performed a melting step from 62 to 95 ºC to obtain the melting curve.  
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Relative gene fold variations were all determined according to the 2
-ΔΔCt
 method using the 
ribosomal unit 18S as a housekeeping gene.  
Table 2.3.2. Primers for bovine analysis 
Gene Molecular Weight Catalog # 
18S 
F TCGAGGCCCTGTAATTGGAA 
R GCTATTGGAGCTGGAATTACCG 
Aggrecan 
F CCTGAACGACAAGACCATCGA 
R TGGCAAAGAAGTTGTCAGGCT 
Coll I 
F AATTCCAAGGCCAAGAAGCATG 
R GGTAGCCATTTCCTTGGTGGTT 
Coll II 
F AAGAAGGCTCTGCTCATCCAGG 
R TAGTCTTGCCCCACTTACCGGT 
Sox9 
F TGGAGACTGCTGAACGAGAG 
R GTACTTGTAGTCCGGGTGGTC 
Versican 
F AGCTGCATGCCGCCTATG 
R ATCCGTAGGTCCGGACTCCTT 
 
2.3.10 Western Blot (WB) 
After the lysis of the samples with buffer for protein extraction, a quantification step was 
performed to determine total protein content using BCA Protein Assay kit (23225, Pierce). 
Acrylamide gels were prepared according to the size of the proteins, generally in concentrations 
of 7 or 12% (w/v). Cell lysates (5µg of each sample) were mixed with protein loading buffer 
containing 5% (v/v) β-mercaptoethanol, and this mix was heated at 95°C for 10 minutes. 
Samples and protein ladder (161-0374, Bio Rad) were run applying 150V during 1h in 
electrophoresis buffer (30g Tris-base (154563, Sigma), 144g Glycine (0167, Amresco) and 10g 
SDS (L5750, Sigma) in 1L H2O). After the run, proteins were transferred to a PVDF membrane 
(LC 2005, Invitrogen) applying 40V during 2h at RT using transfer buffer (3.03g Tris-base, 36g 
Glycine, 200mL Methanol and H2O up to 1L). Then, the membrane was incubated at RT for 2h 
in blocking buffer (4% (w/v) non-fat powered milk in PBST). Membranes were incubated for 
1h at RT with primary antibodies at a final concentration of 1µg/mL in PBST (Table 2.3.3). 
Then a secondary antibody IgG-HRP was added at a concentration of 1µg/mL, and incubated at 
RT for 1h (Table 2.3.4). Finally, the membrane was revealed for HRP detection (34080, Pierce). 
Chemiluminescent images were taken in the ImageQuant
TM 
LAS 4000 mini (GE HealthCare). 
Images were analyzed with ImageQuant
TM
 Image Analysis Software 7.0.  Actin was used as an 
internal protein standard. 
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Table 2.3.3. Primary Antibodies used for Western Blot 
Primary Antibodies Molecular Weight Catalog # Lot Brand 
Actin 43kDa sc-1615 K0612 Santa Cruz 
BMP4 
50kDa (precursor) 
23kDa (mature) 
sc-6896 B1412 Santa Cruz 
Collagen 1A1 
140-210kDa (prec) 
70-90kDa (mature) 
sc-8784 B1211 Santa Cruz 
Collagen 2A1 190kDa sc-7764 F2912 Santa Cruz 
Collagen 10A1 66kDa sc-323750 K1011 Santa Cruz 
Foxa2 52kDa sc-6554  Santa Cruz 
Noggin 55kDa sc-25656 B2409 Santa Cruz 
Runx2 55kDa sc-10758 D1411 Santa Cruz 
Sox9 65kDa sc-17340 K0411 Santa Cruz 
 
Table 2.3.4. HRP-Labeled Secondary Antibodies used for Western Blot 
Secondary Antibodies Catalog # Lot Brand 
Donkey anti-Goat sc-2020 F1212 Santa Cruz 
Donkey anti-Rabbit sc-2317 F2212 Santa Cruz 
 
2.3.11 Glycoproteins separation using lectins 
For each protein sample, 10 µl of saline solution of lectins conjugated to agarose beads (L1394, 
Sigma) were centrifuged for 30 seconds at 1,000g to pellet. Then, the supernatant was discarded 
and replaced by binding buffer (Tris-HCl 20mM). After that, 10 µg of each protein sample were 
incubated with the lectins at room temperature and agitation for 3 hours. Samples were 
centrifuged and the supernatant was discarded. Then samples were resuspended in protein 
charge buffer and boiled for 10 minutes before loading in the polyacrylamide gels. 
2.3.12 Immunofluorescence 
Cell constructs were washed with PBS and then fixed with paraformaldehyde (PFA) 1% (w/v) 
for 1h at RT. Samples were incubated for 2 hours in blocking buffer (BB) (20% (v/v) FBS, 
0.1% (v/v) Triton x-100 solution and 1% (v/v) DMSO in PBS, filtered through 0.45µm filter). 
The primary antibody anti-BMP4 (sc-6896, SCBT) was prepared in BB at 1µg/mL, added to the 
cell construct and incubated for 1.5 hours. Subsequently, samples were washed 3 times with BB 
for 30 minutes and a final wash overnight at 4°C. Secondary antibody (A21084, Invitrogen) was 
prepared in BB at 1µg/mL, was added to the sample and incubated for 1.5 hours in dark 
chamber. Samples were washed 3 times with BB for 30 minutes and a final wash overnight at 
4°C. Finally, samples were counterstained with DAPI to determine the location of nuclei and 
analyzed under fluorescence microscope (Zeiss Axiovert 200M inverted microscope with 
coupled ApoTome system). 
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2.3.13 Cell viability 
The live/dead staining was performed to qualitatively determine proportion of live and dead 
cells. Cell cultures were washed 3 times with PBS and then covered with a solution 2µM of 
EthD-1 and Calcein AM in PBS (L3224, Invitrogen). After 15 minutes of incubation at RT in 
dark chamber, the solution was removed and samples were washed 3 times with PBS, after 
which they were analyzed under fluorescence microscope (Zeiss Axiovert 200M inverted 
microscope with coupled ApoTome system). 
2.3.14 sGAG quantification 
DMMB (1,9-dimethyl-dimethylene blue) assay for sGAG quantification  
Samples were digested overnight at 60ºC with a solution of 250 ng/ml Proteinase K (03115887 
001, Roche).  DMMB working solution which was composed of 0.16% (w/v) DMMB (341088, 
Sigma), 0.24% (w/v) NaCl, 0.30% (w/v) Glycine and 10 mM HCl was prepared. Standards for 
chondroitin-6-sulfate from shark cartilage (27043, Sigma) with concentrations between 0 and 
100 μg/ml were also prepared to get the calibration curve. In a 96-well plate, 20 μl of standards 
and sample supernatants, obtained as previously described, were incubated with 200 μl of 
DMMB working solution. Absorbance was read at 520 nm in a spectrophotometer. The 
calibration curve was used to calculate the amount of chondroitin-6-sulfate in each sample, and 
results were normalized by the total amount of DNA obtained with Hoescht dye for each sample 
as described below.  
Hoescht assay for DNA quantification  
Hoescht working solution was prepared from the dilution 1:1000 of a 10 mg/ml Hoescht 
(861405, Sigma) stock solution with TNE buffer (50 mM Tris–HCl (pH 7.4), 100 mM NaCl 
and 0.1 mM EDTA). Standards for DNA with concentrations between 0 and 10 ng/ml were 
prepared to get the calibration curve. In a fluorescence 96-well plate, 20 μl of standards and 
sample supernatants were incubated with 20 μl of Hoescht working solution. Samples were 
excited at 352 nm and the emission was read at 461 nm in a fluorimeter (VICTOR, Perkin 
Elmer). The obtained calibration curve was used to calculate the amount of DNA in each 
sample. 
2.3.15 Toluidine Blue staining 
Toluidine blue staining was performed to detect GAGs in the 3D cultures. Samples were 
washed with PBS and fixed with 2% (w/v) PFA (P6148, Sigma) in PBS for 1 hour at RT. Fixed 
samples were incubated with 0.05% (w/v) Toluidine Blue (T3260, Sigma) in water during 20 
minutes and then washed several times with distilled water. Finally the samples were analyzed 
under a stereoscopic microscope (Nikon SMZ660). 
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2.3.16 Nile Red 
Nile red staining was performed in order to detect intracellular lipid droplets. Cell cultures were 
washed with PBS, fixed with PFA 2% (w/v) for 2h. Then, samples were covered with a solution 
of 0.01% (w/v)  Nile Red  (72485, Sigma) in Dimethyl Sulfoxide (DMSO) (D5879, Sigma), and 
incubated for 5 minutes at RT in dark chamber. The solution was removed and the culture 
washed 3 times with PBS to finally observe the sample under fluorescence microscope (Zeiss 
Axiovert 200M inverted microscope with coupled ApoTome system). 
2.3.17 DAPI-Phallodin staining 
This staining allows the observation of the cell nuclei and cytoskeletons, thanks to the selective 
binding of the 4’,6-Diamidino-2-phenylindole (DAPI) to the minor groove of double stranded 
DNA, and of phalloidin–tetramethylrhodamine B isothiocyanate to the F-actin of the 
cytoskeleton of cells. Cell cultures were fixed with 2%(w/v) PFA for 1h at RT, and then washed 
3 times with PBS. After this, and to permeabilize the cell membrane, the cultures were 
incubated for 30 minutes in Triton x-100 0.1% (v/v) (X100, Sigma). Then, cell cultures were 
incubated in a dark chamber with 0.1% (w/v) Phalloidin (P1951, Sigma) for 25 minutes. After 
this, phalloidine solution was removed and 1µg/mL DAPI solution (D9542, Sigma) was added 
and samples were incubated for 5 minutes. Cultures were washed 3 times with PBS and then 
observed under fluorescence microscope (Zeiss Axiovert 200M inverted microscope with 
coupled ApoTome system). 
2.3.18 Embryoid Bodies (EBs) preparation 
Mouse Embryonic Stem Cells (mESCs) were cultured in 75-cm2 cell culture flasks, previously 
coated with 0.1% gelatin (G9391, Sigma), in Mouse Embryonic Stem Cells medium (ESCM). 
ESCM contained high-glucose Dulbecco’s modified Eagle medium (DMEM; D5671, Sigma) 
supplemented with 15% (v/v) Fetal Bovine Serum (FBS) (DE14-801F, Lot: 1SB003, Lonza), 
100 U/mL Penicillin / 0.1 mg/mL Streptomycin (P11-010, PAA), 4mM L-Glutamine (M11-004, 
PAA), 1mM Sodium Piruvate (11360-039, Gibco), 100µM Minimum Essential Medium Non-
essential Amino Acid solution (M7145, Sigma), 1500 U/ml Leukemia Inhibitory Factor (LIF) 
(ESG1106,Millipore), 100µM β-mercaptoethanol (M3148, Sigma) and 1% nucleosides (ES-
008-D, Millipore). Once expanded the cells, embryoid bodies formation was performed. Briefly, 
a suspension of mESC in ESCM without LIF and β-mercaptoethanol at final concentration of 
100.000 cells/ml was cultured in non-adherent dishes. Cultures were maintained in the incubator 
at 37ºC and 5% CO2.  Samples were taken at various time points for their analysis by PCR and 
WB. 
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2.3.19 Brachyury In situ hybridization 
MEF cultures in RAD16-I were fixed at days 7, 11 and 15. In situ hybridization was performed 
whole mount and onto 14 µm slices of the tissue-like cell mass obtained after culturing. Slices 
were obtained by cryosectioning of the cell-mass with Leica CM 3050 S cryostat using OCT 
compound (Tissue-tek®, VWR) as freezing support. The DNA probe used for the in situ 
hybridization was synthesized with the PCR DIG Probe synthesis kit (11636090910, Roche) 
using primers kindly provided by D.  Shaywitz (Forward: CATGTACTCTTTCTTGCTGG; 
Reverse: GGTCTCGGGAAAGCAGTGGC). The in situ hybridization was performed 
following the company’s instructions for embryos and for tissue sections. After hybridization of 
the DIG labeled probe, samples were immunostained for digoxigenin using anti-DIG sheep 
antibody (11333089001, Roche) and anti-sheep HRP-conjugated antibody (sc2473, SCBT). 
Reaction with DAB substrate (1718906, Roche) showed the localization of Brachyury mRNA. 
2.3.20 Mechanical characterization 
MEFs constructs were fixed with 2% (w/v) PFA during 1 hour. A compression assay with DMA 
Multi-Frequency-Strain mode and a frequency sweep test was applied to each sample with a 
DMA Q800 (TA Instruments). The conditions of the assay were: Amplitude= 1µm, Preload 
force= 0.001 N and Frequency= 1 Hz. Construct diameter and thickness were measured for each 
sample. Results were obtained with TA Instrument Explorer software and analyzed with TA 
Universal analysis software.  
2.3.21 Statistics 
All values were expressed as mean ± SD. Statistical differences were analyzed with GraphPad 
Prism 6 when samples were prepared in triplicate for the condition analyzed. When comparing 
two groups, unpaired student’s t test was used to test for the significance level. When comparing 
three or more groups statistical analysis was carried out by 1‐way or 2‐way ANOVA, as 
appropriate, followed by Tukey post analysis. 
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2.4 Results  
2.4.1 Influence of matrix properties in the spontaneous differentiation that MEFs 
suffer into cartilage-like tissue in the self-assembling peptide RAD16-I 
Previous results from our group indicate that when primary mouse embryonic fibroblasts 
(MEFs) were cultured in vitro in the self-assembling peptide scaffold RAD16-I using the three-
dimensional (3D) culture system, they acquired multipotential capacity engaging into a 
spontaneous process of chondrogenic differentiation 
44
. In this work, we studied in more detail 
the aforementioned process by evaluating the influence of matrix properties (including stiffness 
and instruction) on the spontaneous chondrogenic differentiation.  
Aiming to study the influence of mechanical properties, cultures of MEFs were prepared using 
0.07% (w/v) RAD16-I which corresponded to low matrix storage modulus (G’ around 0.1kPa) 
and 0.25% (w/v) RAD16-I which corresponded to higher values (G’ around 5 kPa) as it was 
obtained in the dynamic mechanical analysis (DMA) of the gels  (Figure 2.4.1, A). Both types 
of cultures were maintained for 5, 14 and 28 days and analyzed for protein and gene expression 
of specific chondrogenic markers. Samples were prepared in triplicate for each condition and 
day of culture analyzed.  
 
Figure 2.4.1. DMA analysis of RAD16-I and MEFs 3D cultures. DMA was used for the analysis of 
the: (A) Self-assembling peptide at different concentrations, G’ was calculated as function of the peptide 
concentration (C, in w/v percentage)  and (B) MEFs cultured for 28 days in 0.07 and 0.25% (w/v) 
RAD16-I. (Statistical differences are indicated as ** for p<0.01, Unpaired t-student, n=3) 
First of all, it was observed that when MEFs were cultured at low peptide concentration (low G’ 
values) the system underwent morphological changes caused mainly by a complex dynamical 
behavior including cell migration, proliferation and cell-cell network formation that ended, after 
a few days, with the formation of a highly contracted 3D-construct (Figure 2.4.2, A). This 
reduction of the construct size caused an increase in the G’ as it was observed in the DMA 
analysis of the samples, from initial values at 0.07% (w/v) RAD16-I of 0.1 kPa to final values 
after 28 days of culture of around 3 kPa (30 fold increase) (Figure 2.4.1, B). Contrariwise, when 
MEFs were cultured at high peptide concentration (high matrix G’ values) cells could not 
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migrate nor form cell network nor contract the construct (Figure 2.4.2, B). In this case, the 
initial G’ value of 0.25% (w/v) RAD16-I of around 5kPa slightly increased to 6 kPa after 28 
days (1.2 fold increase) (Figure 2.4.1, B). 
 
Figure 2.4.2..MEFs cultured in self-assembling peptide scaffold RAD16-I at two peptide 
concentrations. Evolution of the 3D constructs on time represented by phase contrast and DAPI-
Phalloidine images at 1, 5 and 14 days of culture when MEFs were cultured in (A) 0.07% RAD16-I 
which corresponded to G’ values around 0.1 kPa and (B) in 0.25% RAD16-I which corresponded to G’ 
values around 5 kPa. 
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As expected, cell behavior radically changed depending on the initial peptide concentration 
(0.07 to 0.25% (w/v) RAD16-I or in other words, matrix storage modulus (G’) values between 
0.1 to 5 kPa. For instance, it was observed that the capacity of the cells to migrate and create 
cellular network was highly dependent on the initial G’ value of the construct. Interestingly, the 
formation of the cellular network was associated with the process of a global 3D-construct 
contraction, which promoted the increase of several basic parameters including cell density, 
cell-cell contact and matrix mechanical properties. 
Then, Live-Dead staining was performed to qualitatively determine the proportion of living and 
dead cells in the construct at both peptide concentrations. Even though some dead cells were 
observed, the number of living cells was much higher in both cases, which suggested that 
peptide concentration was not interfering in cell viability (Figure 2.4.3). 
 
Figure 2.4.3. Live and Dead staining of MEFs cultured in RAD16-I. Cultures of MEFs were prepared 
in RAD16-I at (A) 0.07% and (B) 0.25%(w/v) RAD16-I and stained after 14 days of culture. In both 
cases  most of the cells stained green ‐alive‐ and only few nuclei stained red –dead. 
After that, the influence of matrix mechanical properties on the spontaneous chondrogenic 
differentiation was evaluated. Initially, the expression of Collagen type II (Coll II), one of the 
main components of the extracellular matrix of chondrocytes, and Collagen type I (Coll I), 
characteristic of MEFs extracellular matrix, was evaluated by western blot (WB) (Figure 2.4.4, 
A) 
8
. Band quantification was performed using the software of the chemiluminescence 
equipment and the obtained values were first normalized to actin and then to 2D cultures used 
as control (Figure 2.4.4, B, C). Interestingly, when MEFs were cultured at low peptide 
concentration (0.07% (w/v) RAD16-I) Coll II was up-regulated over the time. However, Coll I 
was constantly expressed during the course of the experiment. Instead, at high peptide 
concentration (0.25% (w/v) RAD16-I) the trend of the expression of both collagens changed 
radically compared to low peptide concentration. 
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Figure 2.4.4. Expression of chondrogenic markers depending on mechanical properties. (A)WB 
results of chondrogenic markers when MEFs were cultured at two peptide concentrations for 5, 14 and 28 
days. Actin was used as internal control. Samples were prepared in triplicate. (B) Band areas 
quantification from (A) normalized by Actin and relative to 2D of Collagen type I and (C) Collagen type 
II. (Statistical differences are indicated as:** for p<0.01, and *** for p<0.001, Two-way ANOVA, n=3). 
These results could be better analyzed and interpreted after plotting the ratio Coll II/Coll I.  The 
ratio increased over the time at low peptide concentration whereas it was very low and constant 
at high peptide concentration (Figure 2.4.5).   
 
Figure 2.4.5. Ratio Collagen type II / Collagen type I. MEFs were cultured at two peptide 
concentrations for 5, 14 and 28 days and the Ratio Coll II/Coll I was calculated from western blot band 
areas normalized by Actin. (Statistical differences are indicated as:* for p<0.05, ** for p<0.01, and *** 
for p<0.001, Two-way ANOVA, n=3). 
 Chapter 2: Cartilage tissue engineering using RAD16-I 
 
45 
 
Moreover, the transcription factor Sox9, which is required for the expression of Collagen II was 
also analyzed by WB 
8,46
. As it was expected, its expression was higher in 3D-cultures at low 
peptide concentration than in stiffer ones which correlated with the results obtained for Coll II 
(Figure 2.4.4). 
In addition, the synthesis of proteoglycans (PGs) by the cells was analyzed qualitatively with 
Toluidine Blue staining of the constructs. This dye forms complexes with anionic 
glycoconjugates such as PGs 
47
. Samples cultured at low peptide concentration that up-regulated  
the chondrogenic markers Sox9 and Coll II presented a stronger staining than the samples at 
high peptide concentration (Figure 2.4.6). These results clearly indicated that the initial 
mechanical properties of the system directly affected the chondrogenic differentiation of our 
system. Coincidently, our results agreed with the recently published studies where MSCs 
differentiate to chondrogenic lineage in two types of compliant scaffolds with similar 
mechanical properties as described in this work 
25,32
.  
 
Figure 2.4.6 Toluidine blue staining. MEFs cultured in (A) 0.07% and (B) 0.25% RAD16-I for 28 days. 
As a control, MEFs cultured in the commercial natural matrix Collagen type I were also stained 
with toluidine blue. Although they presented the similar cell behavior observed above for low 
peptide concentration cultures in RAD16-I (cell migration, dense cellular network formation 
and contracted structure), they stained negatively (Figure 2.4.7, A, B, C). It is important to 
mention that most of the cells were alive as observed in the live and dead staining (Figure 2.4.7, 
D).Since Collagen type I is the natural component of the skin it could indicate that this material 
is instructive in guiding MEFs into dermal lineages, preventing them from spontaneously 
undergo chondrogenesis. It is important to mention that although cell density strongly increased 
in both materials, it is not enough to drive the system towards a chondrogenic phenotype. This 
corroborates the hypothesis that only when MEFs were cultured in the self-assembling peptide 
scaffold RAD16-I (non-instructive scaffold) cells engaged in a default chondrogenic 
differentiation process, probably due by the presence of a special cell microenvironment. 
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Figure 2.4.7 MEFs cultured in collagen type I scaffold. . (A,B)Development of celular network was 
observed after 1 day of culture by DAPI-Phalloidine staining.(C) Toluidine Blue staining after 30 days of 
culture showed a negative staining for sGAG, RAD16-I culture of MEFs was used as control. (D) Live 
and Dead after 28 days of culture showed the viability of the cells, almost of cells were alive (green 
staining).  
Then, a quantitative characterization of PGs was performed with MEFs cultured in 3D at low 
peptide concentration due to the results obtained above for Sox9, Coll II and Toluidine 
Blue.  Samples were cultured for 5, 10, 20, 25 and 30 days and analyzed using real time PCR 
for the expression of different proteoglycans (Aggrecan, Versican, Syndecan and Perlecan) and 
the transcription factor Sox9 
48
. It was found that the gene expression of Aggrecan and Versican 
was up-regulated from day 5 of culture onwards in the 3D scaffold. In contrast, Syndecan and 
Perlecan, which are characteristic of embryonic cartilage formation, were not expressed in the 
same conditions. Moreover, Sox9 was up-regulated in the 3D cultures during the 30 days of 
culture as it was previously observed by WB (Figure 2.4.8, A). These results confirmed the 
presence of PGs as previously observed with Toluidine Blue staining. Furthermore, 1,9-
dimethyl-dimethylene blue (DMMB) was used to quantify the synthesis of PGs.  The technique 
is based on the ability of sGAG (mainly chondroitin-6-sulfate) to bind the cationic dye DMMB. 
Results obtained using this method were normalized with the total amount of DNA of each 
sample which was quantified using Hoechst 33258 
49
. As it can be observed, the total amount of 
sulfated GAGs was higher when MEFs were cultured in the peptide scaffold than in 2D cultures 
(Figure 2.4.8, B). 
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Figure 2.4.8 .  sGAG quantification in MEFs cultured at low peptide concentration. (A) qPCR of 
Aggrecan, Versican and Sox9 when MEFs were cultured in 0.07% (w/v) RAD16-I scaffolds for 5, 10, 20, 
25 and 30 days.  Relative gene fold variations were all determined according to the 2
-ΔΔCt
 method using 
the ribosomal unit 18S as a housekeeping gene. (B) sGAG quantification using DMMB of MEFs in 2D 
cultures and MEFs cultured for 30 days in 0.07% (w/v) RAD16-I scaffold. 
Finally, the influence of oxygen diffusion was evaluated in the described spontaneous 
chondrogenic differentiation. As previously mentioned, cartilage is an avascular tissue and as a 
consequence, oxygen concentration (ranging from 1 to 7%) is lower than in other vascularized 
tissues (below 20%). It has been widely described that oxygen diffusion plays an important role 
in chondrogenic differentiation using stem cells, where hypoxic conditions induced earlier 
differentiation as compared to the regular normoxic conditions 
50–52
. Taking this into account, 
the influence of oxygen concentration was evaluated in the spontaneous chondrogenic 
differentiation observed in our system. The experiment designed to study this effect consisted of 
preparing samples of different volumes and same cell densities, and as a consequence, different 
oxygen requirements, which probably resulted in different oxygen concentrations (due to the 
mass transfer phenomena). Samples were fixed after 21 days of 3D culture and stained with 
toluidine blue to detect the presence of GAGs. 
Interestingly, sample size had an important role in the chondrogenic differentiation: only the 
control samples with initial volumes of 80 μl (final diameters   1,6 mm) stained positive for 
toluidine blue. Small samples with initial volumes of 20 and 40 μl (with final diameters   0.5 
and 1.0 mm), did not stain positive for toluidine blue (Figure 2.4.9). These results suggested that 
sample size and as a consequence, oxygen concentration played an important role in the 
observed spontaneous chondrogenic differentiation of MEFs in the self-assembling peptide. 
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Figure 2.4.9. Influence of contruct dimensions in chondrogenic commitment. Toluidine Blue staining 
of MEFs samples with different initial volumes, (A) 80, (B) 40 and (C) 20 µl after 21 days of culture. 
Samples of 80 µl (regular volume) stained strongly positive as compared to the smaller volumes. 
 
2.4.2 Analysis of the isolated adipogenic differentiation of MEFs in RAD16-I  
As it was reported by Quintana et al., MEFs cultured in RAD16-I not only engaged 
spontaneously to chondrogenesis but also some cells acquired adipogenic phenotype. In order to 
better understand the spontaneous adipogenic differentiation of this few cells, we proceeded to 
study in more detail this associated process.  
For this purpose, samples were prepared at the same peptide concentrations studied before (0.07 
and 0.25% (w/v) RAD16-I) and analyzed for the expression of the adipogenic regulator PPARγ 
53,54
. Interestingly, it was found that PPARγ was expressed in 2D cultures and the expression 
was maintained in the 3D cultures over the course of the experiment in both peptide 
concentrations (Figure 2.4.10). These results evidenced the adipogenic potential of these cells in 
the 2D cultures, which is maintained in the 3D constructs as well. 
 
Figure 2.4.10. Expression of the adipogenic marker PPARγ by MEFs analyzed by RT-PCR. 
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Hence, the adipogenic differentiation was confirmed by staining with Nile Red, where some 
lipid droplets were observed occasionally at both peptide concentrations but was notable that the 
amount of these droplets was higher at 0.07% (w/v) RAD6-I (Figure 2.4.11).  
 
Figure 2.4.11. Nile Red staining of MEFs cultured in in 0.07 and 0.25% (w/v) RAD16-I for 28 days. 
MEFs cultured in (A) 0.07%(w/v) and (B) 0.25%(w/v) RAD16-I. 
Then, the influence of the composition of the medium on the adipogenic differentiation was 
evaluated . For this purpose, cultures were prepared using the previously mentioned peptide 
concentrations (0.07% and 0.25% (w/v) RAD16-I) and cultures were maintained in culture 
media composed of MEM-Alpha Modification instead of DMEM, and supplemented with 2nM 
PDFG. The mitogenic activity of PDGF and the presence of nucleosides in the culture media 
promoted cell division and higher cell densities were obtained 
55,56
. Surprisingly, the adipogenic 
commitment of these cells radically changed in the new culture conditions with much higher 
formation of lipid droplets in the cultures at low peptide concentrations (Figure 2.4.12, A,B) 
than at high ones. This is in agreement with the higher expression of PPARγ at low peptide 
concentration values (see Figure 2.4.10). 
We speculate that, as observed in the chondrogenic differentiation, an intimate cell interaction is 
required to develop a tight cellular network that contracts the matrix and to start molecular 
events that end with differentiation processes. Although some adipogenic phenotype was 
observed using regular culture conditions, the differentiation was restricted to isolated cells as 
compared to the global spontaneous chondrogenic differentiation described in the previous 
section (2.4.1). However, the expression of the adipogenic regulator PPARγ in the 2D control 
cultures confirmed their adipogenic potential, which was evident when the culture media was 
supplemented with PDFG and as a consequence higher cell densities were obtained and a global 
adipogenic differentiation was observed. In addition, MEFs were cultured within the scaffold 
collage type I in order to study the influence of matrix instruction in the adipogenic 
commitment. Interestingly, MEFs did not commit to adipogenic lineage when cultured in 
collagen I (Figure 2.4.12, D). As observed in the previous section (2.4.1), this material is very 
instructive and could be guiding MEFs into dermal lineages, preventing them from 
spontaneously undergo adipogenesis. 
Chapter 2: Cartilage tissue engineering using RAD16-I 
50 
 
 
Figure 2.4.12. Influece of media composition and matrix instruction in lipid droplets formation. 
Nile red staining of MEFs cultured in (A, B) 0.07%(w/v) RAD16-I and (C) 0.25%(w/v) RAD16-I and 
maintained in culture media supplemented with PDGF for 28 days. (A) Represents the central part of the 
sample and (B) the edge of the sample were lipid droplets formation was exacerbated. (D) Nile red 
staining performed in MEFs cultured in collagen type I for 28 days and maintained in media 
supplemented with PDGF. 
Remarkably, the analysis of the 2D cultures using both culture media revealed an increased 
formation of lipid droplets only in cultures supplemented with PDGF (Figure 2.4.13). Even 
though some studies report the differentiation of fibroblasts into adipogenic lineage using 
classical induction media, none of them used PDGF for the induction 
34,38,57
. Taking this into 
account, this is the first description of adipogenic differentiation from MEFs with the addition 
of PDGF in 2D cultures, which is enhanced only under certain 3D culture conditions. 
 
Figure 2.4.13. Nile Red staining 2D cultures. (A) MEFs cultured in regular FM media for 7 passages. 
(B) MEFs cultured in media supplemented with PFGD for 7 passages. 
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2.4.3 Characterization of the molecular mechanisms regulating the 
multipotential commitment of MEFs in RAD16-I 
Preparation of EBs as positive controls for genes involved in early tissue organization 
First of all, embryoid bodies (EBs) were prepared as positive controls for the genes that would 
be studied. ESCs were cultured onto non adherent dishes with embryonic media without 
Leukemia Inhibitory Factor (LIF) and then they aggregated forming EBs 
58
, which can 
differentiate into any type of cells and recapitulate some of the aspects of early embryogenesis 
59
. Taking this into account, EBs were used as benchmark for the expression of genes involved 
in early cell differentiation (Figure 2.4.14). 
 
Figure 2.4.14. Embryoid Bodies formation. Evolution of embryoid bodies formation with the time of 
culture. Phase contrast image after (A)1 day, (B) 4 days and (C) 7 days of culture. (Scale bar: 100µm) 
The expression of genes involved in early tissue organization was studied with PCR and WB 
(Figure 2.4.15). Moreover, in each WB or PCR performed, lysates of EBs were used as positive 
control to assure that the observed band was the correct. 
 
Figure 2.4.15. Expression of early organizer genes by EBs. EBs were prepared and cultured for 1,2,3,4 
and 5 days. (A) Noggin expression quantified by qPCR. (B) Foxa2 expression qualitatively studied by 
RT-PCR and WB. 
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Noggin and BMP4 
In order to better understand the possible molecular mechanisms involved in the default 
cartilaginous commitment acquired by MEFs in the self-assembling peptide cultures, the 
expression of genes involved in the early events that take place in the chondrogenic process, 
such as Noggin and BMP4, was studied (8, 22). Cultures were prepared at 0.07 and 0.25 % 
(w/v) RAD16-I, maintained for 5, 14 and 28 days and analyzed for protein and gene expression. 
Remarkably, in the experimental system used in this work, both molecules were found in 2D 
cultures indicating the potentiality of these cells to differentiate into chondrogenic-like lineages. 
However, BMP4 expression was only maintained in 3D cultures at low peptide concentration 
and as a consequence low matrix G’ values ( 0.1 kPa) which correlated with the up-regulation 
of chondrogenic markers observed in section 2.4.1 (Figure 2.4.16).  
 
Figure 2.4.16.  Noggin and BMP4 expression by MEFs in 0.07 and 0.25% (w/v) RAD16-I scaffold.  
(A) RT-PCR from samples cultured for 5, 14 and 28 days. (B) WB from samples cultured for 5, 14 and 28 
days. 
Then, Noggin expression was quantified by qPCR and it was found that at day 5 of culture, its 
expression was higher in cultures at low peptide concentrations than at high ones. This finding 
was in concordance with the results obtained with regular RT-PCR (Figure 2.4.17). 
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Figure 2.4.17.  Noggin qPCR results when MEFs were cultured in 0.07% and 0.25% (w/v) RAD16-I 
for 5 and 10 days.  (Statistical differences are indicated as *** for p<0.001, Two-way ANOVA, n=3) 
It is important to mention, that due to the nature of BMP4 and Noggin, which are factors 
secreted in very low quantities, it was difficult to obtain clear WB results as compared to the 
results obtained with RT-PCR. In addition, the antibody anti-Noggin exhibited an unspecific 
binding to other proteins in the EBs lysates used as positive control and complicated the 
recognition of the correct WB band. Hence, taking into account that Noggin is a glycosylated 
protein and that lectins are capable to bind glycoproteins even in presence of various detergents, 
samples were treated with lectins conjugated to agarose beads in order to isolate them from the 
protein lysate (Figure 2.4.18, A, B). After that, samples were analyzed by WB with the purpose 
to elucidate the correct band.  Remarkably, the results obtained when EB samples were treated 
with the lectins showed a unique band at 53 kDa as compared to the many bands obtained with 
the same sample without treatment (Figure 2.4.18, C).  This test allowed us to identify the 
correct band for Noggin in the analysis of the MEFs 3D cultures lysates by WB. 
. 
Figure 2.4.18. EBs lysate treated with lectins for detection of Noggin by western blot.  (A,B) 
Schematic representation of glycoprotein purification using lectins in which is described (A) the 
adsorption to the lectin, (B) the washing and elution from the resin. (C) WB results of a lysate of EBs 
tretated with lectins (Lectin), and without treatment (EB_d2). 
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Surprisingly, when cultures were prepared using peptide concentrations lower than 0.07% (w/v) 
(0.05, 0.06% (w/v) RAD16-I) which corresponded to G’ values lower than 0.1 kPa, cells 
presented rounded shape, developed weak cellular network and the aforementioned expression 
of Noggin and BMP4 was not observed (Figure 2.4.19). 
 
Figure 2.4.19. Noggin and BMP4 expression when MEFs were cultured at peptide concentrations 
lower than 0.07% (w/v). (A) WB results after 1 and 5 days of culture in RAD16-I. (B) Phase contrast 
image of the rounded cell morphology and cell network developed at 0.05% (w/v) and (C) the elongated 
cell morphology and denser cell network developed at 0.07% (w/v) RAD16-I. 
In accordance to these results, the expression of BMP4 was confirmed by immunofluorescence 
staining only in cells cultured under confluent conditions in 2D. For this purpose, 2D cultures of 
MEFs were prepared at low cell seeding density (5.000 cells/cm
2
)
 
and regular cell seeding 
density (30.000 cells/cm
2
), and immunostained after 2 days of culture (Figure 2.4.20). The 
expression of BMP4 was clearly observed only in cultures at regular seeding density and as a 
consequence increased cell-cell contacts. 
 
 
 
Figure 2.4.20. BMP4 immunofluorescence of MEFs cultured in 2D cultures. (A) High cell seeding 
density (30.000 cells/cm
2
) and (B) Low cell seeding density (5.000 cells/cm
2
).Arrows indicate BMP4 
expression. 
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Then, immunofluorescence staining of 3D cultures showed clear localization of BMP4 only in 
cultures at low peptide concentrations (0.07% (w/v) RAD16-I), where it was previously 
described the formation of a tight cell-cell network, as compared to higher peptide 
concentrations (0.25% (w/v) RAD16-I) which stained negative (Figure 2.4.21).   
 
Figure 2.4.21 BMP4 immunofluorescence of MEFs cultured in 2D- and 3D-system. BMP4 protein 
was immunostained with an antibody anti-BMP4 developed with a secondary antibody Alexafluor680-
congugated (yellow). Nuclei were stained with DAPI (blue). (A) MEFs cultured in 2D-sytem. (B) 3x 
close up of the dashed area from (A). (C) MEFs cultured at 0.07% (w/v) RAD16-I scaffold for 10 days. 
(D) 3x close up of the dashed area from (C). (E) MEFs cultured at 0.25% (w/v) RAD16-I scaffolds for 10 
days. (F) 3x close up of the dashed area from (E). 
Altogether, these results suggested that BMP4 was expressed only when cell-cell contact was 
present (confluent 2D cultures and low peptide concentration 3D-cultures). Thus, we speculate 
that intimate cell interaction is needed in order to up-regulate the expression of this 
chondrogenic inductor.  
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Organizers: Foxa2 and goosecoid 
In view of the results obtained with Noggin and BMP4, it was speculated that the system may 
be up-regulating the expression of other organizers such as Foxa2 and goosecoid.  
Foxa2 or Hepatic Nuclear Factor 3-β (HNF-3β) presents a dual role during embryogenesis, first 
as an organizer and then as an endodermal marker. Moreover, it has been recently found that its 
expression is induced during chondrogenesis and it is necessary for chondrocyte hypertrophy 
7,23
. In the other hand, goosecoid is the first organizer gene isolated from the Spemann organizer 
in Xenopus and its expression has been detected in a wide variety of vertebrates. Both goosecoid 
and Foxa2 are coexpressed in several regions of the early mouse embryo, suggesting the 
possibility of functional interactions between the two genes. Later in embryogenesis the patterns 
of the two genes become distinct and goosecoid and HNF-3β show complementary in the 
mesoderm and the endoderm respectively 
22
. 
The expression of both organizers was analyzed by RT-PCR after 5 and 10 days of culture in 
0.07% (w/v) RAD16-I. Interestingly, transcription factor Foxa2 was up-regulated only in cells 
cultured with media supplemented with PDGF. Instead, when cultures were maintained in 
regular FM its expression was not detected neither in the 2D nor 3D cultures (Figure 2.4.22). 
These results suggest that Foxa2 is not taking part in the regulation of the spontaneous 
chondrogenic differentiation process described in section 2.4.1 since PDFG was not added to 
the culture media. However, when the medium was supplemented with PDGF, its expression 
was observed in both 2D and 3D cultured of MEFs which correlates with the increase in the 
formation of lipid droplets observed in section 2.4.2. This relation between Foxa2 and 
adipogenesis is not described in the literature and as a consequence the role of the transcription 
factor is not clear in our system. 
 
Figure 2.4.22.  Foxa2 gene expression in MEFs. RT-PCR of MEFs cultured in 0.07%RAD16-I for 5 
and 10 days. Cultures were maintained in regular FM (-PDGF) and culture media supplemented with 
PDFG. Embryoid bodies of 5 days were used as positive control.  
Instead, the expression of goosecoid was not detected independently of the days of culture or 
the culture media used. These results suggested that the regulation of chondrogenesis in our 
system is not regulated by part of the organizers genes. Thus, Noggin and BMP4 may be acting 
as chondrogenic regulators and not as organizers. 
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Mesodermal marker: Brachyury  
To provide more insight into the possible patterned chondrogenesis, the expression of 
brachyury, one of the first mesodermal-specific transcription factors that are expressed in the 
early mesoderm, was also studied.  Interestingly, in situ hybridization with a Brachyury probe 
showed that after seven days of culture, cells residing in the external layer of the 3D culture 
expressed the transcription factor. Then, the surface staining migrated inwards the structure 
during the next days (11 days. We speculate that cells originally labeled at the surface moved 
inwards leaving the surface with unlabeled cells (Figure 2.4.23). After the process (15 days), the 
structure ended with a surface layer negative for Brachyury and an internal mass of cells 
positively stained for Brachyury   
 
Figure 2.4.23 Brachyury in situ hybridization of mouse embryonic fibroblasts (MEF) 3D structures 
of different culture times. At seven days, positive staining is detected at the surface of the structure in 
(Panels a-c). At 11 days, positive stained cells are localized in a most internal position of the structure, 
suggesting that they have migrated inward, leaving behind negative cells at the surface (Panels d-g). 
Finally, at 15 days of culture, all positive stained cells are localized internally (Panels h-l). Black asterisks 
indicate the closing up regions. Black arrows indicate cells stained positive for brachyury. 
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These results are in concordance with the findings that Brachyury is required not only for 
patterning but also contributing to the determination of the chondrogenic lineage since forced 
expression of Brachyury in MSCs is sufficient to initiate chondrogenic development bot in vitro 
and in vivo 
60
.  
iPSCs transcription factors 
Finally, in view of the results obtained for the spontaneous processes of chondrogenic and 
adipogenic differentiation, it was speculated that MEFs were undergoing early stage 
reprogramming in the self-assembling peptide RAD16-I. As it was described by Yamanaka, 
pluripotent stem cells can be directly generated from fibroblast cultures by the addition of only a 
few defined factors: c-Myc, Klf4, Oct3/4 and Sox2 
43
. We wondered whether MEFs in the 3D 
culture system in the self-assembling peptide expressed these factors. For this purpose, cultures 
were prepared at 0.07% (w/v) RAD16-I and samples were taken at different times of culture and 
analyzed for the expression of the four transcription factors to show at which specific 
multipotent state the cells were when cultured in 3D compared to designed iPSCs. 
As it was described by Yamanaka, RT-PCR results showed a basal expression of c-Myc and 
Kfl4 in the 2D cultures of MEFs 
43
. Interestingly, only the expression of c-Myc was maintained 
in 3D cultures. A weak expression of Klf4 was observed after 5 days of 3D culture but it was 
totally down-regulated over the time. However, the expression of the two factors, Oct3/4 and 
Sox2, mainly involved in maintenance of pluripotency was not detected (Figure 2.4.24, A). 
Then, qPCR was used to analyze the expression of the transcription factors during the first 48 
hours of culture in the self-assembling peptide. Interestingly, the down-regulation of Kfl4 was 
observed from the first 6 hours in the 3D culture onwards (Figure 2.4.24, B). 
 
Figure 2.4.24. Expression of transcription factors characteristics of iPSCs. (A) RT-PCR of MEFs 
cultured for 5,14 and 28 days in 0.07% RAD16-I, MEFs 2D were used as control. (B) qPCR of Kfl4 and 
c-Myc of MEFs cultured in 0.07% RAD16-I for hours, samples were taken every 6 hours.  Relative gene 
fold variations were all determined according to the 2
-ΔΔCt
 method using the ribosomal unit 18S as a 
housekeeping gene.  
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2.4.4 Evaluation of the self-assembling peptide RAD16-I as a support scaffold for 
chondrogenic differentiation using dedifferentiated bovine chondrocytes.  
Although chondrocytes should be the first choice when using cells for cartilage tissue 
engineering, their main drawback is the limited cell number obtained. As it was described in 
Chapter 1, expansion in cell monolayer causes their dedifferentiation, which is characterized by 
decreased production of cartilage specific ECM (mainly proteoglycans (PGs) and collagen type 
II) 
61
. As chondrocytes attach to a flat surface, they spread and acquire fibroblast-like 
morphologies, which is accompanied by an increase in proliferation and an altered phenotype 
62
. 
There are different ways to overcome this issue and slow the dedifferentiation: supplement 
culture media with growth factors 
63,64
 , vary cell seeding density or hypoxic conditions 
65,66
.  
Remarkably, other studies reported the redifferentiation of dedifferentiated articular 
chondrocytes using high density 3D cultures in a variety of materials such as agarose 
67
, alginate 
beads 
68–70
, fibrin glue 
71
 or compressing cells into pellets 
72,73
. 
According to what has been previously observed, MEFs spontaneously commit to chondrogenic 
lineage when cultured in the self-assembling peptide RAD16-I under certain mechanical 
conditions; together with the limited expansion of chondrocytes in vitro due to the loss of 
chondrogenic and acquirement of fibroblastic phenotype, it was hypothesized that the culture of 
dedifferentiated chondrocytes in the peptidic matrix could favor their redifferentiation to a 
chondrogenic phenotype. 
For this purpose, fresh chondrocytes were extracted from femoral plates of 2 weeks old calves 
as described in Materials and Methods section 2.3.2 
74
.  Then, chondrocytes were expanded and 
dedifferentiated using low density seeding of 8.000 cells/cm
2
 for 5 passages as previously 
described 
75
.  In order to assess their dedifferentiation, cultures were analyzed after each passage 
using qPCR for the expression of the chondrogenic markers: Aggregan, Versican, Sox9 and 
Collagen type I and II. As expected, down-regulation of the proteoglycans Aggrecan and 
Versican was observed over the course of the experiment (Figure 2.4.25, A). Moreover, the 
expression of collagen types I and II, and Sox9 was also down-regulated, which evidenced the 
dedifferentiation of the chondrocytes during the in vitro expansion (Figure 2.4.25, B).  
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Figure 2.4.25. Chondrocytes dediffentiation during expansion in 2D. qPCR was performed to quantify 
the expression of chondrogenic markers by chondrocytes after each passage in vitro. (A) Proteoglycans 
quantification (Aggrecan and Versican), (B) collagen type I and II and Sox9. Relative gene fold variations 
were all determined according to the 2
-ΔΔCt
 method using the ribosomal unit 18S as a housekeeping gene. 
Results were relative to chondrocytes after passage 1 (P1). 
Once dedifferentiation was reached, cells were encapsulated in the self-assembling peptide 
RAD16-I following the 3D culture technique previously performed with MEFs at a final peptide 
concentration of 0.10% (w/v). First of all, similar behavior to MEFs cultured at low peptide 
concentration was observed in terms of cell migration, cell network development and matrix 
contraction (Figure 2.4.26).  
 
Figure 2.4.26. Dedifferentiated chondrocytes behavior in RAD16-I 3D cultures. Phase contrast image 
after (A) 5 days and (B) 30 days of culture. (Scale bar = 1mm) 
Then, samples were cultured for 5, 10, 20, 25 and 30 days and analyzed using real time PCR for 
the expression of proteoglycans (Aggrecan and Versican), the transcription factor Sox9 and 
collagens type I and II 
48
. Remarkably, a recovery in the expression of all the genes analyzed 
was found in 3D compared to control 2D cultures (cells harvested just before the encapsulation 
in the peptidic matrix) (Figure 2.4.27). However, if we look at the expression of collagen type I, 
characteristic of fibroblastic phenotype, a marked up-regulation was observed reaching levels of 
expression higher than collagen type II, characteristic of chondrogenic phenotype. It is 
important to mention that 3D cultures were maintained in FM, and as a consequence without 
chondrogenic inductors. Therefore, the expression of chondrogenic markers seemed to recover 
and it was only influenced by the 3D culture environment as it was previously observed with 
MEFs.  
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Figure 2.4.27. Chondrocytes redifferentiation.  qPCR was performed to quantify the expression of 
chondrogenic markers by chondrocytes after each passage in vitro. (A) Proteoglycans quantification 
(Aggrecan and Versican), (B) collagen type I and II and Sox9. Relative gene fold variations were all 
determined according to the 2
-ΔΔCt
 method using the ribosomal unit 18S as a housekeeping gene. Results 
were relative to chondrocytes before encapsulation in RAD16-I (P5). 
Finally, PGs synthesis was analyzed qualitatively by Toluidine Blue staining which showed the 
presence of proteoglycans after 30 days of culture in the peptidic matrix (Figure 2.4.28, A). 
However, the staining was weaker than MEFs in section 2.4.1. Then, PGs synthesis was 
analyzed quantitatively using DMMB and the obtained results were normalized with the total 
amount of DNA. Interestingly, a clear increase in the synthesis of proteoglycans was observed 
after 30 days of culture in the RAD16-I compared to control 2D cultures before the 
encapsulation in the peptidic matrix (Figure 2.4.28, B). These results corroborated the previous 
analysis of PGs expression obtained by qPCR. 
 
Figure 2.4.28.  sGAG characterization after 30 days of culture in RAD16-I. (A) Toluidine Blue 
staining. Scale bar= 1mm; (B) sGAG quantification using DMMB of dedifferentiated chondrocytes in 2D 
cultures before encapsulation in RAD16-I and after 30 days of culture in RAD16-I. 
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2.5 Discussion 
In view of the multipotential capacity that MEFs acquired when embedded in the self-
assembling peptide RAD16-I 
44
; the possible mechanisms that modulate the spontaneous 
multipotent commitment of these cells were studied. Our main hypothesis was that early 
organizer genes may be involved in the initial steps of the chondrogenic process and their 
expression could be regulated by the mechanical properties of the scaffold matrix. Thus, our 
initial assays were focused on evaluating the influence of matrix properties in the spontaneous 
chondrogenic differentiation that MEFs suffered in the self-assembling peptide RAD16-I. 
Nowadays, an increasingly number of studies demonstrate that cell morphology and function 
strongly depend on substrate mechanical properties 
25,27–29,32,33
. Hence, the results presented in 
this chapter suggested that the spontaneous chondrogenic-like differentiation that MEFs 
suffered when cultured in RAD16-I peptide scaffold was influenced by matrix mechanical 
properties. Indeed, cells only created tight cell-cell networks and up-regulated the expression of 
the chondrogenic markers Coll II, Sox9 and PGs under certain mechanical conditions. 
Coincidently, our results agree with the recently published studies where MSCs differentiate 
toward the chondrongenic lineage in two types of compliant scaffolds with similar mechanical 
properties as described in this work 
25,32,33
. Then, it was observed that the instructive capacity of 
the material was also playing a crucial role in our system. Indeed, collagen type I cultures of 
MEFs stained negative for PGs. These results suggested that the biomechanical and non‐
instructive properties of the self‐assembling peptide environment might have a key role in the 
process 
44
.  Finally, the size of the construct (which affects directly biophysical parameters) was 
an interesting and unexpected key factor in the spontaneous chondrogenic differentiation. 
Certainly, this parameter could reduce the local oxygen pressure and as a consequence it would 
be necessary a threshold sample volume in order to engage in the differentiation process. These 
results are in concordance with published studies of chondrogenic differentiation using stem 
cells in which hypoxic conditions favored the differentiation to the chondrogenic lineage 
50,51,73,76
. Nevertheless, when the chondrogenic potential of human normal dermal fibroblasts 
(hNDFs) in RAD16-I was evaluated in our laboratory (data not presented in this work), the 
chondrogenic differentiation was only obtained by chemical induction 
77
. It is important to 
mention that hNDFs are adult cells and their differentiation potential is not necessarily the same 
than MEFs. However, that study provided proof of concept that hNDFs in self-assembling 
peptide RAD16-I gel have the potential to differentiate into the chondrogenic lineage under 
induction medium.  
Similar results were obtained when the isolated adipogenic differentiation was analyzed in the 
MEFs 3D-cultures. As observed in the chondrogenic differentiation, MEFs did not commit to 
the adipogenic lineage when cultured in collagen type I. Moreover, an intimate cell interaction 
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was required to develop a tight cellular network that contracted the matrix and to start molecular 
events that ended with differentiation processes.  
Afterwards, the molecular mechanisms regulating the multipotent commitment of MEFs in the 
self-assembling peptide RAD16-I were characterized. Interestingly, the balance between the 
chondrogenic inductor BMP4 and its antagonist Noggin played a critical role in the observed 
chondrogenic differentiation of MEFs cultured in RAD16-I. Thus, the chondrogenic inductor 
BMP4 was only expressed under mechanical conditions where the spontaneous chondrogenic 
differentiation was observed. At that point, its antagonist Noggin was also up-regulated. In a 
similar way, in vivo studies demonstrated that Noggin is expressed in condensing cartilage and 
immature chondrocytes, like many BMPs, having an important role in the regulation of 
chondrocyte proliferation and differentiation 
11–14
. As a consequence, these results suggest that 
the spontaneous chondrogenic fate of the system, which is feasible only under certain 
mechanical conditions, could be based on its capacity to self-modulate the expression pattern of 
molecules such as BMP, Noggin and other possible factors implicated in chondrogenesis. 
Regarding to the transcription factors characteristics of iPSCs, only the expression of c-Myc and 
Klf4 was detected in the 3D cultures. These results confirmed that MEFs cultured in the self-
assembling peptide were not reprogramming to a pluripotent stage. Besides, this is in agreement 
with previous results from our laboratory where MEFs combined with RAD16-I were implanted 
in mice and they had an excellent performance in terms of viability and local proliferation. 
Remarkably, they did not migrate out of the scaffold or form teratomas, which is one of the 
properties of pluripotent stem cells 
78
.  
Summarizing, MEFs in the self-assembling peptide RAD16-I did not acquire pluripotency but 
showed a potential mesodermal lineage commitment evidenced by the expression of early 
markers such as Brachyury, BMP4, Noggin or PPAR. As a consequence of this commitment, 
only under certain culture conditions, MEFs acquired the capacity to differentiate into 
chondrogenic and adipogenic lineages. 
Up to now, few studies reported the commitment and differentiation of MEFs into the 
mesenchymal lineage: differentiation into adipocytes 
57
, osteoblastic cells 
45
 or chondrogenic 
lineage 
79
. Interestingly, in all cases the addition of induction media was necessary to obtain the 
desired differentiation. Instead, chondrogenic and adipogenic differentiation of MEFs was 
observed in our system without the need of supplements in the culture media. These results 
suggested that culture conditions in the self-assembling peptide provided a unique environment 
in which MEFs could be acquiring a multipotent state, from which they could give rise to most 
of the cell types of mesodermal germ lineages 
44,45
. The multipotent commitment of these cells 
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could be explained with the recently published study of Saeed and coworkers 
41
. They reported 
that MEFs were not distinguishable from Bone Marrow Stem Cells (BMSCs) based on typical 
BMSCs CD surface marker expression. In addition, they confirmed that MEFs contain a 
subpopulation of stem cells that behave in ex vivo and in vivo assays similar but not identical to 
MSC derived from bone marrow 
41
. Thus, it is not clear whether the observed cell behavior is 
due to transdifferentiation of committed fibroblasts or to differentiation of resident stem cells.  
Finally, it was hypothesized that RAD16-I scaffold could support the chondrogenic 
differentiation of other cell types. In order to test this hypothesis, the use of the self-assembling 
peptide RAD16-I as a support scaffold for chondrogenic differentiation using dedifferentiated 
bovine chondrocytes was evaluated. As mentioned before, several studies reported the 
redifferentiation of dedifferentiated articular chondrocytes using high density 3D cultures in a 
variety of materials such as agarose 
67
, alginate beads 
68–70
, fibrin glue 
71
 or compressing cells 
into pellets 
72,73
. In our system, bovine dedifferentiated chondrocytes appeared to have a similar 
cellular behavior to MEFs embedded in the self-assembling peptide RAD16-I. Briefly, the 
material allowed the development of a tight cell network that culminated with the contraction of 
the structure in a few days. We hypothesized that these intimate cell-cell interactions reactivated 
the expression of molecular regulators that started the chondrogenic differentiation process as 
observed in MEFs. Interestingly, some recovery was observed in the expression of PGs by the 
dedifferentiated chondrocytes, which evidenced the potentiality of this scaffold for its use in 
cartilage tissue engineering applications. However, this recovery was not enough to acquire full 
chondrogenic properties as it was observed in the Collagen type I expression.  
Altogether, it was speculated that the combination of the self-assembling peptide RAD16-I with 
chondrogenic inductors could promote an enhanced redifferentiation of dedifferentiatied 
chondrocytes. Future avenues of research would include the dedifferentiation and 
redifferentiation of human chondrocytes. The way we envision a future clinical application of 
our technology would consist in obtaining small cartilage constructs which could be used as 
building blocks to fill the cartilage defect of the patient and bonded with another carrier 
scaffold. This strategy has the advantage that cartilage defect shape and size are not a drawback. 
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2.6 Concluding Remarks 
- MEFs cultured under certain biomechanical conditions (G’ around 0.1 kPa), were able 
to develop a rich interconnected cellular network which promoted increase of several 
basic parameters including cell density, cell-cell contact and matrix storage modulus. 
This process created a unique environment, which favored the system to engage in a 
spontaneous chondrogenesis differentiation evidenced by the expression of the 
chondrogenic markers Sox9, Coll II and proteoglycans. 
 
- MEFs developed an isolated spontaneous adipogenic differentiation in RAD16-I which 
was favored by the formation of a tight cell network. Interestingly, it was described for 
the first time the adipogenic differentiation of MEFs in 2D and 3D cultures by the 
addition of the growth factor PDGF to the culture media. 
 
- Matrix instruction played an important role in the multipotent commitment acquired by 
MEF in the self-assembling peptide RAD16-I since cultures in collagen type I did not 
engage neither in the spontaneous chondrogenic nor adipogenic differentiation.  
 
- The balance Noggin/BMP4 was found to play a critical role in the observed 
chondrogenic differentiation of MEFs cultured in RAD16-I. Remarkably, the 
chondrogenic inductor BMP4 was only expressed under mechanical conditions where 
the spontaneous chondrogenic differentiation was observed. 
 
- The observed spontaneous chondrogenic differentiation of MEFs in the self-assembling 
peptide together with the partial redifferentiation of dedifferenitiated bovine 
chondrocytes evidenced the potential of this scaffold for its use in cartilage tissue 
engineering applications. 
 
  
Chapter 2: Cartilage tissue engineering using RAD16-I 
66 
 
2.7 References 
1. Brittberg, M. & Lindahl, A. in Tissue Eng. (Blitterswijk, C. van et al.) 533–557 (Elsevier 
Inc., 2008). 
2. Vinatier, C., Mrugala, D., Jorgensen, C., Guicheux, J. & Noël, D. Cartilage engineering: 
a crucial combination of cells, biomaterials and biofactors. Trends Biotechnol. 27, 307–
14 (2009). 
3. Quintana, L., zur Nieden, N. I. & Semino, C. E. Morphogenetic and Regulatory 
Mechanisms During Developmental Chondrogenesis : Tissue Eng Part B 15, 29–41 
(2009). 
4. Hall, B. K. & Miyake, T. Divide, accumulate, differentiate: cell condensation in skeletal 
development revisited. Int. J. Dev. Biol. 39, 881–93 (1995). 
5. DeLise, a M., Fischer, L. & Tuan, R. S. Cellular interactions and signaling in cartilage 
development. Osteoarthritis Cartilage 8, 309–34 (2000). 
6. Heinegård, D. & Saxne, T. The role of the cartilage matrix in osteoarthritis. Nat. Rev. 
Rheumatol. 7, 50–6 (2011). 
7. Long, F. & Ornitz, D. M. Development of the endochondral skeleton. Cold Spring Harb. 
Perspect. Biol. 5, 1–20 (2013). 
8. Goldring, M. B., Tsuchimochi, K. & Ijiri, K. The control of chondrogenesis. J. Cell. 
Biochem. 97, 33–44 (2006). 
9. Anderson, R. M., Lawrence, A. R., Stottmann, R. W., Bachiller, D. & Klingensmith, J. 
Chordin and noggin promote organizing centers of forebrain development in the mouse. 
Development 129, 4975–87 (2002). 
10. Sasai, Y., Lu, B., Piccolo, S. & De Robertis, E. M. Endoderm induction by the 
organizer-secreted factors chordin and noggin in Xenopus animal caps. EMBO J 15, 
4547–55 (1996). 
11. Yoshimura, Y. et al. Colocalization of noggin and bone morphogenetic protein-4 during 
fracture healing. J Bone Min. Res 16, 876–84 (2001). 
12. Zehentner, B. K., Haussmann, A. & Burtscher, H. The bone morphogenetic protein 
antagonist Noggin is regulated by Sox9 during endochondral differentiation. Dev Growth 
Differ 44, 1–9 (2002). 
13. Brunet, L. J. Noggin, Cartilage Morphogenesis, and Joint Formation in the Mammalian 
Skeleton. Science (80-. ). 280, 1455–1457 (1998). 
14. Shum, L., Wang, X., Kane, A. a & Nuckolls, G. H. BMP4 promotes chondrocyte 
proliferation and hypertrophy in the endochondral cranial base. Int. J. Dev. Biol. 47, 
423–31 (2003). 
15. Pizette, S. & Niswander, L. BMPs are required at two steps of limb chondrogenesis: 
formation of prechondrogenic condensations and their differentiation into chondrocytes. 
Dev Biol. 219, 237–49 (2000). 
 Chapter 2: Cartilage tissue engineering using RAD16-I 
 
67 
 
16. Nifuji, A., Kellermann, O. & Noda, M. Noggin inhibits chondrogenic but not osteogenic 
differentiation in mesodermal stem cell line C1 and skeletal cells. Endocrinology 145, 
3434–42 (2004). 
17. Gong, Y. et al. Heterozygous mutations in the gene encoding noggin affect human joint 
morphogenesis. Nat. Genet. 21, 302–4 (1999). 
18. Marcelino, J. et al. Human disease-causing NOG missense mutations: effects on noggin 
secretion, dimer formation, and bone morphogenetic protein binding. Proc. Natl. Acad. 
Sci. U. S. A. 98, 11353–8 (2001). 
19. Cho, K. W. Y., Blumberg, B., Steinbeisser, H. & Robertis, E. M. De. Molecular Nature 
of Spemann’s Organizer: the Role of the Xenopus Homeobox Gene goosecoid. Cell 67, 
1111–1120 (1991). 
20. De Robertis, E. M. et al. Molecular mechanisms of cell-cell signaling by the Spemann-
Mangold organizer. Int. J. Dev. Biol. 45, 189–97 (2001). 
21. Krause, C., Guzman, A. & Knaus, P. Noggin. Int. J. Biochem. Cell Biol. 43, 478–81 
(2011). 
22. Filosa, S. et al. Goosecoid and HNF-3beta genetically interact to regulate neural tube 
patterning during mouse embryogenesis. Development 124, 2843–54 (1997). 
23. Ionescu, A. et al. FoxA family members are crucial regulators of the hypertrophic 
chondrocyte differentiation program. Dev. Cell 22, 927–39 (2012). 
24. Technau, U. & Scholz, C. B. Origin and evolution of endoderm and mesoderm. Int. J. 
Dev. Biol. 47, 531–9 (2003). 
25. Murphy, C. M., Matsiko, A., Haugh, M. G., Gleeson, J. P. & O’Brien, F. J. 
Mesenchymal stem cell fate is regulated by the composition and mechanical properties 
of collagen-glycosaminoglycan scaffolds. J Mech Behav Biomed Mater 11, 53–62 
(2012). 
26. Banerjee, A. et al. The influence of hydrogel modulus on the proliferation and 
differentiation of encapsulated neural stem cells. Biomaterials 30, 4695–9 (2009). 
27. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell 
lineage specification. Cell 126, 677–89 (2006). 
28. Discher, D. E., Janmey, P. & Wang, Y.-L. Tissue cells feel and respond to the stiffness 
of their substrate. Science 310, 1139–43 (2005). 
29. Evans, N. D. et al. Substrate stiffness affects early differentiation events in embryonic 
stem cells. Eur Cell Mater 18, 1–13; discussion 13–4 (2009). 
30. Park, J. S. et al. The Effect of Matrix Stiffness on the Differentiation of Mesenchymal 
Stem Cells in Response to TGF-β. Biomaterials 32, 3921–3930 (2011). 
31. Candiello, J., Singh, S. S., Task, K., Kumta, P. N. & Banerjee, I. Early differentiation 
patterning of mouse embryonic stem cells in response to variations in alginate substrate 
stiffness. J. Biol. Eng. 7, 9 (2013). 
Chapter 2: Cartilage tissue engineering using RAD16-I 
68 
 
32. Kwon, H. J. Chondrogenesis on sulfonate-coated hydrogels is regulated by their 
mechanical properties. J Mech Behav Biomed Mater 17, 337–46 (2013). 
33. Farrell, M. J., Comeau, E. S. & Mauck, R. L. Mesenchymal stem cells produce 
functional cartilage matrix in three-dimensional culture in regions of optimal nutrient 
supply. Eur Cell Mater 23, 425–40 (2012). 
34. Rakar, J., Lönnqvist, S., Sommar, P., Junker, J. & Kratz, G. Interpreted gene expression 
of human dermal fibroblasts after adipo-, chondro- and osteogenic phenotype shifts. 
Differentiation. 84, 305–13 (2012). 
35. Singh, M., Pierpoint, M., Mikos, A. G. & Kasper, F. K. Chondrogenic differentiation of 
neonatal human dermal fibroblasts encapsulated in alginate beads with hydrostatic 
compression under hypoxic conditions in the presence of bone morphogenetic protein-2. 
J. Biomed. Mater. Res. A 98, 412–24 (2011). 
36. Junker, J., Sommar, P., Skog, M., Johnson, H. & Kratz, G. Adipogenic, chondrogenic 
and osteogenic differentiation of clonally derived human dermal fibroblasts. Cells. 
Tissues. Organs 191, 105–118 (2010). 
37. Sommar, P. et al. Engineering three-dimensional cartilage- and bone-like tissues using 
human dermal fibroblasts and macroporous gelatine microcarriers. J. Plast. Reconstr. 
Aesthet. Surg. 63, 1036–46 (2010). 
38. Lorenz, K. et al. Multilineage differentiation potential of human dermal skin-derived 
fibroblasts. Exp. Dermatol. 17, 925–32 (2008). 
39. Shui, C. & Scutt, A. M. Mouse embryo-derived NIH3T3 fibroblasts adopt an osteoblast-
like phenotype when treated with 1alpha,25-dihydroxyvitamin D(3) and dexamethasone 
in vitro. J. Cell. Physiol. 193, 164–72 (2002). 
40. Chen, F. G. et al. Clonal analysis of nestin(-) vimentin(+) multipotent fibroblasts isolated 
from human dermis. J. Cell Sci. 120, 2875–83 (2007). 
41. Saeed, H., Taipaleenmäki, H., Aldahmash, A. M., Abdallah, B. M. & Kassem, M. Mouse 
embryonic fibroblasts (MEF) exhibit a similar but not identical phenotype to bone 
marrow stromal stem cells (BMSC). Stem Cell Rev. 8, 318–28 (2012). 
42. Thomson, J. a. Embryonic Stem Cell Lines Derived from Human Blastocysts. Science 
(80-. ). 282, 1145–1147 (1998). 
43. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–76 (2006). 
44. Quintana, L. et al. Early tissue patterning recreated by mouse embryonic fibroblasts in a 
three-dimensional environment. Tissue Eng Part A 15, 45–54 (2009). 
45. Garreta, E., Genové, E., Borrós, S. & Semino, C. E. Osteogenic Differentiation of Mouse 
Embryonic Stem Cells and Mouse Embryonic Fibroblasts in a Three-Dimensional. 
Tissue Eng Part A 12, 2215–2227 (2006). 
46. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R. & de Crombrugghe, B. Sox9 is required 
for cartilage formation. Nat. Genet. 22, 85–9 (1999). 
 Chapter 2: Cartilage tissue engineering using RAD16-I 
 
69 
 
47. Terry, D. E., Chopra, R. K., Ovenden, J. & Anastassiades, T. P. Differential Use of 
Alcian Blue and Toluidine Blue Dyes for the Quantification and Isolation of Anionic 
Glycoconjugates from Cell Cultures : Application to Proteoglycans and a High-
Molecular-Weight Glycoprotein Synthesized by Articular Chondrocytes. Anal Biochem 
285, 211–219 (2000). 
48. Knudson, C. B. & Knudson, W. Cartilage proteoglycans. Semin Cell Dev Biol. 12, 69–78 
(2001). 
49. Kopesky, P., Vanderploeg, E., Kurz, B. & Grodzinsky, A. J. Self-assembling peptide 
hydrogels modulate in vitro chondrogenesis of bovine bone marrow stromal cells. Tissue 
Eng Part A 16, (2009). 
50. Koay, E. J. & Athanasiou, K. a. Hypoxic chondrogenic differentiation of human 
embryonic stem cells enhances cartilage protein synthesis and biomechanical 
functionality. Osteoarthritis Cartilage 16, 1450–6 (2008). 
51. Merceron, C. et al. Differential effects of hypoxia on osteochondrogenic potential of 
human adipose-derived stem cells. Am J Physiol Cell Physiol 298, C355–64 (2010). 
52. Schipani, E. Hypoxia and HIF-1 alpha in chondrogenesis. Semin. Cell Dev. Biol. 16, 
539–46 (2005). 
53. Zur Nieden, N. I., Kempka, G., Rancourt, D. E. & Ahr, H.-J. Induction of chondro-, 
osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: effect 
of cofactors on differentiating lineages. BMC Dev. Biol. 5, 1 (2005). 
54. Kawai, M. & Rosen, C. J. PPARγ: a circadian transcription factor in adipogenesis and 
osteogenesis. Nat Rev Enocrinol. 6, 629–636 (2010). 
55. Caplan, A. I. & Correa, D. PDGF in bone formation and regeneration: new insights into 
a novel mechanism involving MSCs. J. Orthop. Res. 29, 1795–803 (2011). 
56. Graham, S. et al. Investigating the role of PDGF as a potential drug therapy in bone 
formation and fracture healing. Expert Opin. Investig. Drugs 18, 1633–54 (2009). 
57. Alexander, D. L., Ganem, L. G., Fernandez-Salguero, P., Gonzalez, F. & Jefcoate, C. R. 
Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of 
commitment to adipogenesis. J. Cell Sci. 111 ( Pt 2, 3311–22 (1998). 
58. Doetschman, T. C., Eistetter, H., Katz, M., Schmidt, W. & Kemler, R. The in vitro 
development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk 
sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 87, 27–45 (1985). 
59. Leahy, A., Xiong, J. W., Kuhnert, F. & Stuhlmann, H. Use of developmental marker 
genes to define temporal and spatial patterns of differentiation during embryoid body 
formation. J. Exp. Zool. 284, 67–81 (1999). 
60. Hoffmann, A. et al. The T-box transcription factor Brachyury mediates cartilage 
development in mesenchymal stem cell line C3H10T1/2. J. Cell Sci. 115, 769–81 
(2002). 
Chapter 2: Cartilage tissue engineering using RAD16-I 
70 
 
61. Chung, C. & Burdick, J. A. Engineering cartilage tissue. Adv. Drug Deliv. Rev. 60, 243–
62 (2008). 
62. Brodkin, K. R., García, a J. & Levenston, M. E. Chondrocyte phenotypes on different 
extracellular matrix monolayers. Biomaterials 25, 5929–38 (2004). 
63. Martin, I., Vunjak-Novakovic, G., Yang, J., Langer, R. & Freed, L. E. Mammalian 
chondrocytes expanded in the presence of fibroblast growth factor 2 maintain the ability 
to differentiate and regenerate three-dimensional cartilaginous tissue. Exp. Cell Res. 253, 
681–8 (1999). 
64. Mandl, E. W. et al. Fibroblast growth factor-2 in serum-free medium is a potent mitogen 
and reduces dedifferentiation of human ear chondrocytes in monolayer culture. Matrix 
Biol. 23, 231–41 (2004). 
65. Murphy, C. L., Thoms, B. L., Vaghjiani, R. J. & Lafont, J. E. Hypoxia. HIF-mediated 
articular chondrocyte function: prospects for cartilage repair. Arthritis Res. Ther. 11, 213 
(2009). 
66. Watt, F. M. Effect of seeding density on stability of the differentiated phenotype of pig 
articular chondrocytes in culture. J. Cell Sci. 89 ( Pt 3), 373–8 (1988). 
67. Buschmann, M. D., Gluzband, Y. a, Grodzinsky, a J., Kimura, J. H. & Hunziker, E. B. 
Chondrocytes in agarose culture synthesize a mechanically functional extracellular 
matrix. J. Orthop. Res. 10, 745–58 (1992). 
68. Homicz, M. R. et al. Human septal chondrocyte redifferentiation in alginate, 
polyglycolic acid scaffold, and monolayer culture. Laryngoscope 113, 25–32 (2003). 
69. Häuselmann, H. J. et al. Phenotypic stability of bovine articular chondrocytes after long-
term culture in alginate beads. J. Cell Sci. 107, 17–27 (1994). 
70. Bonaventure, J. et al. Reexpression of Cartilage-Specific Genes by Dedifferentiated 
Human Articular Chondrocytes Cultured in Alginate bEDS. Exp. Cell Res. 212, 97–104 
(1994). 
71. Perka, C., Spitzer, R. S., Lindenhayn, K., Sittinger, M. & Schultz, O. Matrix-mixed 
culture: new methodology for chondrocyte culture and preparation of cartilage 
transplants. J. Biomed. Mater. Res. 49, 305–11 (2000). 
72. Schulze-Tanzil, G. et al. Redifferentiation of dedifferentiated human chondrocytes in 
high-density cultures. Cell Tissue Res. 308, 371–9 (2002). 
73. Babur, B. K. et al. The interplay between chondrocyte redifferentiation pellet size and 
oxygen concentration. PLoS One 8, e58865 (2013). 
74. Sah, R. L. et al. Biosynthetic response of cartilage explants to dynamic compression. J. 
Orthop. Res. 7, 619–36 (1989). 
75. Gan, L. & Kandel, R. a. In Vitro Cartilage Tissue Formation by Co-culture of Primary 
and Passaged Chondrocytes. Tissue Eng. 13, 831–842 (2007). 
 Chapter 2: Cartilage tissue engineering using RAD16-I 
 
71 
 
76. Malladi, P., Xu, Y., Chiou, M., Giaccia, A. J. & Longaker, M. T. Effect of reduced 
oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal 
cells. Am. J. Physiol. Cell Physiol. 290, C1139–46 (2006). 
77. Bussmann, B. M. et al. Chondrogenic potential of human dermal fibroblasts in a 
contractile soft self-assembling peptide hydrogel. J Tissue Eng Regen Med (2013). 
78. Dégano, I. R. et al. The effect of self-assembling peptide nanofiber scaffolds on mouse 
embryonic fibroblast implantation and proliferation. Biomaterials 30, 1156–65 (2009). 
79. Lengner, C. J. et al. Primary mouse embryonic fibroblasts: a model of mesenchymal 
cartilage formation. J. Cell. Physiol. 200, 327–33 (2004).  
  
Chapter 2: Cartilage tissue engineering using RAD16-I 
72 
 
 
 
  
  Chapter 3: MEFs osteogenic differentiation 
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3:  Evaluation of the biologically induced osteogenic 
differentiation of MEFs in the self-assembling peptide RAD16-I 
 
 
  
Chapter 3: MEFs osteogenic differentiation 
 
74 
 
  
  Chapter 3: MEFs osteogenic differentiation 
 
75 
 
3.1 Introduction 
3.1.1 Overview 
Bone tissue is mainly composed by a natural composite of collagen type I and hydroxyapatite 
containing a highly vascularized network which plays a crucial role in supplying cells with 
oxygen and nutrients and removing waste products 
1
. Unlike other tissues, bones possess the 
capacity to regenerate, remodel and repair in response to injury. However, the supply of 
additional bone grafts is needed when the required bone regeneration exceeds the natural 
potential for self-healing, as in large bone defects occurring after trauma, infection, tumor 
resection or skeletal abnormalities 
2
. In the clinical setting, the gold standard to treat bone 
defects consists of the transplantation of autologous bone grafts, usually harvested from the iliac 
crest and fibular grafts. Nonetheless, some of the disadvantages are the limited availability of 
autologous material and donor-site morbidity 
2
. Allografts and xenografts are also available but 
their use is often associated with infection, disease transmission, and immunological rejection 
3
. 
Traditionally, bone tissue engineering strategies have been mainly focused on the development 
and application of three-dimensional porous scaffolds with similar composition to the bone. 
Delivery of cells and growth factors has been coupled in order favor the formation of new bone 
1,4–6
. However, challenges still remain in the inability to reproduce an engineered well 
vascularized bone that truly mimics natural bone blood vessels. Although tissue engineering of 
bone has been traditionally focused on direct (intramembranous) bone formation, nowadays the 
interest in endochondral bone formation is increasing since it is a more physiological approach 
which recreates most aspects of in vivo bone formation. These studies consist mainly on 
creating a cartilage template in vitro followed by its implantation in vivo where the template is 
vascularized and remodeled 
7
.  
3.1.2 Endochondral Ossification 
The osseous tissues in mammals develop through two distinct processes, intramembranous 
ossification and endochondral ossification. Intramembranous bone formation, which occurs in 
many of the craniofacial bones, involves direct differentiation of mesenchymal cells into the 
bone-forming osteoblasts, which deposit and mineralize the bone matrix. In contrast, 
endochondral ossification, which occurs in the remainder of the mammalian skeleton, generates 
bone via a cartilage intermediate 
8,9
. 
Endochondral bone development begins with the formation of a cartilage template (Figure 
3.1.1). Briefly, as it is detailed in Chapter 2 for chondrogenic differentiation, the first step is 
mesenchymal condensation after which cells in the core of the condensation differentiate into 
chondrocytes that secrete a cartilage matrix rich in collagen types II, IX, and XI, and specific 
proteoglycans such as aggrecan. Then, cells at the periphery of the condensation form the 
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perichondrium, which continues to express collagen type I and demarcates the developing 
skeletal element from the surrounding mesenchyme. All chondrocytes undergo rapid 
proliferation that drives the linear growth of the skeletal elements and form the model for the 
future bone. Then, the chondrocytes stop dividing and increase their volume dramatically, 
becoming hypertrophic chondrocytes. The orderly maturation of chondrocytes produces zones 
of proliferation, hypertrophy, and bone formation, linearly progressing from the articular ends 
(epiphysis) to the midshaft (diaphysis) of the skeletal element. The hypertrophic chondrocytes 
are characterized by the expression of type X collagen that enables the mineralization by 
calcium carbonate. Later, the terminal hypertrophic chondrocytes express additional molecular 
markers such as matrix metalloproteinase 13 (MMP13), which plays a critical role in cleaving 
the extracellular matrix proteins within the hypertrophic cartilage and thus facilitating vascular 
invasion. This invasion brings osteoprogenitors that differentiate into osteoblasts, which 
establish the primary ossification center to generate the trabecular bone 
10
. These osteoblast cells 
replace apoptotic chondrocytes and generate bone matrix and thus are the crucial cellular 
mediators of endochondral ossification 
11
. Moreover, vascularization leads to further 
degradation of the matrix by MMP9
12
. Only a small region at either end of the growing bone 
will remain cartilaginous. This structure, called the growth plate cartilage, will control 
longitudinal growth of the bone 
13
. 
 
Figure 3.1.1 Schematic diagram of endochondral ossification. (A, B) Mesenchymal cells condense and 
differentiate into chondrocytes to form the cartilaginous model of the bone. (C) Chondrocytes in the 
center of the shaft undergo hypertrophy and apoptosis while they change and mineralize their 
extracellular matrix. Their deaths allow blood vessels to enter. (D, E) Blood vessels bring in osteoblasts, 
which bind to the degenerating cartilaginous matrix and deposit bone matrix. (F-H) Bone formation and 
growth consist of ordered arrays of proliferating, hypertrophic, and mineralizing chondrocytes. Secondary 
ossification centers also form as blood vessels enter near the tips of the bone. (Image from Developmental 
Biology 6th Edition. Gilbert SF) 
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The orderly progression from proliferating chondrocytes to bone formation is subjected to 
regulation by key extracellular signals and nuclear factors. Among them, hormones such as 
growth hormone (GH), insulin-like growth factors (IGFs), thyroid hormone, androgen, estrogen 
and glucocorticoids tightly regulate longitudinal bone growth. Moreover, locally produced 
factors such as bone morphogenetic proteins (BMPs), fibroblast growth Factors (FGFs), TGFβ, 
Wnts, Ihh, parathyroid hormone-related peptide and retinoids are known to influence the 
process (Figure 3.1.2). Lastly, a number of nuclear factors have also been shown to regulate 
chondrocyte hypertrophy such as Sox9 and Runx2 
9,13–16.. 
 
Figure 3.1.2. Overview of the effects of factors secreted by chondrocytes on growth plate cell 
function and invasion. Under the control of circulating hormones, chondrocytes secrete growth factors 
that act on chondrocytes to regulate their proliferation and hypertrophy (upper two panels), and on cells of 
the ossification front (lower panel), to regulate their invasion of the growth plate cartilage. Arrows 
indicate stimulatory pathways, and crossed lines indicate inhibitory pathways. (Image from Mackie et al 
2008 
14
) 
 
3.1.3 Role of endothelial cells in the endochondral ossification process  
As detailed in the previous section, endochondral bone formation is characterized by the blood 
vascular invasion into previously avascular cartilage. At early stages of differentiation, since 
cartilage is an avascular tissue, it strongly produces anti-angiogenic factors such as transforming 
growth factor beta (TGF-β1), chondrocyte inhibitor of angiogenesis (hCHIAMP), TIMP-1, 
TIMP-2, and Chondromodulin-I (ChM-I) 
11
. However, hypertrophic chondrocytes in mature 
cartilage rapidly suffer an angiogenic switch characterized by the secretion of angiogenic 
molecules that stimulate endothelial cell migration from the subchondral bone into growth 
plates, including vascular endothelial growth factor (VEGF), transferrin, acid and basic 
fibroblast growth factor (FGF) or connective tissue growth factor (CTGF) 
11
. Nowadays, a 
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wealth of data has demonstrated that an intimate functional relationship exists between 
endothelial cells (ECs) and osteoblasts (OBs) during bone formation and repair. Several studies 
have identified and characterized factors involved in the “dialog” between both types of cells 
suggesting that this cell-to-cell communication could be crucial to the coordinated cell behavior 
necessary for the development and remodeling of bone 
17
. In addition to the angiogenic factors 
secreted by the hypertrophic chondrocytes, ECs produce growth factors including bone 
morphogenetic protein-2 (BMP2), vasoconstrictor endothelin-1 (ET1) and insulin-like growth 
factor (IGF) which affect the migration and proliferation of OBs and the differentiation of 
osteoprogenitor cells. The vasculature is crucial for the progressive conversion of the cartilage 
scaffolds into bones during endochondral ossification. As a consequence, it plays a crucial role 
for bone health throughout life. For this reason, failure in the blood supply may contribute to 
osteoporosis, and critically hamper fracture healing 
18
. In the last years, different groups have 
been focused on characterizing the crosstalk between ECs and OBs in order to obtain new 
strategies for bone tissue engineering 
19
. Coculture models on conventional 2D surfaces or 
within 3D structures have been used for the analysis of the cell-to-cell communication.  The 3D 
models could be obtained without scaffold by the formation of spheroids, or with scaffold by 
the association of these two cell types into a biomaterial composite 
19,20
.  Biocompatible 
scaffolds offer an adequate 3D architecture and design to promote the rate of bone formation 
and vascularization by enhancing cell contact between the two cell types. Several types of 
biomaterials have been used for this application such as polylactide-glycolic acid (PLGA) 
21
, 
polyurethane 
22
, alginate 
23
 or silk fibroin fibers 
24
. Regarding to the cell types used, different 
types of endothelial cells have been used such as human umbilical vein endothelial cells 
(HUVECs), human dermal microvascular endothelial cells (HDMECs) or endothelial progenitor 
cells 
19
. Moreover, mesenchymal stem cells and osteoblasts have been mainly used as 
osteoprogenitor cells 
25–27
. Interestingly, independently of the method used, the osteogenic and 
angiogenic potentials in the cocultures increased as compared with the monocultures, which 
evidenced the importance of the crosstalk between both types of cells in the osteogenic 
differentiation and the potential role of ECs as osteogenic mediators. 
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3.2 Hypothesis and specific aims 
As it was detailed in Chapter 2, when mouse embryonic fibroblasts (MEFs) were cultured in 
vitro in the self-assembling peptide scaffold RAD16-I under certain biomechanical conditions, 
they acquired multipotential capacity engaging into a spontaneous process of chondrogenic 
differentiation. However, MEFs only underwent osteogenic differentiation under specific 
chemical induction as it was published in Quintana et al 2009.  
In view of these results together with the ability of ECs to act as osteogenic mediators, we 
hypothesized that the presence of ECs could promote a switch in MEFs to an osteogenic-like 
commitment due to a crosstalk between the chondrogenic-like cells and the ECs recreating an 
endochondral ossification process.  Therefore, the specific aims for this chapter are the 
following: 
(1) To develop a coculture system using ECs and MEFs in order to induce the switch of 
MEFs to an osteogenic commitment. 
(2) To evaluate the osteogenic-like commitment of the coculture system by analyzing the 
expression of hypertrophic markers and matrix mineralization. 
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3.3 Materials and Methods 
3.3.1 Culture of mouse embryonic fibroblasts (MEFs) 
MEFs isolated from C57BL=6 embryos at day 14 were purchased from the American Type 
Culture Collection (scrc-1008; ATCC). The use of these cells has been approved by the Ramon 
Llull University Ethics Committee (CER URL 2013-001). MEFs (<10th passage) were cultured 
in 75-cm2 flasks in fibroblast medium (FM), which contains high-glucose Dulbecco’s modified 
Eagle medium (DMEM; D5671, Sigma) supplemented with 15% (v/v) Fetal Bovine Serum 
(FBS) (DE14-801F, Lot: 1SB003, Lonza), 100 U/mL Penicillin / 0.1 mg/mL Streptomycin 
(P11-010, PAA), 2mM L-Glutamine (M11-004, PAA), 1mM Sodium Piruvate (11360-039, 
Gibco) and 100µM Minimum Essential Medium Non-essential Amino Acid solution (M7145, 
Sigma). Cultures were maintained in the incubator in humidified atmosphere at 37ºC and 5% 
CO2. 
3.3.2 Culture of human umbilical vein endotelial cells (HUVECs) 
Human Umbilical Vein Endothelial Cells (HUVECs) (CC-2519, Lot: 3F0060, Lonza) were 
cultured in 25-cm2 flasks, previously coated with 0.1% (w/v) gelatin (G9391, Sigma), in 
Endothelial Basal Medium-2 (EBM-2) (CC-3156, Lonza) supplemented with Endothelial Cell 
Growth Media SingleQuots kit (EGM-2) (4176, Lonza). Cultures were maintained in the 
incubator at 37ºC and 5% CO2.  
3.3.3 3D culture technique 
To obtain a 3D culture, a solution of commercial 1% (w/v) RAD16-I (PuraMatrix™,354250, 
Beckton Dickinson) was diluted in sucrose 10% (w/v) (S1888, Sigma), to obtain a concentration 
of 0.14% (w/v). This solution was mixed with an equal volume of a cell suspension (4 x 10
6
 
cells/mL) in sucrose 10% (w/v), to obtain a final concentration of 2 x 10
6
 cells/mL in 0.07% 
(w/v) of RAD16-I in sucrose 10% (w/v). 80µL of this mix were loaded into 9mm diameter cell 
culture inserts (PICM01250, Millipore), previously placed into a 6-well culture plate and 
equilibrated with culture media. Immediately, cell-peptide cultures were placed for 30 minutes 
in the incubator at 37°C and 5% CO2, to allow the formation of the hydrogel by the action of the 
high ionic strength and the neutral pH of the medium. Elapsed this time, to dilute the content of 
sucrose, subsequent washing steps were performed by aspiration of the culture media in the well 
(outside of the insert), and the addition of the same amount (500µL) of fresh medium. The plate 
was placed again in the incubator for 10 minutes and this step was repeated 3 times, after which 
2.5mL of fresh medium were added outside the insert and the plate placed in the incubator for 
30 more minutes, to finally allow the construct to form, preventing its rupture. At this point, the 
addition of medium over the cell culture began, by adding 10µL in the inner wall of the insert 
letting it slowly slide to the gel, until a volume of 40µL is reached. The plate was placed once 
again in the incubator for 15 minutes and then the addition of fresh medium over the cell 
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construct continued, by addition of 20µL inside the insert, until a final volume of 200µL. The 
3D cell cultures were maintained in the incubator at 37°C and 5% CO2, for 5, 14 or 28 days. The 
medium was changed every second day by removing 500µL of medium from the well and the 
addition of 500µL of fresh medium inside the insert. (Figure 2.3.1, Chapter 2). 
3.3.4 Coculture of MEFs with HUVECs 
In order to coculture MEFs with HUVECs, two protocols were performed: 
1)  In the first method,  MEFs 3D-cultures at final concentration of  2 x 10
6
 cells/mL in 0.07% 
(w/v) RAD16-I were prepared as usual. After 1, 5 or 10 days of culture, a suspension of 120.000 
HUVECs in sucrose 10% (w/v) was loaded on top of the 3D cultures and maintained for 10 
days in FM.  
2) The second method consisted on the encapsulation of both cell types together. 3D-cultures 
were prepared following the 3D culture protocol but combining a solution of HUVECs and 
MEFs with the self-assembling peptide RAD16-I to obtain at a final concentration of 1 x 10
6
 
cells/mL of each cell type and 0.07% (w/v) RAD16-I. Cultures were maintained for 5 or 21 
days in FM (Figure 3.3.1). 
In both methods, medium was changed every second day and the cultures were maintained in an 
incubator at 37°C and 5% CO2. 
 
Figure 3.3.1. MEFs and HUVECs coculture schematic protocols. 1) Loading HUVECs suspension 
over a MEFs 3D encapsulation in 0.07% (w/v) RAD16-I after 1, 5 or 10 days of regular culture in 
FM.The cocultures were maintained for 10 days independently of the day of loading. 2) Encapsulation of 
HUVECs and MEFs together by mixing 80.000 cells of each type and maintaining the cocultures for 5 
and 21 days. 
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3.3.5 Reverse Transcription Polymerase Chain Reaction  
The RNA was extracted from the samples using peqGold total RNA kit (12-6834-02, Lot: 
072412, PeqLab). After the removal of the genomic DNA, cDNA was synthesized using 
QuantiTect Reverse Transcription kit (205311, Qiagen). The cDNA obtained was then analyzed 
by RT-PCR, using either Deep Vent DNA Polymerase (M0258S, New England Biolabs) or Taq 
DNA Polymerase master mix (D1806, Sigma). In both cases, 50ng of cDNA sample were 
added, dNTPs at a final concentration of 200µM and primers at a final concentration of 0.3µM 
(Table 3.3.1). In the case of Deep Vent, 0.2 units of polymerase were added, instead of 1 unit of 
polymerase added when Taq Polymerase was used. The amplification reaction was performed 
according the following parameters: Stage 1: 5 min at 95°C, Stage 2: 40 cycles of 30s at 95°C, 
15s at T°m (depending on the primers used) and 20s at 72°, Stage 3: 1 min at 72°C. The gene 
used as a housekeeping was the ribosomal subunit 18S. DNA fragments were visualized under 
UV light in a 2% (w/v) agarose gel to estimate their size. 
Table 3.3.1. Designed primers used for RT-PCR 
Gene F/R Sequence (5’ - 3’) Length 
18s 
F GCTACCACATCCAAGGAAGGCAG 
234bp 
R CGCTCCCAAGATCCAACTACGAG 
Coll I 
F TGACTGGAAGAGCGGAGAGT 
151bp 
R GTTCGGGCTGATGTACCAGT 
Coll X 
F CAAGCCAGGCTATGGAAGTC 
154bp 
R AGCTGGGCCAATATCTCCTT 
Runx2 
F GCCGGGAATGATGAGAACTA 
180bp 
R GGACCGTCCACTGTCACTTT 
VEGF-A 
F TCACCGCCTTGGCTTGTCACA 93bp 
225bp R GGAGAGATGAGCTTCCTACAG 
 
3.3.6 Western Blot 
After the lysis of the samples with buffer for protein extraction, a quantification step was 
performed to determine total protein content using BCA Protein Assay kit (23225, Pierce). 
Acrylamide gels were prepared according to the size of the proteins, generally in concentrations 
of 7 or 12% (w/v). Cell lysates (5µg of each sample) were mixed with protein loading buffer 
containing 5% (v/v) β-mercaptoethanol, and this mix was heated at 95°C for 10 minutes. 
Samples and protein ladder (161-0374, Bio Rad) were run applying 150V during 1h in 
electrophoresis buffer (30g Tris-base (154563, Sigma), 144g Glycine (0167, Amresco) and 10g 
SDS (L5750, Sigma) in 1L H2O). After the run, proteins were transferred to a PVDF membrane 
(LC 2005, Invitrogen) applying 40V during 2h at RT using transfer buffer (3.03g Tris-base, 36g 
Glycine, 200mL Methanol and H2O up to 1L). Then, the membrane was incubated at RT for 2h 
in blocking buffer (4% (w/v) non-fat powered milk in PBST). Membranes were incubated for 
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1h at RT with primary antibodies at a final concentration of 1µg/mL in PBST (Table 3.3.2). 
Then a secondary antibody IgG-HRP was added at a concentration of 1µg/mL, and incubated at 
RT for 1h (Table 3.3.3). Finally, the membrane was revealed for HRP detection (34080, Pierce). 
Chemiluminescent images were taken in the ImageQuant
TM 
LAS 4000 mini (GE HealthCare). 
Images were analyzed with ImageQuant
TM
 Image Analysis Software 7.0.  Actin was used as an 
internal protein standard. 
Table 3.3.2. Primary antibodies used for Western Blot 
Primary Antibodies Molecular Weight Catalog # Lot Brand 
Actin 43kDa sc-1615 K0612 Santa Cruz 
Collagen 1A1 
140-210kDa (prec) 
70-90kDa (mature) 
sc-8784 B1211 Santa Cruz 
Collagen 2A1 190kDa sc-7764 F2912 Santa Cruz 
Collagen 10A1 66kDa sc-323750 K1011 Santa Cruz 
Runx2 55kDa sc-10758 D1411 Santa Cruz 
 
Table 3.3.3.HRP-Labeled secondary antibodies used for Western Blot 
Secondary Antibodies Catalog # Lot Brand 
Donkey anti-Goat sc-2020 F1212 Santa Cruz 
Donkey anti-Rabbit sc-2317 F2212 Santa Cruz 
 
3.3.7 Collagenase treatment 
Protein lysates were treated with collagenase from Clostridium histolyticum (C0130, Sigma) in 
order to degrade the collagen present in the samples. For each protein lysate, the volume 
necessary to obtain 10 µg of protein were mixed with equal volume of collagenase solution at 
2mg/ml to obtain a final concentration of 1 mg/ml. Samples were incubated with the 
collagenase at 37 ºC for different times: 30 min, 1 hour and overnight. After that samples were 
analyzed by WB. 
3.3.8 Cell viability 
The live/dead staining was performed to qualitatively determine proportion of live and dead 
cells. Cell cultures were washed 3 times with PBS and then covered with a solution 2µM of 
EthD-1 and Calcein AM  in PBS (L3224, Invitrogen). After 15 minutes of incubation at RT in 
dark chamber, the solution was removed and the sample washed 3 times with PBS, after which 
the sample was analyzed under fluorescence microscope (Zeiss Axiovert 200M inverted 
microscope with coupled ApoTome system). 
3.3.9 Von Kossa staining 
Von Kossa staining was performed to detect matrix mineralization. Cell cultures were washed 
with PBS and fixed with PFA 2% (w/v) in PBS for 1h at RT. Then, cultures were washed 
several times with distilled water, to completely remove the PBS in order to prevent their 
precipitation with the silver nitrate solution. Then, cultures were incubated for 1h with a 
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solution of 5% (w/v) silver nitrate (209139, Sigma) in dark chamber, time after which the 
culture was washed several times with distilled water and placed under a bright light source for 
10 minutes. Finally, samples were observed under phase contrast microscopy using an inverted 
Nikon microscope (Nikon eclipse TS100). 
3.3.10 Labeling of HUVECs 
HUVECs were labeled using Qtracker 565 Cell Labeling kit (Q25031MP, Invitrogen), 
following the manufacturer’s protocol. Briefly, the labeling solution was prepared mixing equal 
volumes of components A and B in EBM-2.  Then, a 2D culture of HUVECs (in a 25-cm2 cell 
culture flask) was incubated with this solution for 1 hour at 37°C. Labeling solution was 
completely aspirated and 5mL of fresh medium were added. The culture was then cultured as 
usual. This labeling permits the identification and localization of the cells due to fluorescent 
emission at 565 nm of the nanocrystals which allows their observation under fluorescence 
microscope. (Zeiss Axiovert 200M inverted microscope with coupled ApoTome system). 
3.3.11 Statistics 
All values were expressed as mean ± SD. Statistical differences were analyzed with GraphPad 
Prism 6 when samples were prepared in triplicate for the condition analyzed. When comparing 
two groups, unpaired student’s t test was used to test for the significance level. When comparing 
three or more groups statistical analysis was carried out by 1‐way or 2‐way ANOVA, as 
appropriate, followed by Tukey post analysis. 
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3.4 Results 
First of all, in order to evaluate if the MEFs 3D-cultures undergoing spontaneous chondrogenic 
differentiation were committed to a terminal differentiation of hypertrophic chondrocytes, the 
transcription factor Runx2 and the hypertrophic marker Collagen type X (Coll X) were studied. 
For this purpose, cultures of MEFs were prepared at the peptide concentration where the 
spontaneous chondrogenesis was previously observed (0.07% (w/v) RAD16-I) and they were 
maintained for 5, 14 and 28 days.   
When analyzing Coll X expression by western blot (WB), it was observed that the anti-Coll X 
antibody bounded to two different proteins, and depending on the band considered as correct, 
the results totally changed (Figure 3.4.1, A). Thus, samples were treated with collagenase to 
degrade the collagen band and to elucidate which was the correct band. Collagenase treatment 
was performed with the protein lysates following the manufacturer’s protocol and using 
different times of incubation. Interestingly, it was found that the band degraded by the 
collagenase was the one weighing 54 kDa, which was then only present in 2D cultures (Figure 
3.4.1, B).  The weight of the band corresponded with the theoretical value provided by the 
manufacturer (55 kDa). Thus, Coll X was only expressed in 2D cultures and its expression was 
down-regulated in 3D.  
 
Figure 3.4.1. Collagen type X analysis by western blot. (A) Coll X was analyzed by WB in the MEFs 
2D cultures and 3D cultures maintained for 5, 14 and 28 days. (B) WB of MEFs 2D cultures and 3D 
cultures maintained for 5 days treated with the collagenase. Results show from left to right for each 
sample: lysate without treatment, lysate treated for 30 minutes, 1 hour and overnight (ON) at 37ºC, and 
sample maintained ON at 37ºC without collagenase as negative control.  
Remarkably, the results obtained after collagenase treatment and with RT-PCR, showed a clear 
expression of Coll X in the 2D controls but absent in 3D-cultures (Figure 3.4.2), suggesting that 
the system did not undergo hypertrophy in the scaffold system and maintained its chondrogenic 
commitment. Instead, results obtained using both techniques (WB and RT-PCR) showed that 
Runx2 was expressed in 2D cultures and down-regulated but still expressed in 3D once (Figure 
3.4.2). Although Runx2 is a transcription factor that plays an important role in the maturation of 
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chondrocytes to a hypertrophic stage, the presence of Sox9 (as observed with qPCR and WB in 
Chapter 2) might have a dominant effect against hypertrophy as previously reported 
28
.  
 
Figure 3.4.2. Hypertrophic characterization of MEFs cultured in 0.07% (w/v) RAD16-I scaffold. 
(A) RT-PCR results of Coll X and Runx2 after 5, 14 and 28 days of culture. 18s was used as 
housekeeping gene. (B) WB results of Coll X and Runx2 when MEFs were cultured for 5, 14 and 28 
days. 
3.4.1 Switch to osteogenic-like differentiation due to biological induction 
It was observed that 3D-constructs undergoing spontaneous chondrogenesis did not undergo 
hypertrophy (by the absence of Coll X expression). Thus, it was hypothesized that the presence 
of endothelial cells could promote osteogenic-like commitment since several studies suggest the 
potential role of endothelial cells as osteogenic mediators 
19,25
. 
In order to test the hypothesis, two types of cocultures were prepared with MEFs and 
endothelial cells to promote cross-talk between both cell types (See Materials and Methods 
3.3.4). One type consisted of preparing cultures of MEFs at low peptide concentration (0.07% 
(w/v)) to promote spontaneous chondrogenic differentiation. Then, after 1, 5 and 10 days of 
culture, a suspension of HUVECs was added on top of the cell construct and the cocultures were 
maintained for 10 days independently of the loading day. From this point onwards, this type of 
coculture will be referred as “loading coculture”. On the other hand, the second type consisted 
of the encapsulation of both cell types together obtaining a final concentration of 1x10
6
 cells/mL 
of each type and 0.07% (w/v) RAD16-I. These cocultures were maintained for 5 and 21 days. In 
this case, this type of coculture will be referred as “encapsulation coculture” in this thesis. 
Before starting with the 3D coculture systems, HUVECs 2D cultures were prepared in order to 
study their maintenance in fibroblast media, since it would be the culture media of the 3D 
cocultures. Cells were seeded at 20.000 cells/cm
2
 and maintained in different types of media: 
complete FM; conditioned FM from MEFs 2D cultures; conditioned FM from MEFs 3D 
cultures in 0.07% (w/v) RAD16-I undergoing chondrogenesis; and conditioned FM from 3D 
cultures of MEFs in 0.25% (w/v) RAD16-I (Figure 3.4.3). Cultures in complete endothelial 
medium (EBM) were used as benchmark. As expected, lower viability was observed in 
endothelial cells cultured in FM than in control EBM. However, viability appeared to increase 
when HUVECs were cultured in conditioned FM from cultures undergoing chondrogenesis after 
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14 days of culture (Figure 3.4.3). These results suggested that MEFs could be secreting factors 
that promoted the maintenance of endothelial cells. 
 
Figure 3.4.3. HUVECs maintenance in fibroblast media. 2D cultures were prepared and maintained for 
3 days in (A) complete endothelial media used as control, (B) complete FM, (C) conditioned FM from 
MEFs 2D cultures, (D) conditioned FM from 3D cultures of MEFs in 0.07% (w/v) RAD16-I after 5 days 
and (E) 14 days and (F) conditioned FM from 3D cultures of MEFs in 0.25% (w/v) RAD16-I. (Scale 
bar=200 µm) 
Loading cocultures for the biological osteogenic induction of MEFs  
The loading coculture was the first type of coculture prepared, which consisted of adding the 
HUVECs on top of the MEFs 3D cultures after 1, 5 and 10 days of culture. For better 
localization and identification in the cocultures, HUVECs were labeled. Briefly, a custom 
targeting peptide was used to deliver nanocrystals into the cytoplasm of live cells, these 
nanocrystals were distributed in vesicles and their fluorescent emission at 565 nm allowed their 
observation under fluorescence microscope (Figure 3.4.4).  
 
Figure 3.4.4. HUVECs labeling with fluorescent nanocrystals. (A) Phase contrast image and (B) 
Fluorescence image of passage 4 HUVECs labeled with Qtracker® 565. (Scale bar=200µ) 
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Remarkably, HUVECs loaded on top of MEFs 3D cultures were mainly localized in the edges 
of the constructs as it was observed by fluorescence microscopy after 1 and 7 days of the 
loading (Figure 3.4.5). 
 
Figure 3.4.5. HUVECs on top of MEFs 3D cultures. (A) Phase contrast image and (B) Fluorescence 
image of HUVECs after 1 day of loading. (C) Phase contrast image and (D) Fluorescence image of 
HUVECs after 7 day of loading. 
In addition, independently of the day of HUVECs addition, it was observed that a part of cells 
fell into the bottom of the cell culture insert, being capable of grow in the membrane. 
Surprisingly, the cells just below the 3D cell culture grew and proliferate in higher proportion 
(Figure 3.4.6, A,B), compared with those cells in the periphery of the cell culture insert which 
showed a rounded morphology (Figure 3.4.6, C,D). These results suggested that MEFs were 
secreting factors that favored the maintenance of endothelial cells as previously observed in the 
2D cultures with conditioned media. Fluorescence images clearly elucidate that the cells 
growing below the MEFs 3D cultures were the endothelial cells and not fibroblasts.  
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Figure 3.4.6. HUVECs growing in the cell culture insert membrane. (A) Phase contrast image and (B) 
Fluorescence image of HUVECs below the MEFs 3D cultures. (C) Phase contrast image and (D) 
Fluorescence image of HUVECs in the periphery of the MEFs 3D cultures. (Scale bar=200 µm) 
Then, the possible switch to osteogenic commitment after 10 days of coculture independently of 
the day of loading (5 or 10 days), was evaluated by assessing the expression of hypertrophic 
markers (Coll X, Runx2) and the angiogenic factor VEGF 
13,29
. In addition, the expression of 
Coll I and II was also studied over time to assess the change to hypertrophy, which is the first 
step in the endochondral ossification process. Finally, in order to confirm ossification, von 
Kossa staining was performed to detect calcium mineralization of the extracellular matrix which 
is the final step of osteogenic differentiation 
30
. 
In terms of hypertrophic markers, RT-PCR results showed an expression of Runx2 which 
seemed higher in cocultures than in MEFs 3D-constructs (Figure 3.4.7). Instead, the expression 
of Runx2 was observed with WB only in cocultures when endothelial cells were loaded after 10 
days of culture (Figure 3.4.8, A). The results obtained were contradictory since a clear 
expression of Runx2 was observed by RT-PCR.  Therefore, we speculated that this effect could 
be influenced by the fact that Runx2 is a transcription factor expressed in low amounts and 
hence it may be difficult to observe by WB.   
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Figure 3.4.7. RT-PCR of MEFs and loading cocultures. Runx2, Coll X, Coll I and VEGF expression 
of 2D cultures of MEFs, 3D cultures of  MEFs after 14 and 28 days of culture in  0.07%(w/v) RAD16-I 
and 3D cocultures where HUVECs were loaded after 5 days (5+10)  or loaded after 10 days (10+10)  and 
cocultured for 10 more extra days. 
Remarkably, RT-PCR results showed a clear up-regulation of Coll X only in cocultures 
containing endothelial cells (Figure 3.4.7). However, WB showed that its expression was weak 
at both times of culture (Figure 3.4.8, A). This was the first time that Coll X was expressed in 
our 3D-culture system and as a consequence it could be an evidence of the hypertrophic switch 
of MEFs due to their cross-talk with endothelial cells. Besides, VEGF expression, which it is 
necessary for the angiogenic switch during bone development, was observed by RT-PCR in all 
the cultures tested which suggested a constitutive expression of this marker in MEFs (Figure 
3.4.7).   
 
Figure 3.4.8. Western blot of MEFs and loading cocultures. (A) Runx2, Coll I, II and X expression of 
2D cultures of MEFs and 3D cocultures where HUVECs were loaded after 5 days (5+10)  or loaded after 
10 days (10+10)  and cocultured for 10 more extra days. Actin expression was used as internal control. 
(B) Ratio Coll II/ Coll I calculated from the western blot band areas normalized by Actin from (A). 
(Statistical differences are indicated as* for p<0.05, Unpaired t-student, n=3). 
Then, the expression of collagens type I and II was also studied, according to the results 
obtained by WB, Coll I was expressed all the days of culture, while Coll that the expression of 
Coll II was up-regulated over the time of the culture (Figure 3.4.8, A). These observations were 
reflected in the ratio Coll II / Coll I, which increased over the time of culture (Figure 3.4.8, B). 
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These results suggested that MEFs were committing to chondrogenic lineage, which is 
necessary for further endochondral ossification. However, the ratio Coll II/ Coll I was lower 
than the observed in the MEFs 3D-constructs described in Chapter 2 (Figure 2.4.5).  
Finally, Von Kossa staining was performed to determine the mineralization of the ECM. In this 
staining, the calcium ions, mainly in phosphate and carbonate salts, are substituted by silver 
cations from a silver nitrate solution supplied to the cell culture, which subsequently reduces, 
forming black precipitates observable under the microscope. Remarkably, mineralization of the 
extracellular matrix was only observed in the coculture system by evident formation of black 
silver precipitates easily observed under the microscope. Besides, it was observed that when 
HUVECs were loaded after 1 or 5 days of MEFs culture, mineralization was confined mostly at 
the edges of the constructs but when the HUVECs were loaded after 10 days, mineralization 
was more generalized in the surface of the cocultures (Figure 3.4.9).   
 
Figure 3.4.9. Von Kossa staining of loading cocultures.  HUVECs were loaded over MEFs cultures 
after (A, B) 1, (C) 5, (D) and 10 days of culture and fixed 10 days later. 
 
 
 
 
Chapter 3: MEFs osteogenic differentiation 
 
92 
 
When looking at the fluorescence images of cocultures where the endothelial cells were loaded 
after 5 days of culture and fixed after 10 days of coculture, HUVECs were located over the 
MEFs cultures and were associated to zones on which the Von Kossa staining was positive 
(Figure 3.4.10). These results suggested that matrix mineralization was developed at the 
interaction site between MEFs and endothelial cells. 
 
Figure 3.4.10. Localization of labeled HUVECs. Endothelial cells were loaded after 5 days of culture 
and fixed 10 days later. (A) Phase contrast image and (B) Fluorescence image. 
 
Encapsulation cocultures for the biological osteogenic induction of MEFs  
The second type of cocultures prepared consisted of the encapsulation of MEFs and HUVECs in 
0.07% (w/v) RAD16-I and at a final concentration of 1x10
6
 cells/mL for each cell type in order 
to maintain the cell density of 2x10
6
 cells/mL used in the MEFs 3D cultures. Then, these 
cocultures were maintained for 5 and 21 days with FM. 
First of all, it was observed that MEFs migrated in the cocultures, proliferated and developed 
cell-cell networks as described in Chapter 2 for MEFs cultures (Figure 3.4.11, A, B). However, 
although final cell density was the same in the cocultures and in the cultures of MEFs, the 
amount of fibroblasts was half as much and as a consequence the cell network was weaker and 
the structure did not contract as observed before (Figure 3.4.11, C). Then, viability was 
evaluated qualitatively using a live and dead staining which showed that almost all cells were 
alive after 21 days of coculture (Figure 3.4.11, D).   
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Figure 3.4.11. Encapsulation cocultures behavior.(A) Phase contrast image of cocultures after 1 day 
and (B) 5 days of culture. (C) Coculture morphology after 5 days of culture, same contraction was 
observed after 21 days of culture. (D) Live and dead staining after 21 days of culture. 
In addition, HUVECs labeled with the nanocrystals as previously described were used for the 
encapsulation cocultures. The visualization of the cocultures under fluorescent microscopy 
allowed the localization of the labeled cells (Figure 3.4.12). 
 
Figure 3.4.12. Labeled HUVECs localization. (A) Phase contrast image and (B) Fluorescence image of 
encapsulation cocultures after 1 day of culture.  
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Then, RNA extraction of the samples was performed in order to obtain cDNA for the analysis of 
gene expression. However, due to the low cell density after 21 days of culture, the obtained 
concentrations of RNA were very low. In addition, the ratios 260/230 and 260/280 obtained 
indicated presence of proteins, solvent or other contaminants. As a consequence, the RT-PCR 
with those samples was not performed, and samples were only analyzed for protein expression 
with WB. 
Regarding hypertrophic markers, the expression of Runx2 was only observed in 2D control 
samples of MEFs but not in any coculture (Figure 3.4.13, A). These results could be influenced 
by the fact that Runx2 is a transcription factor expressed by MEFs, and in this type of coculture 
the quantity of this cell type is half as much as in the regular encapsulations. Hence, it may be 
difficult to observe the expression of Runx2 with WB like in the loading cocultures where 
Runx2 was perfectly observed by RT-PCR but its expression was not detected with WB. 
Remarkably, a weak band was observed again related to the expression of Coll X after 5 and 21 
days of coculture which could indicate a change in cell behavior to osteogenic commitment 
(Figure 3.4.13, A). 
 
Figure 3.4.13. Western blot of MEFs and cocultures. (A) Runx2, Coll I, II and X expression of 2D 
cultures of MEFs, encapsulation cocultures after 5 and 21 days of culture. Actin expression was used as 
internal control. (B) Ratio Coll II/ Coll I calculated from the western blot band areas normalized by Actin 
from (A). 
Then, the expression of collagens type I and II was also studied, according to the results 
obtained by WB, Coll I was expressed all the days of culture, while Coll II seemed to be 
expressed at day 21 of culture (Figure 3.4.13, A). These observations were reflected in the ratio 
Coll II / Coll I, which increased over the time of culture (Figure 3.4.13, B). However, these 
values were not significantly different from values obtained for 2D cultures of MEFs used as 
control. These results suggested that MEFs were not committing to chondrogenic lineage, which 
is the first step of endochondral ossification, contrary to loading cocultures described before. 
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Finally, Von Kossa staining after 21 days of culture revealed an isolated and localized 
mineralization in some areas with tubular structures, which suggested the presence of 
endothelial cells (Figure 3.4.14). We hypothesized that this mineralization was located in areas 
of direct interaction between fibroblasts and endothelial cells where cells engaged in a local 
remodeling of the ECM.  
 
Figure 3.4.14. Von Kossa staining of encapsulation cocultures after 21 days of culture. Arrows 
indicate mineralized areas.  
Cocultures of MEFs and HUVECs in 2D 
Finally, 2D cocultures were prepared to better understand the dialog between fibroblasts and 
endothelial cells observed in the previous sections. For this purpose, HUVECs and MEFs were 
cultured separately in 2D at a seeding density of 30.000 cell/cm
2
 and maintained during 3 days 
in complete endothelial and fibroblast media respectively. Then, a suspension of HUVECs to a 
final concentration of 15.000 cells/cm
2
 was loaded on MEFs cultures, and maintained for 7 days 
in different culture mediums: FM, FM+EBM (1:1) or EBM. 
Over the time, some areas with higher densities of cells were generated over the MEFs 2D 
cultures. These areas were better localized when the cell nuclei were stained with DAPI. 
Interestingly, this effect was exaggerated when cocultures were maintained in complete 
endothelial culture medium (Figure 3.4.15). These results suggested that the growth factors 
added in the culture media together with the intimate cell interactions between fibroblasts and 
endothelial cells induced the formation of these structures. Remarkably, it was also observed 
that some cells underwent adipogenic differentiation evidenced by formation of lipid droplets 
stained with Nile Red (Figure 3.4.15, D,F). This lipid formation was only observed in the 
presence of EBM, which is composed of a cocktail of growth factors that could induce the 
adipogenic differentiation. 
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Figure 3.4.15. 2D cocultures of MEFs and HUVECs.  Cultures were prepared as described and 
maintained for 7 days in (A, B) Fibroblast media (FM); (C, D) Endothelial media and Fibroblast media 
(FM+EBM) (1:1) and (E, F) Endothelial media (EBM). (B, D, F) Fluorescence images show the nuclei 
stained with DAPI (blue) and lipid droplets stained with Nile Red (green). (Scale bar=200µm) 
In view of the results obtained in the previous chapter where MEFs underwent adipogenesis in 
presence of PDGF together with the mesodermal origin of fibroblasts, we hypothesized that 
MEFs were the cell type that committed to the observed adipogenesis. In addition, it was 
reported that endothelial cells enhanced the adipogenic potential of preadipocytes which could 
indicate a combined effect with the growth factors present in the culture media 
31
. On the other 
hand, some studies suggested an endothelial origin of murine and human adipocytes 
32,33
, which 
could indicate that HUVECs were responsible for the adipogenic differentiation observed in  the 
cocultures. Thus, the cell type involved in the formation of lipid droplets observed in the 2D 
cocultures described in this section remained unclear. 
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Finally, with the purpose to elucidate the cell type that formed the areas of high cell density, 
Platelet Endothelial cell adhesion molecule (PECAM) was analyzed. PECAM is a major 
constituent of endothelial cell intercellular junction, and it is not present in fibroblasts 
34
. The 
expression of PECAM was analyzed by immunofluorescence in order to locate its expression. 
As expected, the areas of high cell density that recreated tubular structures were clearly positive 
for the expression of the endothelial cell marker, which evidenced that these areas were mainly 
composed by HUVECs (Figure 3.4.16). 
 
Figure 3.4.16. PECAM immunofluorescence. Cultures were prepared as described and maintained for 7 
days A) Endothelial media and Fibroblast media (1:1) and B) Endothelial media. PECAM protein was 
immunostained with an antibody anti-PECAM developed with a secondary antibody Alexafluor680-
congugated (red). Nuclei were stained with DAPI (blue). 
3.5 Discussion 
Bone grafts are needed when the required bone regeneration exceeds the natural potential for 
self-healing, as in large bone defects occurring after trauma, infection, tumor resection or 
skeletal abnormalities 
2
. Although in the clinical setting, the gold standard to treat bone defects 
consists of the transplantation of autologous bone grafts, the availability of patients’ own bone 
tissue that can be used for these procedures is limited 
2
. Even though several strategies of bone 
tissue engineering have been developed, challenges still remain in the inability to reproduce an 
engineered well vascularized bone that truly mimics natural bone blood vessels. This parameter 
is crucial to ensure optimal cell survival and implant integration after in vivo engraftment 
35
. For 
years it has been recognized that engineering of large bone constructs will be feasible only if the 
hurdle of vascularization is overcome 
36
.  
Although tissue engineering of bone has been traditionally focused on direct (intramembranous) 
bone formation, nowadays several groups are interested in endochondral bone formation since it 
is a more physiological approach which recreates most aspects of in vivo bone formation. These 
studies consists mainly of creating a cartilage template in vitro followed by its implantation in 
vivo where the template is vascularized and remodeled 
7,36–39
. Since cartilage is an avascular 
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tissue, its cells are equipped to survive the poor oxygenation and nutritional conditions inherent 
to implanted tissues 
36
. For this reason, forming bone through the production of a cartilaginous 
template may circumvent issues with supply of oxygen and nutrients of larger engineered 
constructs. Moreover, our long bones grow and most fractures heal through this mechanism 
which evidences the attractive characteristics of endochondral bone tissue engineering 
36
. 
Following this hypothesis, the switch from chondrogenic to ostegenic-like commitment of 
MEFs in the self-assembling peptide RAD16-I has been described in this thesis. Up to now, 
osteogenic differentiation with MEFs in our laboratory had only been obtained thanks to the 
addition of specific chemical induction 
40,41
. In that case, MEFs cultured in the self-assembling 
peptide were maintained with fibroblast media supplemented with dexamethasone, β-
glycerophosphate, ascorbic acid and 1α,25-(OH)2 vitamin D3 as previously described 42. 
Osteogenic differentiation was assessed based on matrix mineralization, collagen I synthesis, 
ALP activity, and expression of the osteoblast transcription factor Runx2 
40,41
. Similar results 
were also reported using mouse and human fibroblast, in both cases the osteogenic 
differentiation was obtained only when cells were maintained in osteogenic induction media 
43,44
.  
However, a more physiological approach was described in this chapter which consisted on 
challenging the 3D-cultures of MEFs undergoing chondrogenesis to coculturing them with 
endothelial cells. It was hypothesized that the presence of endothelial cells could promote a 
switch in MEFs to an osteogenic-like commitment due to a crosstalk between the chondrogenic-
like cells and the endothelial cells recreating an endochondral ossification process. Under these 
new conditions, the hypertrophic markers Coll X and Runx2 were up-regulated and von Kossa 
staining clearly showed matrix mineralization at the interaction site between MEFs and 
endothelial cells. These results evidenced that MEFs switched to osteogenic commitment due to 
the biological induction of the endothelial cells. Remarkably, this is the first description of 
osteogenic differentiation of fibroblast due to the crosstalk with endothelial cells. In spite of a 
deeper understanding of the osteogenic switch is needed, preliminary results suggest that the 
future in vivo implantation of the MEFs 3D-constructs in a mouse model of ectopic bone 
formation or in a fracture site would promote the formation of a vascularized bone graft. 
Coculture systems of MSCs and endothelial cells have also been reported as strategies for bone 
tissue engineering. In that cases, the main objective was to obtain pre-vascularized bone grafts 
in vitro and to avoid the aforementioned vascularization problems once the graft is implanted in 
vivo 
19,45
. 
Interestingly, when cocultures of fibroblasts and endothelial cells were prepared in 2D, cell 
behavior radically changed. Osteogenic differentiation was not observed; however, some cells 
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underwent adipogenic differentiation evidenced by formation of lipid droplets. Since MEFs in 
the 2D cultures did not engage in the spontaneous chondrogenic differentiation observed in 3D, 
obtained results agree with the hypothesis that it is necessary a first step of chondrogenic 
commitment to later continue with the osteogenic differentiation process. Instead, 2D cocultures 
could be used to better understand the adipogenic differentiation of MEFs or to support the 
model for how adipogenesis and angiogenesis are coordinated during adipose tissue expansion 
31–33
 . 
3.6 Concluding Remarks 
- MEFs undergoing chondrogenesis in the self-assembling peptide RAD16-I switched to 
osteogenic-like commitment due the biological induction of ECs in a coculture system. 
This is the first description of the osteogenic differentiation of fibroblast due to the 
crosstalk with endothelial cells. 
 
- The osteogenic commitment of MEFs was evidenced by the expression of collagen type 
X and matrix mineralization. Additionally, other factors expressed by the mentioned 
cocultures were Runx2 and VEGF-A, which could promote the possible formation of 
new blood vessels, necessary for the endochondral ossification. 
 
- Von Kossa staining showed matrix mineralization in areas of direct interaction between 
MEFs and ECs, which suggested an effective cross talk between MEFs and HUVECs 
that could be studied more in detail in future research projects. 
 
- Preliminary results of osteogenic differentiation suggest that future in vivo implantation 
of the MEFs 3D-constructs in a mouse model of ectopic bone formation or in a fracture 
site would promote the formation of a vascularized bone graft. 
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Chapter 4:  Development of a new biomaterial for tissue 
engineering applications based on the self-assembling peptide 
RAD16-I 
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4.1 Introduction 
4.1.1 Overview 
Nowadays, one of the major challenges in tissue engineering is vascularization of engineered 
tissues. Regardless of the specific approach, this is an important issue because any engineered 
tissue construct that involves living cells needs an adequate blood supply for cell survival in 
tissues of macroscopic dimensions 
1–3
. In vivo almost all tissues are vascularized with a 
maximum distance between capillaries of 200 μm which correlates with the diffusion limit of 
oxygen 
4
. For this reason, any engineered tissue that exceeds 400 µm must be vascularized to 
have easy access to oxygen and nutrients, as well as elimination of carbon dioxide and other 
cellular waste products (Figure 4.1.1) 
2
. Only cells from skin, cartilage and cornea can be 
supplied with nutrients from blood vessel systems that are further away 
4
.  
 
 
Figure 4.1.1. Schematic description of diffusion and transport processes in vascularized tissues in 
vivo. The surrounding tissue is supplied with oxygen, nutrients and drugs via the vasculature. Waste 
products and CO2 are removed from the tissue into the blood vessels. (Image adapted from Novosel et 
al.
4
)  
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4.1.2 Vascular tissue engineering 
The strategies that have been designed in tissue engineering in order to solve this issue are 
mainly divided in two groups: 1, promotion of rapid vascularization after transplantation by the 
host’s own system and 2, pre-vascularization of the engineered construct in vitro 2 (Figure 
4.1.2). 
 
Figure 4.1.2. Schematic drawing of angiogenesis and inosculation. Angiogenesis is characterized by 
the ingrowth of newly formed blood vessels from the host tissue (red vessels).  In the inosculation, the 
pre-formed blood vessels (blue vessels) develop interconnections to the host microvasculature within the 
construct or within the surrounding host tissue. (Image adapted from Laschke et al.
5
)  
In the first case, the ingrowth of newly formed blood vessels into an implanted tissue construct 
is a highly dynamic process. The initial step in this process is activation of host 
microvasculature at the implantation site by angiogenic growth factors, such as vascular 
endothelial growth factor (VEGF) or basic fibroblast growth factor (FGFβ) 6. These factors can 
be produced by the host tissue itself or delivered by artificially designed systems. Then, upon 
angiogenic stimulation, endothelial cells degrade their surrounding basement membrane and 
migrate to form capillary sprouts and proliferate, elongating the newly blood vessels 
3,7
. Several 
approaches have been developed to stimulate angiogenesis in the tissue construct focusing on 
scaffold bioactivation by the incorporation of deliverable growth factors (GF). Some examples 
reported their covalent immobilization to scaffolds, non-covalent bound to nanoparticles or 
entrapment in microspheres with defined degradation rates 
6
. The main disadvantage of this 
strategy is that angiogenesis is a time-consuming process and when the vascularization is 
achieved most cells could be dead due to the absence of oxygen and nutrients during the initial 
days after implantation. 
On the other hand, pre-vascularization or inosculation approaches use pre-formed microvascular 
networks within tissue constructs prior to their implantation in order to decrease the time of 
vascularization. The pre-vascularization can be obtained in vitro normally using endothelial 
cells. In vivo approaches include implantation of the scaffold in a well-vascularized area, and, 
after sufficient vascularization, the construct is explanted again and can be inserted into the 
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ischemic target site where it should rapidly develop interconnections with the host 
microvasculature 
6
. The main disadvantage of the in vivo approach is the need of at least three 
surgeries: the implantation of the cell-free scaffold, the removal and the proximate insertion of 
the pre-vascularized biomaterial. Interestingly, inosculation was observed in nude mice within 
the first 4 days after implantation as compared to the 14 days that took the ingrowth of new 
blood vessels in the no pre-vascularized control 
8
. However, experimental studies indicate that 
this approach does not ensure appropriate blood perfusion of grafted tissue constructs during the 
very first days after implantation 
5
. Hence, many attempts have emerged to improve the existing 
approaches by tailoring scaffolds with growth factors combined with different types of cells. 
Cells 
Independently of the strategy used, the source of cells used to create a vascular network is a 
critical issue. The generation of functional vessels has been reported using different mature 
endothelial cells (ECs) including human dermal microvascular ECs (HDMECs) or human 
umbilical vein ECs (HUVECs) 
9
. Furthermore, the coculture of ECs with different cell types 
such as fibroblasts, adipocytes or osteoblasts is crucial to support angiogenic mechanisms 
4,10,11
. 
However, ECs present some disadvantages such as low proliferation rates, heterogeneity in the 
genotype and phenotype, requirement of an invasive procedure to harvest. Alternatively, 
endothelial progenitor cells (EPCs) have been widely used in tissue engineering applications 
due to their ability to migrate and incorporate into ischemic tissue and promote 
neovascularization. Moreover, EPCs can be derived from bone marrow, fat tissue and peripheral 
blood. This type of cells has also been cocultured with different cell types such as fibroblasts or 
mesenchymal stem cells showing a modulation of the angiogenic process 
9,12
. Finally, a wide 
spectrum of studies reported the use of different types of stem cells in vascular tissue 
engineering including bone marrow, adipose derived or mesenchymal stem cells 
13
. 
Growth factors 
Angiogenic growth factors are used alone or in combination with cells and biomaterials as 
powerful initiators of neovascularization. They can activate endothelial or progenitor cells and 
promote migration towards the growth factor gradient. Moreover, they stimulate cell assembly, 
vessel formation and maturation. The main factors contributing to the initiation of angiogenesis, 
and induction of endothelial cell proliferation and migration are: vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (FGFβ) and hepatocyte growth factor (HGF) 4,14. 
However, VEGF and its receptors constitute the key signaling system for angiogenic activity in 
tissue formation. In addition, different cytokines serve as indirect angiogenic factors and are 
involved in the regeneration of endothelial tube. Among them, platelet-derived growth factor 
(PDGF) and angiopoietines are agents that recruit pericytes and smooth muscle cells; and 
transforming growth factor beta (TGFβ) causes ECM deposition for stabilization of new vessels 
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15
. The main issue when designing a new strategy is to properly deliver these signaling 
molecules locally and temporally to obtain the desired biological outcomes, while avoiding 
unfavorable side effects. 
Scaffolds 
In the last years, different types of biomaterials have been developed as scaffolds for vascular 
tissue engineering which can be divided in natural and synthetic biomaterials. In the group of 
natural materials, the reuse of biological structures is a future promising approach for tissue 
engineering applications. This procedure consists on the decellularization of a mammalian 
section, and the repopulation of the matrix with desirable human primary cells. Some examples 
illustrate the extensive use of decellularized small pig intestine or vascular tissues like aorta 
4,16,17
. However, the main problem associated with this approach is the rejection of allografts and 
xenografts. Besides, natural derived polymers such as collagen 
18
, gelatin 
19
 or hyaluronan 
20,21
 
have been widely reported for vascular tissue engineering applications 
22
.  
On the other hand, the use of synthetic polymers is increasing due to their controlled properties 
and composition, although improving their biocompatibility and bioactivity is a major concern 
in the field of biomaterials. Among others, some synthetic polymers reported for vascular tissue 
engineering applications are poly(vinylalcohol) 
23
, polycaprolactone 
24,25
 and polyethylene 
glycol 
26,27
. As part of synthetic materials, self-assembling peptides are gaining importance in 
vascular tissue engineering due to their application as drug delivery systems for angiogenic 
growth factors. As it has been reviewed in Chapter 1, this class of peptides is characterized by 
self-assembling under physiological conditions into a network of interweaving nanofibers of 
around 10 nm diameter, forming a hydrogel scaffold with pores sizes of 50–200 nm and over 
99% water content
28
. Other properties of self-assembling peptides are the ease of synthesis, 
modulation of mechanical properties, injectability, biocompatibility, biodegradability and 
options for the incorporation of bioactive motifs or molecules 
29,30
. Some examples of their use 
in vascular tissue engineering exhibited the delivery of VEGF165, or combined delivery of 
PDGF and FGFβ to promote cardiac regeneration after infarct using in vivo models31–33. 
Interestingly, intramyocardial injection of the self-assembling peptide RAD16-II combined with 
VEGF improved post-infarction neovascularization in rats and pigs
31
. Moreover, the delivery of 
VEGF from a tailored self-assembling peptide showed improved cardiac function, reduced scar 
size and collagen deposition in a rat model
32
. Finally, the dual delivery of PDGF and FGF lead 
to myocardial protection, stable vessel formation, and improvement in cardiac function also in a 
rat model 
33
.  Remarkably, in all cases there was recovery of damaged tissue thanks to the 
stimulation of angiogenesis. These results prove their potentiality as delivery systems for 
vascular tissue engineering. 
   
109 
 
4.1.3 Heparin as a strategy for growth factor delivery 
Heparin has numerous important biological activities associated with its interaction with diverse 
proteins. It is a linear polydisperse sulphated polysaccharide consisting mainly of repeating 
units of 1→4-linked pyranosyluronic acid and 2-amino- 2-deoxyglucopyranose (glucosamine) 
residues. The presence and frequency of these saccharide units vary with the tissue source from 
which heparin is extracted (Figure 4.1.3). It possesses the highest negative charge density of all 
known biological macromolecules and has an average of 2.7 negative charges per disaccharide 
provided by sulfonic and carboxyl groups. Consequently, the most common binding between 
heparin and proteins is through ionic interactions and as a consequence most heparin-binding 
sites in proteins are characterized by the presence of clusters of positively charged basic amino 
acids. Non-electrostatic interactions such as hydrogen bonding and hydrophobic interactions can 
also contribute to the stability of heparin–protein complexes 34,35.  
 
Figure 4.1.3. Heparin structure. Heparin is a linear polysaccharide with variable composition consisting 
on repeating units of disaccharides with its major sequence containing a containing an uronic acid residue 
and a glucosamine residue. Its composition varies depending on the tissue.(X= H or SO3
-
; Y= Ac or SO3
-
) 
(Image adapted from Murugesan et al. 2008 
34
) 
Heparin is widely used as anticoagulant due to its binding to the protease inhibitor antithrombin 
that accelerates its reaction with the protease thrombin and the formation of an active complex 
between protease and inhibitor 
35
. Moreover, heparin can modulate various cellular functions 
such as cell growth, differentiation, morphology, and migration 
36
. However, heparin has been 
used to develop new materials for GF delivery in tissue engineering approaches due to its 
growth factor binding affinity 
1,32
. This binding is important in sequestering growth factors in 
the ECM to localize their activity, to protect them from degradation and in some cases to 
enhance their binding to cell surface receptors 
37
. For this reason, polymeric growth factor 
delivery systems based on heparin are widely used because they can store growth factors 
similarly to the native ECM 
38
. As an example of this strategy, a self-assembling peptide 
containing a heparin-binding domain have been designed to obtain a strong binding affinity to 
heparin. Interestingly, angiogenesis was promoted when this designed peptides was used in a rat 
corneal assay in vivo 
1
. Similar strategies report the binding of heparin with other types of 
materials through covalent interaction to polymers such as alginate, polycaprolactone and 
collagen or entrapped within chitosan 
1,24,39–41
. It is important to mention that the aim of all these 
strategies was to promote angiogenesis by releasing heparin binding growth factors. 
 110 
 
4.2 Hypothesis and specific aims 
Self-assembling peptides are ECM-mimetic, synthetic biomaterials traditionally used for the 
culture and maintenance of mammalian cells
42–45
 . Nevertheless, nowadays they are also used as 
drug delivery hydrogels with different purposes 
30,46
. Altogether, the growth factor binding 
affinity of heparin evidences the attractive properties to tailor new biomaterials for tissue 
engineering applications. Thus, we hypothesized that the combination of heparin and the self-
assembling peptide RAD16-I could lead to the development of a new injectable nanofiber 
scaffold with drug binding and release capacities. Therefore, the aims for this chapter are the 
following: 
(1) To develop a new biomaterial for tissue engineering applications composed by the self-
assembling peptide RAD16-I and heparin.  
(2) To characterize the new biomaterial in terms of nanofiber formation and growth factor 
delivery.  
(3) To evaluate the behavior of human dermal microvascular endothelial cells (HDMVECs) 
within the new biomaterial and the control self‐assembling peptide in terms of tubular-
like structures development. 
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4.3 Materials and Methods 
4.3.1 Culture of endothelial cells 
Human Umbilical Vein Endothelial Cells (HUVECs) (CC-2519, Lonza) and Human Dermal 
Microvascular Endothelial cells (HDMECs) (C-12210, Promocell) (<10th passage) were 
cultured in 25-cm2 flasks, previously coated with 0.1% gelatin (G9391, Sigma), in Endothelial 
Basal Medium-2 (EBM-2) (CC-3156,Lonza) supplemented with Endothelial Cell Growth 
Media Single Quots kit (EGM-2) (4176,Lonza). Cultures were maintained in the incubator in 
humidified atmosphere at 37ºC and 5% CO2.  
4.3.2 Culture of human Normal Dermal Fibroblasts  
Human normal dermal fibroblasts (hNDF), isolated from the skin of anonymous adult patients, 
were kindly provided by Dr. Jesús Otero Hernández from “Hospital Universitario Central de 
Asturias”. Cells were seeded in 75-cm2 flasks using Dulbecco’s modified Eagle medium 
(DMEM; D5671, Sigma) supplemented with 10 % (v/v) fetal bovine serum (DE14-801F, 
Lonza), 100 U/mL Penicillin / 0.1 mg/mL Streptomycin (P11-010, PAA) and 2mM L-
Glutamine (M11-004, PAA). Cultures were maintained in humidified atmosphere at 37ºC and 
5% CO2.  
4.3.3 3D culture technique using endothelial cells 
To obtain a 3D culture, a solution of commercial 1% (w/v) RAD16-I (BD 
PuraMatrix™,354250, Beckton Dickinson) was diluted in Sucrose 10% (w/w) (S1888, Sigma), 
to obtain a concentration of 0.1% (w/v). When using the composite RAD16-I-Heparin 95µl of 
RAD16-I 0.5% (w/v) and 5 µl of Heparin (H3149, Sigma) 0.01% (w/v) were combined and 
diluted to a final concentration of 0.1 (w/v) RAD16-I. This solution was mixed with an equal 
volume of a cell suspension (10 x 10
6
 cells/mL) in sucrose 10%, to obtain a final concentration 
of 5 x 10
6
 cells/mL in 0.05% (w/v) RAD16-I in sucrose 10%. 80µL of this mix were loaded into 
9mm diameter cell culture inserts (PICM01250, Millipore), previously placed into a 6-well 
culture plate and equilibrated with culture media.  Immediately, cell-peptide cultures were 
placed for 30 minutes in the incubator at 37°C and 5% CO2, to allow the formation of the 
hydrogel by the action of a high ionic strength and the neutral pH of the medium. Elapsed this 
time washing steps, to dilute the content of sucrose, were performed by aspiration of the culture 
media in the well (outside of the insert), and the addition of the same amount (500µL) of fresh 
medium. The plate was placed again in the incubator for 10 minutes and this step was repeated 
3 times, after which 2.5mL of fresh medium were added outside the insert and the plate placed 
in the incubator for 30 more minutes, to finally allow the construct to form, preventing its 
rupture. At this point, the addition of medium over the cell culture began, by adding 10µL in the 
inner wall of the insert letting it slowly slide to the gel, until a volume of 40µL is reached. The 
plate was placed once again in the incubator for 15 minutes and then the addition of fresh 
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medium over the cell construct continued, 20µL inside the insert, until a final volume of 200µL.  
3D cell cultures were maintained in the incubator at 37°C and 5% CO2. The medium was 
changed every second day by removing 500µL of medium from the well and the addition of 
500µL of fresh medium inside the insert. 
4.3.4 3D culture technique using fibroblasts 
In this case RAD16-I and the composite RAD-Heparin were prepared at a final concentration of 
0.30% (w/v) RAD16-I. Then, that solution was mixed with an equal volume of a cell suspension 
4 x 10
6
 cells/mL in sucrose 10% (S0389, Sigma) to obtain a final concentration of 2 x 10
6
 
cells/mL, 0.15% (w/v) of RAD16-I in 10% (w/v) sucrose. Then, the cell-peptide suspension was 
loaded into cell culture insert (PICM01250, Millipore) previously placed and equilibrated with 
FM inside 6-well culture plate. Once the mixture was loaded, the medium from the bottom 
membrane penetrates in the insert inducing the self-assembly of RAD16-I. Once the gel was 
formed, 40 μl of culture medium were added in the inner wall of the tissue culture insert and 
were let slide slowly to the top of the hydrogel, then the plate was placed in the incubator for 20 
minutes. This step was repeated 3 times but adding 60μl of culture medium and placing the 
plate 10 minutes in the incubator. These steps favored the leaching of the sucrose. Finally, once 
aspirated the remaining medium in the well, 0.5 mL of fresh medium were added inside the 
tissue culture insert, and 2.5 mL were added in the well. 3D cell cultures were maintained in the 
incubator at 37°C and 5% CO2. The medium was changed every second day by removing 
500µL of medium from the well and the addition of 500µL of fresh medium inside the insert. 
Cultures were maintained for 8 days and then analyzed for viability. 
4.3.5 2D culture on top of self-assembling peptide 
RAD-Heparin composites were prepared combining 95µl of RAD16-I 0.5% (w/v) and 5 µl of 
Heparin (H3149, Sigma) 0.01% (w/v) and the mixture was diluted to a final concentration of 
0.1%(w/v) RAD16-I. Control RAD16-I samples were also prepared with a final concentration 
of 0.1% (w/v). 80 µl of each type of sample were loaded into a cell culture insert (PICM-1250, 
Millipore) previously placed into a 6-well culture, and 500 µl of complete endothelial culture 
media were added under the insert to start the self-assembling process. Samples were let for 30 
minutes at room temperature to allow the gel formation process. Once this time elapsed, 200 µl 
of endothelial culture media were added in the inner wall of the insert letting it slowly slide to 
the gel and 2.5mL of fresh medium were added outside the insert. Then, a suspension of 
120.000 HUVECs in 200 µl of endothelial culture media was loaded over the gel. Cell cultures 
were maintained in the incubator at 37°C and 5% CO2. The medium was changed every second 
day by removing 500µL of medium from the well and the addition of 500µL of fresh medium 
inside the insert. 
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4.3.6 Sample preparation for staining 
RAD-Heparin composites were prepared combining 95µl of RAD16-I 0.5% (w/v) and 5 µl of 
heparin sodium salt solution (H3149, Sigma) in a concentration range between 0.01 and 1 % 
(w/v), control RAD16-I samples were prepared with a final concentration of 0.5% (w/v). 100 µl 
of each type of sample were loaded into a cell culture insert (PICM-1250, Millipore) previously 
placed into a 6-well culture plate, and 500 µl of PBS were added under the insert to star the self-
assembling process. Samples were let for 30 minutes at room temperature to allow the 
gelification process. Once this time elapsed, 200 µl of PBS were added in the inner wall of the 
insert letting it slowly slide to the gel and 2.5mL of PBS were added outside the insert. 
4.3.7 Toluidine Blue staining 
Toludine Blue staining was performed to study the presence of highly negative charges 
provided by the heparin molecules. Samples were incubated with Toluidine Blue 0.05% (w/w) 
in water during 20 minutes and then washed several times with distilled water. Finally the 
samples were analyzed under a stereoscopic microscope (Nikon SMZ660). 
4.3.8 Congo Red staining  
Congo Red staining was performed to study the presence of the beta-sheet structure 
characteristic of the self-assembling peptide RAD16-I. Samples were incubated with 0.1% (w/v) 
Congo Red (75768, Sigma) in water for 5 minutes and washed several times with PBS. Finally 
the samples were analyzed under Stereoscopic microscope (Nikon SMZ660). 
4.3.9 Scanning Electron Microscopy (SEM)  
Briefly, samples were fixed in 5% (w/v)  gluteraldehyde and dehydrated in successive ethanol 
washes. Dehydrated samples were dried using a CO2 critical point dryer and subsequently 
coated with gold. Finally, samples were examined under SEM (NovaNano SEM 230 model, 
FEI, The Netherlands). 
4.3.10 Circular dichroism (CD) 
Circular dichroism (CD) spectroscopy was performed on a JASCO-715 spectropolarimeter 
equipped with a Peltier system. RAD16-I samples were diluted from a peptide stock solution 
(1% (w/v), 5.38 mM) in deionized water to a final concentration of 100 μM. RAD-Heparin 
composites were prepared using different blending ratios and diluted in deionized water to a 
final concentration of 100μM RAD16-I. CD data were acquired in a range of 195-250 nm at a 
band width of 1 nm, scan speed of 20 nm/s and path length 1mm. 
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4.3.11 Growth factor release quantification by ELISA 
RAD-Hep composite gels were prepared combining 95µl of RAD16-I 0.5% (w/v) and 5 µl of 
0.01% (w/v) Heparin (H3149, Sigma); control RAD16-I samples were prepared with a final 
concentration of 0.5% (w/v). Both types of gels were prepared in triplicate and incubated with a 
solution of 500 ng/ml VEGF165 or FGFβ in binding buffer (EBM-2 with 0.1%BSA and protease 
inhibitor) for 3 hours in the incubator at 37ºC and 5% CO2. Then, the growth factor solution was 
removed and the gels were incubated with binding buffer to allow the release of VEGF165 or 
FGFβ. Noncumulative studies were performed consisting on removing all the binding buffer 
with the growth factor released and adding fresh binding buffer to the gels. Samples were taken 
at 12, 24 and 36 hours and analyzed with ELISA kits for VEGF165 (EHVEGF2, 
Themoscientific) and FGFβ (KHG0021, Invitrogen) following the manufacturer’s protocol. 
4.3.12 Statistics 
All values were expressed as mean ± SD. Statistical differences were analyzed with GraphPad 
Prism 6 when samples were prepared in triplicate for the condition analyzed. When comparing 
two groups, unpaired student’s t test was used to test for the significance level. When comparing 
three or more groups statistical analysis was carried out by 1‐way or 2‐way ANOVA, as 
appropriate, followed by Tukey post analysis. 
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4.4 Results 
4.4.1 Development and characterization of a new bi-component material  
The main objective of this chapter was to develop a new self-assembling nanofiber matrix 
containing heparin moieties with angiogenic capacity for tissue engineering applications (Figure 
4.4.1). The first strategy envisaged the use of a self-assembling peptide with heparin binding 
domains (HBD) to allow the binding of heparin and as a consequence of growth factors 
containing HBD such as VEGF165 or FGFβ.. 
 
Figure 4.4.1. Schematic process of VEGF binding and release to the self-assembling peptide with 
heparin moieties. 
In our laboratory, a functionalized peptide scaffold based on RAD16-I (AcN–
RADARADARADARADA–CONH2) has been previously designed by direct solid phase 
synthesis extension at the amino terminal with the short-sequence motif TAGSCLRKFSTM. 
This peptide motif from the α1 chain of collagen type IV is known for its ability to specifically 
bind to heparin in a dose-dependent manner 
29
. For this reason, it was used in combination with 
RAD16-I to obtain a self-assembling peptide with heparin binding capacity. In order to study 
the binding to glycosaminoglycans (GAGs), gels with blending ratio 95:5 (RAD16-I: RAD-
TAG) and the control RAD16-I at a final concentration of 0.5% (w/v) were prepared and 
incubated with solutions of heparin and chondroitin sulphate (CS). Toluidine blue staining was 
performed to detect heparin and CS molecules thanks to its ability to form complexes with 
anionic glycoconjugates such as proteoglycans (PGs) and glycosaminoglycans (GAGs) 
47
. This 
staining revealed that both molecules (heparin and CS) bound to the gels independently of the 
presence of the HBD, even at low heparin concentrations, suggesting an unspecific binding 
(Figure 4.4.2). Interestingly, when CS samples were stained presented an intense blue color; 
instead, heparin samples stained purple. This effect is due to the different interaction between 
the dye and the negative molecules as previously described 
47
.  
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Figure 4.4.2. Glycosaminoglycans binding to self-assembling peptides. Toluidine blue staining of (A) 
RAD16-I and (B) RAD16-I:RAD-TAG (95:5) gels previously incubated overnight with solutions of 
1mg/ml chondroitin sulphate (CS), and 1, 0.1 and 0.01 mg/ml heparin. 
The next step was to evaluate the possibility of combine heparin and the self-assembling peptide 
with blending ratio 95:5 (RAD16-I: RAD-TAG) in order to assess the degree of interaction 
between both molecules. Different composites were prepared with blending ratios mg RAD16-
I:RAD-TAG/mg Heparin ranging from 99,5/1 to 9,5/1. Interestingly, the combination was 
structurally very stable at physiological pH and developed a nanofiber composite self-
assembling peptide-heparin. Toluidine Blue stained gels in a dose dependent manner (Figure 
4.4.3, A). Moreover, Congo red staining showed the formation in all cases of β-sheet secondary 
structures and as a consequence of the nanofiber formation (Figure 4.4.3, B). 
 
Figure 4.4.3. Self-assembling peptide RAD-TAG behavior with increasing quantities of heparin. (A) 
Toluidine blue staining, (B) Congo Red. 
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Thus, a similar behavior was observed when mixing RAD16-I directly with heparin which 
evidenced again the unspecific binding of heparin to the self-assembling peptide RAD16-I 
(Figure 4.4.4).  For this reason, it was decided to simply combine RAD16-I and heparin, which 
eased the complexity of the protocol and reduced its cost due to the absence of the modified 
peptide synthesis. 
 
Figure 4.4.4. Self-assembling peptides RAD16-I and RAD-TAG behavior with increasing quantities 
of heparin. (A) RAD16-I, (B) RAD16-I:RAD-TAG (95:5). 
Several RAD-heparin composites were prepared combining 95µl of RAD16-I 0.5% (w/v) and 5 
µl of heparin in a concentration range between 0.01 and 1 % (w/v), which corresponded to a 
ratio mg RAD16-I/mg Heparin between 950/1 and 9,5/1. Control RAD16-I samples were also 
prepared at a final concentration of 0.5% (w/v). The permanent blue/purple color observed after 
the staining indicated the presence of highly negative charges provided by the heparin 
molecules associated with the self-assembling nanofiber network in a dose dependent manner 
(Figure 4.4.5, A) 
48
. In addition, Congo Red, which stained β-sheet structures characteristic of 
the self-assembled RAD16-I 
49
 , showed that heparin was not interfering in the self-assembling 
process, independently of the  heparin quantity (Figure 4.4.5, A).   
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Figure 4.4.5. Influence of heparin in the RAD16-I self-assembling process. (A) Congo red and 
Toluidine blue staining of RAD16-I and composites with increasing quantities of heparin. Ratios mg 
RAD16-I/mg Heparin from 950/1 to 9,5/1. (B) CD of RAD16-I and composites with ratios mg RAD16-
I/mg Heparin from 1000/1 to 10/1.    
In addition, the effect of heparin in the β-sheet secondary structure characteristic of the peptide 
RAD16-I was studied by circular dichroism (CD) 
50,51
. CD is a spectroscopy technique that 
refers to the differential absorption of the left and right circularly polarized components of 
plane-polarized radiation 
51
. It is a useful tool for the structural characterization of proteins and 
peptides. A typical CD spectrum for a β-sheet structure shows a minimum molar ellipticity 
around 218 nm, which represents the β-sheet content and a maximum at 195 nm which 
corresponds to the backbone twist of the peptide in β-sheet configuration. The CD spectrum of 
an α-helix shows two minimums at 209 and 222 nm whereas random coil peptides or proteins 
are represented by a strong minimum in the 190-200 nm range (Figure 4.4.6) 
52,53
. 
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Figure 4.4.6. CD spectra of poly(Lys) in the α-helical (α), β-sheet (β), and random coil (r) 
conformations. (Greenfield and Fasman, 1969 
54
) 
First, RAD16-I was analyzed separately and as expected, it showed a typical CD spectrum for a 
β-sheet structure showing a minimum molar ellipticity (degcm2/decimole) around 216 nm and a 
maximum at 195 nm (Figure 4.4.5, B). After that, the secondary structures of the composites 
were similarly studied to elucidate whether the addition of heparin was affecting the β-sheet 
secondary structure. Three types of composites were prepared with ratios mg RAD16-I/mg 
Heparin: 950/1, 95/1 and 9,5/1. The addition of heparin was translated into weaker β-sheet 
structures, represented with a decrease in the intensity of molar ellipticity in the minimum at 
216 nm and the maximum at 198 nm. This effect was observed in a dose dependent trend : the 
higher the concentration of heparin, the weaker the β-sheet structure (Figure 4.4.5, B).   
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Then, Scanning Electron Microscopy (SEM) imaging was used to visualize and characterize the 
morphology of the nanofibers. As expected due to the CD analysis, a network of interweaving 
nanofibers was observed when the composite (950/1) and the control RAD16-I were analyzed. 
Although the diameter of the nanofibers was in the same range (around 20 nm), their length was 
shorter in the presence of heparin than in the control (Figure 4.4.7). 
 
Figure 4.4.7 . Scanning Electron Microscopy. RAD16-I and the composite with ratios mg RAD16-I/mg 
Heparin 950/1 were prepared at a final concentration of 0.5% (w/w) RAD16-I. (A) SEM image of 
RAD16-I, (B) 2x close up from (A). (C) SEM image of composite, (D) 2x close up from (C). 
Interestingly, areas with higher density of nanofibers, forming bundles but maintaining the 
nanofiber structure, were detected in a dose dependent manner in the composites with increasing 
quantities of heparin (Figure 4.4.8). We speculated that these areas were formed due to the 
strong ionic interaction between heparin, which is a highly sulfated anionic polysaccharide, and 
RAD16-I, which is an amphiphilic peptide consisting on repeating units of hydrophilic-
hydrophobic aminoacids with alternating positive and negative charges in the hydrophilic phase. 
As a consequence, we also speculated that these nanofiber bundles corresponded to the areas 
stained with toluidine blue also observed in a dose dependent manner (Figure 4.4.8). 
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In view of these results, it was decided to use the lowest heparin concentration, ratio 950/1 for 
the subsequent analysis of growth factor delivery and cell cultures because its CD was slightly 
different from the control self-assembling peptide and it also maintained its structural properties 
as observed by SEM. 
 
Figure 4.4.8. Scanning Electron Microscopy of composites RAD-Heparin. Composites were prepared 
with ratios mg RAD16-I/mg Heparin: 950/1, 450/1 and 150/1. (A,B) SEM images and (C) Toluidine Blue 
of 950/1 composite. (D, E) SEM images and (F) Toluidine Blue of 450/1 composite. (G ,H) SEM images 
and (I) Toluidine Blue of 150/1 composite. 
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4.4.2 Growth factor delivery  
After analyzing the influence of heparin on the self-assembling process and the nanofiber 
formation, the suitability of the composite for drug delivery purposes was assessed. For this 
purpose, a non-cumulative quantification of the angiogenic factors VEGF165 and FGFβ released 
by the composite and the control RAD16-I was performed. Interestingly, it was observed that 
the control scaffold released almost all the VEGF165 in the first 12 hours and that the amount of 
GF after 24 hours nearly reached zero. Nevertheless, the peptide-heparin composite gradually 
released VEGF165 over the course of the experiment (36 hours) (Figure 4.4.9, A). In the case of 
FGFβ, no significant differences in the release of GF were found between the control RAD16-I 
and the composite (Figure 4.4.9, B).  
 
Figure 4.4.9. Characterization of RAD16-I and the composite RAD-Hep as drug delivery hydrogels. 
Non-cumulative quantification of (A) VEFG,  and (B) FGFβ released by RAD16-I and the composite 
after 12, 24 and 36 hours of delivery. (Statistical differences are indicated as:* for p<0.05, ** for p<0.01, 
and *** for p<0.001, Two-way ANOVA, n=3) 
In order to know if the released growth factor was biologically active, a functional study was 
performed, which consisted of adding the released growth factor to a 2D culture of HUVECs 
cultured in Endothelial Basal Media-2 without any additional growth factor. After 48 hours, cell 
cultures were stained with DAPI in order to count the cells of each type of culture: growth 
factor released from the control RAD16-I, growth factor released from the composite and the 
control without the addition of any growth factor (Figure 4.4.10, A). The results showed a clear 
effect of the released growth factors on HUVECs maintenance and proliferation with higher cell 
numbers in the cases were the growth factor was added to the culture media than the control 
where almost all cells were dead (Figure 4.4.10, B). These results elucidated that both, VEGF165 
and FGFβ, maintained their biological activity after being released by the hydrogels. No 
significant differences, in terms of cell number, were found between growth factors released 
from RAD16-I or the composite. 
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Figure 4.4.10. Functional study of the released growth factor. A) DAPI staining of 2D endothelial 
cells cultures after 48 hours of culture with the released growth factors from RAD and RAD-heparin 
composite and, B) Cell count of 2D cultures from A). (Statistical differences are indicated as *** for 
p<0.001, Two-way ANOVA, n=3) 
4.4.3 Evaluation of the angiogenic capacity of the new bi-component material 
Afterwards, the angiogenic capacity of both materials was tested using human dermal 
microvascular endothelial cells (HDMECs). First, cells were cultured in a 2D model (on top of 
both hydrogels) exhibiting a noticeable spatial re-arrangement in both materials after 1 day of 
culture (Figure 4.4.11, A, B). Then, the development of tubular-like structures was studied by 
encapsulating the endothelial cells in both materials. The hypothesis was that the lower the 
peptide concentration (the lower the matrix stiffness), the easier to develop tubular structures by 
the cells. 
55,56
. Thus, cells cultured in 0.1% (w/v) RAD16-I presented rounded morphology 
compared to the cultures at low peptide concentration (0.05% (w/v) RAD16-I), which 
developed tubular structures independently of the presence of heparin after 2 days of culture. 
(Figure 4.4.11, C, D, E, F).  
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Figure 4.4.11. 2D and 3D cultures of HDMECs using RAD16-I and RAD-Hep. RAD16-I and the 
composite with ratios mg RAD16-I/mg Heparin 950/1 were prepared at a final concentration of 0.05% 
and 0.1% (w/w) RAD16-I. Phase contrast images show 2D soft cultures of HDMVECs after 1day of 
culture on top of (A) RAD16-I and (B) composite. When 3D cultures were prepared at final concentration 
0.1% (w/w) RAD16-I cells looked rounded after 2 days (C, E) as compared to cultures at final 
concentration 0.05% (w/w) where cells were elongated creating tubular structures (D, F). These structures 
were clearly observed when cultures were stained with DAPI-Phalloidin in 3D cultures prepared with 
0.05% (w/w) (G) RAD16-I and (H) composite. (Scale bars= 200 µM) 
Remarkably, both materials (RAD16-I and the composite) supported robust capillary 
morphogenesis. Indeed, HDMVECs formed capillary-like networks when cultured at high 
protein concentration (10% (v/v) FBS) and this was in concordance with what had been 
previously demonstrated for HUVECs in RAD16-I 
56
 (Figure 4.4.11, G,H). However, this effect 
was not observed when cells were cultured in complete endothelial basal media with the regular 
protein concentration (2% (v/v) FBS). In this case, cells formed tubular-like structures in both 
biomaterials but only when cells were cultured with medium containing heparin (Figure 4.4.12, 
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A, C). Instead, when HDMECs were cultured in the medium without heparin, the formation of 
tubular-like structures was much higher in the composite than in RAD16-I where cells looked 
rounded (Figure 4.4.12 B, D). These results evidenced the biological activity of the heparin 
present in the scaffold, which promoted a positive effect on tubular-like structures formation 
and as a consequence it compensated the absence of heparin in the culture media. 
.  
Figure 4.4.12. HDMECs cultured in RAD16-I and RAD-Heparin composite maintained in EBM 
supplemented with 2%FBS. RAD16-I and the composite with ratio mg RAD16-I/mg Heparin 950/1 
were prepared at a final concentration of 0.05% (w/w) RAD16-I. HDMVECs were encapsulated in both 
materials and maintained for 2 days. DAPI-Phalloidin showed that when cells were cultured in media 
containing heparin there were not differences between capillary-like structures formation in (A) RAD16-I 
and (C) RAD-Hep. Instead when cells were cultured in the media without the addition of heparin (C) cells 
looked round in the control RAD16-I and the capillary-like structures were only observed in the (D) 
RAD-Heparin composite. 
The effect of heparin on cell viability was evaluated using human normal dermal fibroblasts 
(hNDFs). Interestingly, cell viability was not affected by the presence of heparin compared to 
the control (RAD16-I) where almost all cells were alive (Figure 4.4.13, A, C). Moreover, a 
similar cell behavior was observed: cells elongated and developed a network as it was evidenced 
by the DAPI-Phalloidin staining (Figure 4.4.13, B, D). 
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Figure 4.4.13. hNDFs cell viability and network development in RAD16-I and the composite RAD-
Hep. RAD16-I and the composite with ratios mg RAD16-I/mg Heparin 950/1 were prepared at a final 
concentration of 0.15% (w/w) RAD16-I. hNDFs were encapsulated in both types of materials and 
maintained for 8 days. (A, C) Live and dead staining showed no differences in cell viability between 
different types of materials (Scale bars= 50 µM). (B, D) DAPI-Phalloidin staining showed similar cell 
behavior in all materials with cell elongation and development of a tight network. (Scale bars= 200 µM) 
4.5 Discussion 
In this chapter it was described the development of a new biomaterial for tissue engineering 
applications formed by simple combination of the self-assembling peptide RAD16-I and heparin 
sodium salt solution. Self-assembling peptides are ECM-mimetic, synthetic biomaterials 
traditionally used for the culture and maintenance of mammalian cells 
42–45
; however, nowadays 
they are also used as drug delivery hydrogels with different purposes 
30,46
. On the other hand, 
heparin is a class of glycosaminoglycan with growth factor binding affinity which is important 
in sequestering growth factors in the ECM to localize their activity protecting them from 
degradation and in some cases enhancing their binding to cell surface receptors 
37
. Altogether it 
evidences the attractive qualities that motivated the combination of the self-assembling peptide 
RAD16-I and heparin to obtain a new scaffold for tissue engineering applications with drug 
delivery capacity. Interestingly, the combination of both materials exhibited structural stability 
at physiological pH, developing into a nanofiber composite. Further material characterization 
showed that the β-sheet structure characteristic of the self-assembling peptide RAD16-I and, as 
   
127 
 
a consequence, the subsequent self-assembling process and nanofiber formation was not 
interfered by the presence of heparin at chosen working concentration. 
Remarkably, the composite could be used as a drug delivery system to bind and release 
physiologically significant quantities of VEGF165 in vitro during the first 24-36h to promote a 
possible pro-angiogenic effect in an in vivo model. It is hypothesized that VEGF165 associated to 
the matrix could be released by competing with free soluble heparin. Since heparin can be 
administrated and it is naturally present in the blood, the release of the VEGF165 from the 
glycopeptidic matrix would be physiologically regulated promoting local angiogenesis by 
neighbor capillaries. Moreover, HDMVECs developed tubular-like structures in the composite 
scaffold when they were maintained in culture medium without heparin. These results suggested 
the biological activity of the heparin present in the scaffold and its possible use in vascular 
tissue engineering applications in combination with the growth factor delivery.  
This material has been developed as part of the European project RECATABI (REgeneration of 
CArdiac Tissue Assisted by Bioactive Implant, EU 7
th
 frame Program) with the purpose to 
promote vascularization of ischemic areas after myocardial infarction. In addition to the assays 
with endothelial cells presented in this chapter, in vitro studies of cardiogenic differentiation 
with MSCs have been performed using the new composite in our laboratory. Interestingly, when 
MSCs were cultured in the composite hydrogel they presented an aligned growth characteristic 
of cardiogenic differentiation while control samples (RAD16-I) showed a disordered pattern. 
However, cardiogenic differentiation was analyzed and preliminary results showed that there 
were not differences in protein and gene expression due to the presence of heparin in the 
scaffold. Future approaches would include its use in in vivo models of angiogenesis such as the 
chick embryo chorioallantoic membrane (CAM), which is an extra embryonic membrane which 
serves as a gas exchange surface and its function is supported by a dense capillary network. 
Because of its extensive vascularization and easy accessibility has been broadly used to 
investigate mechanisms of angiogenesis 
57
. The final approach of this material would be its use 
in an in vivo model of myocardial infarction to promote vascularization of ischemic areas which 
was the main purpose of the project. 
Importantly, this new biomaterial could be used in other tissue engineering applications due to 
the ability of heparin to bind different growth factors including TGFβ, which is a well-known 
chondrogenic inductor with heparin binding affinity. According to the literature, heparinized 
scaffolds seem to induce and enhance chondrogenic differentiation. This effect could be 
explained due to the unique bioactivities of heparin moieties that can hold various growth 
factors safely and protect them from denaturation 
58
. In addition, it was also speculated that 
heparin could deposit GAGs produced by cells via heparin-binding affinity 
58
. Taking all this 
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into account, the new biomaterial developed in this thesis is actually being used in our 
laboratory as a scaffold to support in vitro chondrogenic differentiation as part of the project 
BIOCART (BIOactive and biomimetic scaffolds for CARTtilage regeneration, AO Fundation 
Switzerland). This project aims to develop potential injectable scaffolds that mimic the natural 
extracellular matrix of cartilage for their use in clinical applications of cartilage repair. Up to 
now, promising results have been obtained which showed enhanced MSCs viability in the 
presence of heparin as compared to the controls. Moreover, preliminary results showed that 
heparin promoted higher expression of chondrogenic markers than the controls in the self-
assembling peptide RAD16-I. It was speculated that heparin could be sequestering growth 
factors, such as TGFβ, in the ECM and localizing their activity as compared to the control 
cultures in RAD16-I. Ongoing experiments are focused on studying the influence of heparin in 
the chondrogenic differentiation process. Afterwards, future approaches would include its use in 
an in vivo model of cartilage defect in order to obtain cartilage recovery. 
Stupp and coworkers reported the development of a self-assembling peptide with similar 
characteristics to the composite developed in this thesis 
1
. It contains a heparin binding domain 
that self-assembles into nanofiber gels when mixed with heparin and activates heparin-binding 
angiogenic growth factors. It was demonstrated that the presentation of growth factors (VEGF 
and FGFβ) via the heparinized gel enhanced their angiogenic bioactivity in vitro and induced an 
extensive angiogenic response in an in vivo rat corneal assay 
1,59
. Afterwards, it was used for the 
delivery of angiogenic factors into pancreatic islets evidencing the versatility of the heparinized 
self-assembling peptide 
60
. However, the advantage of our composite is the commercial 
availability of both components which facilitates its use and reduces its cost due to the absence 
of peptide synthesis. 
Altogether the results presented in this chapter indicate that the new composite is a promising 
“easy to prepare” material for different tissue engineering applications. It is made by simple 
combination of two commercial products: self-assembling peptide RAD16-I (PuraMatrix
TM
) and 
heparin sodium salt solution. Remarkably, the commercial availability of clinical grade 
PuraMatrix
TM
 and heparin enables its future use for in vivo studies. 
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4.6 Concluding Remarks 
- A new biomaterial for tissue engineering applications has been developed by simple 
combination of self-assembling peptide RAD16-I and heparin sodium salt. The 
availability of clinical grade RAD16-I and heparin enables its future use in in vivo 
applications, including human trials. 
 
- This new biomaterial could be used as a drug delivery system to bind and release 
physiologically significant quantities of VEGF165 in vitro during the first 24-36h to 
promote pro-angiogenesis in an in vivo model. 
 
- The composite material presented promising results for its use in vascular tissue 
engineering applications; however, it could be used for other tissue engineering 
applications including cartilage and cardiac regeneration. 
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Design of tissue engineering strategies for cartilage tissue engineering using the self-assembling 
peptide RAD16-I: 
- MEFs cultured under certain biomechanical conditions (G’ around 0.1 kPa), were able 
to develop a rich interconnected cellular network which promoted increase of several 
basic parameters including cell density, cell-cell contact and matrix storage modulus. 
This process created a unique environment, which favored the system to engage in a 
spontaneous chondrogenesis differentiation evidenced by the expression of the 
chondrogenic markers Sox9, Coll II and proteoglycans. 
 
- MEFs developed an isolated spontaneous adipogenic differentiation in RAD16-I which 
was favored by the formation of a tight cell network. Interestingly, it was described for 
the first time the adipogenic differentiation of MEFs in 2D and 3D cultures by the 
addition of the growth factor PDGF to the culture media. 
 
- Matrix instruction played an important role in the multipotent commitment acquired by 
MEF in the self-assembling peptide RAD16-I since cultures in collagen type I did not 
engage neither in the spontaneous chondrogenic nor adipogenic differentiation.  
 
- The balance Noggin/BMP4 was found to play a critical role in the observed 
chondrogenic differentiation of MEFs cultured in RAD16-I. Remarkably, the 
chondrogenic inductor BMP4 was only expressed under mechanical conditions where 
the spontaneous chondrogenic differentiation was observed. 
 
- The observed spontaneous chondrogenic differentiation of MEFs in the self-assembling 
peptide together with the partial redifferentiation of dedifferenitiated bovine 
chondrocytes evidenced the potential of this scaffold for its use in cartilage tissue 
engineering applications. 
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Evaluation of the biologically induced osteogenic differentiation of MEFs in the self-assembling 
peptide RAD16-I: 
- MEFs undergoing chondrogenesis in the self-assembling peptide RAD16-I switched to 
osteogenic-like commitment due the biological induction of ECs in a coculture system. 
This is the first description of the osteogenic differentiation of fibroblast due to the 
crosstalk with endothelial cells. 
 
- The osteogenic commitment of MEFs was evidenced by the expression of collagen type 
X and matrix mineralization. Additionally, other factors expressed by the mentioned 
cocultures were Runx2 and VEGF-A, which could promote the possible formation of 
new blood vessels, necessary for the endochondral ossification. 
 
- Von Kossa staining showed matrix mineralization in areas of direct interaction between 
MEFs and ECs, which suggested an effective cross talk between MEFs and HUVECs 
that could be studied more in detail in future research projects. 
 
- Preliminary results of osteogenic differentiation suggest that future in vivo implantation 
of the MEFs 3D-constructs in an in vivo mouse model of ectopic bone formation or in a 
fracture site would promote the formation of a vascularized bone graft. 
Development of a new biomaterial for tissue engineering applications based on the self-
assembling peptide RAD16-I: 
- A new biomaterial for tissue engineering applications has been developed by simple 
combination of self-assembling peptide RAD16-I and heparin sodium salt. The 
availability of clinical grade RAD16-I and heparin enables its future use in in vivo 
applications, including human trials. 
 
- This new biomaterial could be used as a drug delivery system to bind and release 
physiologically significant quantities of VEGF165 in vitro during the first 24-36h to 
promote pro-angiogenesis in an in vivo model. 
 
- The composite material presented promising results for its use in vascular tissue 
engineering applications; however, it could be used for other tissue engineering 
applications including cartilage and cardiac regeneration. 
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Diseño de estrategias de ingeniería de tejidos para la reparación de cartílago usando el péptido 
de auto-ensamblaje RAD16-I: 
- Los MEFs cultivados en el péptido de auto-ensamblaje RAD16-I en ciertas condiciones 
mecánicas (G’ alrededor de 0.1 kPa), desarrollaron una densa red celular que promovió 
el aumento de diferentes parámetros incluyendo densidad celular, contactos célula-
célula y el módulo de almacenamiento de la matriz. Este proceso creó un ambiente que 
favoreció que el sistema iniciara un proceso espontáneo de diferenciación condrogénica 
caracterizado por la expresión de los marcadores condrogénicos Sox9, Colágeno II y 
proteoglicanos. 
 
- Los MEFs iniciaron un proceso aislado de diferenciación adipogénica espontánea en el 
péptido de auto-ensamblaje RAD16-I el cual fue favorecido por la formación de una 
densa red celular. De forma interesante, se describió por primera vez la diferenciación 
adipogénica de los MEFs en cultivos 2D y 3D mediante la suplementación del medio de 
cultivo con el factor de crecimiento PDGF. 
 
- La instrucción de la matriz jugó un papel muy importante en la capacidad de 
diferenciación multipontencial adquirida por los MEFs en el péptido RAD16-I ya que 
los cultivos de MEFs en colágeno tipo I no iniciaron los procesos espontáneos de 
diferenciación condrogénica y adipogénica descritos en la matriz peptídica. 
 
- El balance Noggin/BMP4 tuvo un papel muy importante en la diferenciación 
condrogénica observada cuando los MEFs se cultivaron en el péptido RAD16-I. 
Notablemente, los MEFs solo expresaron el inductor condrogénico BMP4 bajo ciertas 
condiciones mecánicas en las cuales se observó la diferenciación condrogénica 
espontánea.   
 
- La diferenciación condrogénica espontánea de los MEFs y la rediferenciación parcial de 
los condrocitos bovinos desdiferenciados cuando se cultivaron en la matriz peptídica 
RAD16-I prueban la potencialidad de este material para ser usado en estrategias de 
ingeniería de tejidos de reparación de cartílago. 
 
 
Evaluación de la diferenciación osteogénica inducida biológicamente de los MEFs en el péptido 
de auto-ensamblaje RAD16-I: 
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- Los MEFs experimentando diferenciación condrogénica en el péptido RAD16-I se 
redirigieron hacia una diferenciación osteogénica debido a la inducción biológica de las 
células endoteliales. Esta es la primera vez que se describe la diferenciación osteogénica 
de los fibroblastos debido a un “diálogo” con células endoteliales. 
 
- La diferenciación osteogénica de los MEFs fue probada por la expresión del marcador 
hipertrófico colágeno tipo X y la mineralización de la matriz. Además, otros factores 
expresados por los cocultivos fueron el marcador hipertrófico Runx2 y el factor de 
crecimiento vascular VEGF, lo que podría inducir la formación de nuevos capilares los 
cuales son necesarios para el proceso de osificación endocondral. 
 
- La tinción de Von Kossa mostró la mineralización de la matriz en las zonas de 
interacción  entre los MEFs y las células endoteliales lo que sugiere un diálogo entre los 
MEFs y las HUVECs que podría ser estudiado con más detalle en futuros proyectos. 
 
- Los resultados preliminares diferenciación osteogénica sugieren que la futura 
implantación de los cultivos tridimensionales de MEFs en un modelo in vivo de 
formación de hueso ectópico, o en una fractura, promoverían la formación de un 
implante de hueso vascularizado. 
Desarrollo de un nuevo biomaterial basado en el péptido de auto-ensamblaje RAD16.I para 
aplicaciones de ingeniería de tejidos: 
- Un nuevo biomaterial para aplicaciones de ingeniería de tejidos se ha desarrollado 
mediante la simple combinación del péptido de auto-ensamblaje RAD16-I y la sal 
sódica de heparina. La disponibilidad de RAD16-I y heparina de grado clínico permite 
su futuro uso en aplicaciones in vivo, incluyendo ensayos en humanos. 
 
- El nuevo biomaterial se podría usar como un sistema de la unión y liberación de 
cantidades fisiológicas del factor de crecimiento VEGF165  durante las primeras 24-36 
horas para así promover un posible efecto pro-angiogénico en un modelo in vivo. 
 
- El material compuesto de heparina y RAD16-I  presentó resultados prometedores para 
su uso en aplicaciones de ingeniería de tejido vascular; sin embargo, podría ser usado en 
otras aplicaciones de ingeniería de tejidos como la reparación de cartílago o cardíaca. 
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Appendix I 
Supplementary Video. Attached CD. 
MEFs behavior in soft 3D peptide scaffolds. MEFs were seeded in low elastic modulus 3D self-
assembling peptide scaffolds (G’ around 0.1kPa). Interestingly, their behavior denotes multiple 
cellular activities including migration, cell network formation, proliferation and matrix 
contraction. The scaffold was placed in an incubation chamber associated with an inverted 
microscope. The 30 seconds video represents series of pictures taken during the first 12 hours of 
culture. 
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Appendix II 
The data presented in this Thesis has been published or is under process of publication. 
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Chapter 2 and Chapter 3: 
Fernández-Muiños, T., Suárez-Muñoz, M., Sanmartí-Espinal, M., Semino, C.E., Matrix 
dimensions, stiffness and structural properties modulate spontaneous chondrogenic commitment 
of mouse embryonic fibroblasts. Tissue Engineering.Part A. (Accepted October 15
th
 2013) 
Chapter 4: 
Fernández-Muiños, T.*, Recha-Sancho, L.*, López-Chicón, P., Castells-Sala, C., Semino, 
C.E., Bimolecular based self-assembling hidrogel for tissue engineering applications. (In 
preparation) *Equal contribution 
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Chicón, P., Aloy-Reverté, C., Caballero-Camino, J., Márquez-Gil, A., Semino, C.E., Current 
applications of tissue engineering in biomedicine. Biochips and Tissue Chips, S2: 004. (2013) 
doi: 10.4172/2153-0777.S2-004 (Review article) *Equal contribution 
 
Wu, J., Marí‐Buyé, N., Lopez, L., Fernández Muiños, M. T., Borrós, S., Favia, P., Semino, C. 
E., Nanometric self‐assembling peptide layers enhance CYP3A2 expression of primary rat 
hepatocyte sandwich cultures. Journal of Nanobiotechnology, 8, 29 (2010).  
 
Quintana Ll., Fernández Muiños T., Genove.E., Olmos M., Borros S., Semino C.E. Early 
tissue patterning is recreated by mouse embryonic fibroblasts in a three-dimensional 
environment. Tissue Engineering.Part A. Volume 15, 1, (2009) 
 
Book chapters: 
Fernández Muiños, M.T., Semino, C.E., Self-assembling peptides as a synthetic extracellular 
matrix. Polymer concepts in regenerative medicine. From nano- to macro-structures. Series 
editors: Monleón,M and Vicent,MJ   WILEY & SONS (Under edition) 
Marí‐Buyé, N., Fernández Muiños, M. T., Semino, C. E., Three‐dimensional cultures in soft 
selfassembling nanofibers. In Methods in Bioengineering: 3D Tissue Engineering (2010). Series 
editors: Berthiaume, F. and Morgan, J. Artech House. ISBN: 978-1-59693-458-0 
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